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Abstract
This thesis presents a thorough study on the newly developed glucoCEST magnetic
resonance imaging (MRI) technique and its application for the assessment of ma-
lignant brain tumours. The key asset in glucoCEST is that it allows the detection of
small concentrations of glucose using standard MRI scanners and has the potential
to become a novel imaging tool for the investigation of diseases in which glucose
metabolism is affected, in particular cancer.
The physical principles and the rationale behind the glucoCEST technique are
described in detail and factors influencing the measurements (both physiological
and hardware related) are analysed using computer simulations and evaluated with
in vitro experiments. Special attention is given to the analysis of the first four
sugars along the glycolytic pathway i.e. glucose, glucose 6-phosphate, fructose
6-phosphate and fructose 1,6-biphosphate as contributors to the overall observed
signal. The results of this analysis give grounds for the argument of the intracel-
lular origin of the glucoCEST signal, which opens the possibility of characterising
tumours based on their metabolism using MRI.
A preclinical glucoCEST study on mice bearing human xenograft glioblastoma
is also presented in which cancers with diverse phenotype are scanned longitudi-
nally throughout the different stages of tumour development. While not conclusive,
the results suggest that the glucoCEST technique is able to identify the presence of
cancer at an earlier stage than standard MRI methods.
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Overview
Tumours are heterogeneous by nature. They display a huge diversity of physiolog-
ical patterns, yet most of them share one common characteristic, increased glucose
consumption. This phenomenon, known as the Warburg effect, has been exploited
by [18F]-fluorodeoxyglucose positron emission tomography (FDG-PET) as a dis-
criminator of tumour malignancy and to assess anti-cancer treatment response for
many years. Currently FDG-PET is considered the gold-standard tumour screening
technique. Nevertheless it holds two important disadvantages, namely its elevated
cost and the use of radioactive tracers. These drawbacks limit the extent of FDG-
PET as a routine screening modality.
On the other hand, chemical exchange saturation transfer (CEST) is a fast emerg-
ing magnetic resonance imaging (MRI) technique that is pushing the boundaries of
MRI sensitivity. The physical mechanism of exchange of magnetisation makes it
possible to detect metabolites down to the millimolar concentration range. In addi-
tion, due to its sensitivity to several physiological parameters, CEST is particularly
suited for in vivo applications. These features allow CEST to obtain information
that was out of reach for MRI until recently, such as the detection of protein con-
tent, biomarker of tissue pH, or molecular imaging using endogenous CEST agents,
to cite a few examples. The number of applications is quickly increasing and the
full potential of CEST yet to be seen.
In a recent work by our group, a new way of detecting glucose uptake based on
CESTMRI was presented, named glucoCEST.1 Amajor advantage of the technique
is that it uses natural glucose to produce image contrast and therefore no radioactive
tracer is needed. This offers a potential alternative to FDG-PET for cases where the
use of radiation is not advisable. In addition, compared to PET systems, MRI is
more widely available and cost effective. Owing to these virtues, glucoCEST may
offer a more economic, accessible and safer alternative to FDG-PET.
In the present work the glucoCEST technique, will be investigated as a marker of
glucose metabolism. The focus of this work will be the study of tumour metabolism,
and particularly the assessment of brain gliomas with glucoCEST. However, as a
technique that could inform on glucose utilisation, glucoCEST can be potentially
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useful in a number of metabolic disorders.
This work presents an extensive analysis of the glucoCEST technique, from the
conceptual idea, to the optimisation of the technique and its evaluation as a potential
biomarker of tumour growth and metabolism in various models of cancer.
In Chapter 1 the concept of CEST-MRI and the underlyingmechanisms governing
its contrast is introduced. The main features of in vivo CEST will be described and
the current uses and development of the technique will be outlined.
Chapter 2 presents the rationale behind the use of glucoCEST in the context of
cancer. The benefits, drawbacks and the recommended good practices are discussed,
as well as presenting a review of the studies published to date.
In Chapter 3 themathematical formulation of CEST is presented. Computer based
simulations are used to provide an extensive analysis of the main variables modulat-
ing the CEST contrast. Additionally, the optimisation of parameter values for best
glucoCEST results are derived.
Chapter 4 presents an experimental study in which the chemical exchange proper-
ties of different sugars along the the glycolytic pathway are thoroughly investigated.
In Chapter 5 the origin of the glucoCEST contrast and the possibility of intracel-
lular signal contribution is discussed. To do so a System Dynamics model of blood
delivery and glucose consumption in cancerous and healthy tissues is developed to
simulate their respective glucoCEST response.
Chapter 6 presents an animal study on human xenograft glioma models in which
the potential of glucoCEST as a diagnostic tool in brain cancer is assessed.
Lastly, Chapter 7 includes the ongoing and future projects regarding exogenous
CEST as a continuation of the work done in this thesis.
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1. Introduction to Chemical
Exchange Saturation Transfer
Chemical exchange saturation transfer (CEST) is a promising MRI technique that
can provide images with unique physiological information capable of improving the
diagnostic potential of MRI examinations in the clinic.
While the contrast in most MRI methods is based on the concentration and relax-
ation properties of free water protons in tissues, CEST contrast relies critically on
hydrogen atoms located at specific chemical structures (labile protons), other than
water. More specifically, CEST contrast is generated as the consequence of the ex-
isting interaction between these labile protons and free water protons, which can be
detected with a standard MRI readout as a reduction of the MR signal intensity.
Labile protons are first ‘tagged’ using a radio frequency (RF) pulse at their own spe-
cific resonant frequency. Consequently, the magnetic state of these ‘tagged’ spins
is transferred to water through dipolar or chemical interactions which eventually
results in a reduction of the observable MR signal. This is the principle behind off-
resonance saturation based imaging methods, which includes CEST MRI.
1.1. Off-resonance saturation based imaging
Electrons orbiting atoms in different chemical structures produce variations in the
local magnetic environment. As a consequence protons of specific chemical groups
have their own characteristic Larmor frequency, each separated by a few parts per
million (ppm) from the central resonant frequency. This phenomenon, called chem-
ical shift, is the basis of NMR (nuclear magnetic resonance) spectroscopy, and it is
fundamental in the context of ‘off-resonance’ imaging as it allows the delivery of
energy to selected chemical structures by irradiation with frequency selective RF
pulses. Due to the interactions between spins in the labelled structures and water
(mediated predominantly by either dipolar coupling or chemical exchange), high
energy spin states (irradiated with RF pulses) get transferred to water protons. Con-
stant spin interactions over a sufficiently long excitation RF pulse result in a signif-
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icant net energy transfer from labelled molecules to water. The overall result is the
partial saturation (equal density of high and low energy states) of the water protons
which reduces the available MR signal to produce an image. The intensity of the
effect is largely dependent on the rate of the spin interaction and the concentration
of labelled protons. The process of magnetisation transfer acts as an amplification
mechanism, enabling the indirect measurement of metabolites at very low molecu-
lar concentrations. Studies have reported amplifications of more than 800 fold the
standard MRI sensitivity.1
The advantages of the off-resonance saturation sequences include: the increased
sensitivity that allows the detection of molecules at concentrations much lower than
what is achievablewith conventionalMRI, the possibility of imagingmacromolecule
content with very short T2 relaxation times2 or the possibility of mapping important
physiological parameters such as pH.3
Depending on the nature of the molecular interactions, the off-resonance satura-
tion techniques tend to be grouped into two main categories, Magnetisation Transfer
(MT) imaging and CEST. TheMT imaging method is associated with the dipolar in-
teractions between protons in free water molecules and bound-water molecules, usu-
ally within the hydration layer of large macro-molecules. Several mechanisms are
involved in MT, including intra-molecular dipolar cross-relaxation, cross-relaxation
by nuclear Overhauser effect (NOE) between backbone protons and the exchange-
able protons in the macromolecule side chain, and finally fast chemical proton ex-
change with water.4
Clinical applications of MT are extensive. Some examples include, contrast en-
hancement betweenmyo-cardium and venous blood inMR angiography,5 biomarker
of demyelination in disorders of the central nervous system such as multiple scle-
rosis, Parkinson’s and Huntington’s disease,6,7,8,9 or investigation of white matter
lesions after traumatic brain injury.10
CEST, on the other hand, refers to the process by which magnetic information be-
tween spins is transferred via a chemical interaction, where hydrogen atoms in spe-
cific molecules physically swap position with protons in free water. The relatively
fast exchange rate between the spins (CEST operates in the intermediate exchange
rate, see section 1.3) makes the labile proton resonant frequency distribution consid-
erably narrower (~100Hz) than that observed in MT (~100KHz) due to an exchange
narrowing effect. Moreover, unlike MT which is predominantly observed in semi-
solid macromolecular structures, CEST also occurs in small sized molecules such as
dissolved sugars and amino-acids. The high mobility (low correlation time) of these
molecules, confers them a relatively long T2 relaxation time, which again produces
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a narrow absorption-bandwidth, in this case due to motional narrowing.
As in MT, the net effect in CEST is an observable reduction of longitudinal mag-
netisation which is caused by the progressive transfer of energy from irradiated pro-
tons to water protons. However, compared to MT, CEST provides sharper spectral
bandwidths, allowing a selective saturation of the different molecules, as well as the
possibility of labelling small molecules, usually undetectable by other MR imaging
techniques.
The following sections present a description of the main features observed in
CEST and the parameters that govern its behaviour, as well as a review of the dif-
ferent uses and applications.
1.2. The Z-Spectrum
Figure 1.2.1.: Z-spectrum of the mouse brain. Depending on the off-
resonance saturation frequency images will display: a) no attenuation in
case of no exchange. b) attenuation due to exchange from interacting
protons. c) attenuation due to direct saturation close to water.
The first phase of a CEST experiment involves the saturation of solute protons that
will subsequently exchange magnetisation with water. To do so, most CEST exper-
iments begin with the application of a long (on the order of seconds) off-resonance
RF pulse (or train of pulses), followed by a standard readout, ideally with a proton
density weighted acquisition. This procedure is repeated for a number of different
frequency offsets, usually covering a range of frequencies centred at the water reso-
nant frequency, which results in the acquisition of as many images as offset points.
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Provided there is chemical exchange (or other type of magnetic transfer), the images
obtained will display a certain degree of signal attenuation when the RF pulse is ap-
plied at the resonant frequency of the exchangeable molecules. The profile obtained
by plotting the signal intensity as a function of the off-resonance frequency is called
the Z-spectrum, and is the basic measure for the vast majority of CEST experiments.
See illustration of the Z-Spectrum in figure 1.2.1.
1.3. Features of the Z-spectrum in vivo
As mentioned earlier, CEST is sensitive only in a narrow range chemical exchange
rate. Let us imagine two spin populations at different magnetic environments res-
onating at their own specific frequency, separated by their chemical shiftΔ𝜔. In the
slow exchange limit, when the exchange rate is very small compared to the chemi-
cal shift (𝑘 << Δ𝜔), no exchange of hydrogen atoms take place (within the NMR
time) which results in two defined NMR peaks and no CEST effect. On the other
extreme, in the fast exchange limit (𝑘 >>Δ𝜔), rapid proton swaps between the two
magnetic environments leads to a single averaged resonance frequency with only
one distinct NMR peak, from which no metabolites can be separated. The optimum
exchange rate for CEST lies between these two limits, in the so called ‘intermediate’
exchange regime (𝑘 ∼Δ𝜔), where chemical interaction between the two set of spins
can affect each other, while still being able to distinguish them.
1.3.1. Chemical exchange mediated peaks
Among the organic chemical structures found in biology, hydrogen atoms within
-OH and -NH chemical bonds tend to have the correct intermediate exchange rate
able to produce CEST contrast.
Hydroxyl groups Present in all water molecules, hydroxyl (-OH) groups are
the key component in the CEST process, allowing other labile protons to interact
with hydrogen in water, which is ultimately how the CEST effect can be detected.
Hydroxyls in molecules other than water also allow the CEST labelling of polysac-
charides and sugars, like glycogen and glucose. These hydrogen nuclei resonate
around 1 to 3 ppm from water and while they are usually not readily visible in a
Z-spectrum in vivo (due to their low intensity and proximity to water), they are crit-
ically important in this work as they make the glucoCEST technique possible.
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Figure 1.3.1.: Simulations of two identical exchanging pools with 3.5 ppm
chemical shift. Blue) A very slow exchange rate produces sharp NMR
peaks but no CEST. Red) A very fast exchange rate leads to a single reso-
nant frequency where the pools cannot be distinguished. Green) With an
intermediate exchange rate, magnetisation is transferred from one pool to
the other, producing the CEST effect.
Amide, amine and imino groups Exchange sites containing -NH bonds in-
clude the imino, amine and amide groups. These are predominantly found in pro-
teins structures and amino-acids, and have their resonant frequency between 2 and
3.5 ppm donwfield (higher frequency) from water. Among these groups, amides
in the backbone of protein chains (forming the peptide bonds), have been particu-
larly important in the CEST literature, as they are considered to be the source for
the Amide Proton Transfer (APT) contrast, manifested as a peak in the Z-spectrum
at ∼3.5 ppm offset. APT has been reported in a number of publications as a non-
invasive method to image tissue pH, based on the fact that the chemical exchange
rate of these amide protons is highly sensitive to in vivo pH variations.11,12,13 On
the other hand, side chain amides, as well as amine and imino groups tend to res-
onate around 2 ppm from water, with a more rapid exchange rate. Many important
molecules in biology contain such chemical groups including amino-acids, several
neuro-transmitters such as adrenaline, dopamine, acytylcholine and nucleosides in
ADN (and RNA) like adenine, citosine or guanosine.
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Figure 1.3.2.: Types of hydrogens in proteins. The six-residue pep-
tide Gln-Asp-His-Pro-Lys-Leu illustrates backbone amide hydrogens (in
black), fast exchanging hydroxyl, amine and side-chain amide hydrogens
(in orange, blue and green respectively) and nonexchangeable hydrogens
bonded to carbon (in grey).14
1.3.2. Non-pure CEST manifestations in the Z-spectrum
In addition to the already discussed CEST sensitive groups, protons in certain con-
ditions can also modulate the Z-spectrum. These include protons associated with
magnetisation transfer (MT) and Nuclear Overhauser Effects (NOE).
1.3.2.1. Magnetisation Transfer
As previously mentioned MT originates in large macromolecules and its effect is
present in a wide spectral range (∼100KHz) centred around water. While it is not
driven by a chemical exchange (magnetisation transfer is mediated by dipolar cou-
pling), it does however affect the interpretation of the CEST data, as it also reduces
the available longitudinal magnetisation.
1.3.2.2. Nuclear Overhauser Effect
Closely related to MT, the NOE effect is thought to originate from protons in the
aliphatic region, 3 to 5 ppm upfield (lower frequency) from water. Even though the
underlying mechanisms are not fully understood, the effect is considered to be ini-
tially mediated by the cross relaxation via dipole-dipole interaction of the backbone
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protons in medium sized molecules (small proteins). Once irradiated at their own
resonant frequency, these backbone -CH and -COCH3 (Acetyl) hydrogen atoms can
transfer magnetisation to exchangeable protons (-NH, -NH2, -OH) within the same
molecule, which can then interact with water though chemical exchange. These ef-
fects, referred to as exchange-relayedNOEs, are believed to be a possible contributor
to CEST signal centred around -3.5ppm.15,16
While intermolecular NOEs (between molecules) also exist, they are more sig-
nificant between large macro-molecules and the hydration layer around them. With
restricted molecular motion and short inter-atomic distances, protons are stronger
coupled, leading to more efficient cross relaxation. As size of the molecules increase
and structures become ‘semisolid’ the inter-molecular NOEs become important and
contribute to generate the broad MT effect.
The practical difference of NOE with respect to MT, is that unlike MT, NOE
manifests with narrow absorption line-width (∼ 3 ppm) at the aliphatic region. Un-
fortunately, the fact that the offset frequency in NOE is opposite to the one in CEST,
makes the analysis of the Z-spectrum and quantification of the exchangeable pool
sizes more complicated. As such, until recently the majority of the CEST studies
have regarded the NOE peak as ‘contamination’ of the CEST signal, and little at-
tention has been paid to its significance. In recent publications however, researches
acknowledge that the NOE effect might offer an additional source of contrast, pos-
sibly as valuable as CEST.17,18,19
The combined effect of these processes shapes the Z-spectrum. Finding ways to
untangle the contribution of each spin population is a subject of intense research
in the CEST community. Most of the proposed methods use symmetry arguments
aimed at untangling DS and MT effects as their profile is effectively symmetri-
cal around the water frequency. For non-symmetrical contributions to to the Z-
spectrum, like the aliphatic NOEs, others methods exploit the characteristic times
and power dependencies in each of the exchange process in order to quantify their
effect. Some examples of these proposed methods are described in section 1.6.1.
1.4. Factors influencing the Z-spectrum
Besides the actual protons involved in the CEST mechanism, other external param-
eters exert a strong influence on the Z-spectrum. Some of these parameters can be
adjusted and therefore optimised, while others need to be understood to evaluate
their impact.
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1.4.1. RF saturation power B1
A poorly saturated exchangeable proton pool will, in principle, produce a smaller
CEST contrast. However, strong RF pulses produce undesired saturation of the wa-
ter signal due to the off-resonance spill-over effect (DS). This results in the broad-
ening of the water shape-line, which results in the reduction of the available MR
signal, especially close to water. Therefore the sensitivity of the CEST technique to
detect protons resonating close to the water frequency is hindered by the applied B1
irradiation power. Optimisation of the RF power for each application is critical in
order to avoid excessive masking of the exchange processes occurring close to the
water resonance frequency.
In another context, intense and prolonged saturation RF pulses can easily lead to
SAR depositions above the regulated safe levels, which may constrain the detection
sensitivity for fast exchangeable protons in the clinical setup. Additionally, the solid-
state RF amplifiers in clinical MRI systems tend to have a low duty cycle limit,
reducing even further the saturation efficiency in fast exchanging protons.
1.4.2. Field strength B0
The chemical shift between two hydrogen moieties is linearly proportional to the
strength of the magnetic field B0. On the other hand, DS effect is dependent on the
intensity of the applied saturation RF pulse B1, but not on the strength of B0. This
implies that at high field the observed CEST peaks can be better resolved due to the
larger separation and the lower attenuation from DS. Additionally, the strength of
B0 field will alter the relation between the chemical shift and the protons exchange
rate, leading to a better or worse regime for CEST (𝑘 ∼ Δ𝜔). In this sense, CEST
imaging of fast exchanging protons is more efficient at high fields.
1.4.3. Solute concentration
In order to observe the CEST effect, the concentration of the exchangeable protons
needs to be sufficiently high. At the current stage of technology and for the naturally
occurring endogenous CEST protons, the sensitivity threshold is in the milli-molar
range for in vivo applications.
1.4.4. Relaxation times
Both longitudinal and transverse relaxation times are crucial parameters. In par-
ticular the water T1 relaxation time controls the extent of signal reduction from a
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given CEST process, with longer T1 resulting in larger CEST signals. Direct satura-
tion is strongly modulated by the transverse relaxation T2, which results in blurring
of the CEST peaks around water at short T2. On the exchangeable molecule side,
longer T2 values are associated with narrow absorption bandwidth which can pro-
duce sharper and deeper CEST peaks if the chemical exchange rate is in the slow to
intermediate regime (𝑘 ≲Δ𝜔).
1.4.5. Exchange rate
As explained in the previous section CEST works best in the intermediate exchange
regime. Deviations from the optimum chemical exchange reduces the effect of
CEST.
Figure 1.4.1.: Exchange rate of the main CEST sensitive functional
groups. Data obtained from van Zijl et al20
.
For hydroxyl groups in sugars for instance, the exchange rate typically falls be-
tween 1000 to 10000 Hertz, and their chemical shift (from water) is around 1 to 3
ppm, which in a 9.4 Tesla scanner corresponds to 400 to 1200 Hertz. This suggests
that the hydroxyl groups are generally in a regime faster than optimal for CEST and
as such a decrease of the exchange rate would likely yield to the enhancement of the
CEST contrast.
Proton exchange rate 𝑘 is greatly influenced by the molecular structure in which
they are located. Protons in complex structures like proteins generally have slow
exchange rates due to the protection factor of the highly folded structures.21,22 As
such, the exchange rate of hydrogen atoms in the backbone of the molecules are
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greatly reduced due to the restricted accessibility to the solvent compared to protons
on the surface.
Figure 1.4.2.: Exchange rate of side chain hydroxyl protons of acetyl-
threonine-OCH3 versus pH in aqueous solution. The different curves
represent measurements at 36°, 30°, 20°, 10°and 4°(from top to bottom
respectively). Figure reproduced from Liepinsh et al.23
Additionally, several environmental factors can alter the effective chemical ex-
change rate between protons, i.e temperature,24,25,23 pH,26,27,13 concentration of ex-
change catalysers such as phosphates, or viscosity of the solvent.28 Hydrogen ex-
change rate depends upon the pH and other exchange catalyst by the general rela-
tionship:
𝐾 = 𝑘𝑎×10−𝑝𝐻+𝑘𝑏×10𝑝𝐻−𝑝𝐾𝑤+𝑘0
where 𝑘𝑎 and 𝑘𝑏 are the acid- and base-catalysed rate constants respectively and 𝑘0
represents the combined contributions from the possible exchange catalysts. 𝑝𝐾𝑤
is the water auto-dissociation constant, which is approximately 14 at 25° C. The
relationships between exchange rate and pH of amide and amine groups found in
vivo have been reported in the literature12,27 as:
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𝐾𝑎𝑚𝑖𝑑𝑒𝑠 = 5.57×10𝑝𝐻−6.4
𝐾𝑎𝑚𝑖𝑛𝑒𝑠 = 10𝑝𝐻−4.5
The temperature dependency is implicit in the three catalyst constants 𝑘𝑎, 𝑘𝑏 and
𝑘0 which are governed by the by the Arrhenious equation displayed below:
𝑘𝑥 =𝐴𝑒−𝐸𝑎⁄𝑅𝑇
where 𝑅 is the universal gas constant (8.314×10−3𝑘𝐽/𝑚𝑜𝑙/𝐾), Ea is the acti-
vation energy (in kJ/mol) and A is a reaction dependent constant which includes
factors like the frequency of the molecular collisions and their orientation.
Figure 1.4.3.: Exchange rates of the side chain hydroxyl proton of acetyl-
theonine-OCH3 at 4°C in the presence of sodium phosphate at a total
concentration of 0, 5 and 10 mmolar (circles, square and squares respec-
tively). Phosphate is one of the most effective exchange catalyst at neutral
pH. Figure reproduced from Liepnsh et al.23
The pH dependency of the chemical exchange rate of amide protons has allowed
APT technique to become an effective non-invasive method to probe pH in vivo,
where a unit of pH drop typically reduces the exchange rate by 90%, making APT
contrast very sensitive to tissue local pH.29,30
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1.4.6. Saturation length
The saturation time is another parameter usually cited in CEST literature and it refers
to the duration of the saturation RF pulse. The most common approach in CEST is to
use long saturation times allowing multiple exchange cycles to occur and ensure the
spin system reaches a state of dynamic equilibrium between the magnetisation of the
exchanging pools. This state is referred to as ‘steady state saturation’ and ensures
maximal transfer of magnetisation. However, CEST is not a linear process and the
largest reduction in the water signals occurs at the beginning of the saturation pulse.
For this reason, a well design sequence with short saturation times (without reaching
steady state) can produce better contrast efficiency. This approach is very convenient
for the clinical setup as it can reduce acquisition time and SAR deposition. However,
it also complicates the analysis and quantification of the CEST results as the complex
dynamics of the exchange process are more difficult to interpret.
1.5. CEST data analysis
As a relatively new technique CEST lacks rigid standardised measures to quantity
the magnitude of the chemical exchange process. While post-processing methods
and new metrics are in constant development, currently the most common metric
to analyse CEST data is probably the magnetisation transfer ratio asymmetry or
𝑀𝑇𝑅𝑎𝑠𝑦𝑚 which is defined by the equation:
𝑀𝑇𝑅𝑎𝑠𝑦𝑚 = [𝑀(−Δ𝜔)−𝑀(+Δ𝜔]/Μ𝑟𝑒𝑓
where𝑀𝑟𝑒𝑓 is the signal of water at the reference offset (𝑀𝑟𝑒𝑓 =𝑀0 when an
image with no saturation is used as reference) and 𝑀(Δ𝜔) the water signal when
the saturation RF pulse is applied atΔ𝜔 offset from the water resonant frequency.
The contrast in the CEST image is then obtained by evaluating the𝑀𝑇𝑅𝑎𝑠𝑦𝑚
curve at a particular offset (or by integrating it for a range of frequencies). For in-
stance, APT contrast is generated by evaluating the 𝑀𝑇𝑅𝑎𝑠𝑦𝑚 at 3.5 ppm on a
pixel by pixel basis. Amine weighted contrast on the other hand would be produced
as the integration of the𝑀𝑇𝑅𝑎𝑠𝑦𝑚 around 2 ppm frequency offset from water.
The raw CEST data would generally require some pre-processing steps, which typ-
ically would involve sorting of the frequency offsets, correction of field inhomo-
geneities and normalisation of signal intensity.
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1.5.1. Data sorting and interpolation
The acquired images are sorted according to the frequency offsets used in the satura-
tion phase to form a Z-spectrum per pixel in the image. At this stage, the data would
be usually interpolated (and sometimes smoothed) in order to generate a denser fre-
quency resolution.
1.5.2. Field inhomogeneity corrections
Field inhomogeneities across the image slice produce variations of the water Larmor
frequency. In order to achieve reliable𝑀𝑇𝑅𝑎𝑠𝑦𝑚 curves, the water frequency has
to be accurately determined and corrected for every pixel in the image. To do so,
conventional field maps obtained by double echo phase images31 can be acquired or
alternatively the water saturation shift referencing (WASSR) method proposed by
Kim et al32 can also be used. This method uses pre-saturation pulses but applied at
very weak power (B1=∼ 0.1 𝜇T) and short length in order to saturate only water.
Thus the saturated water peak is used as the reference frequency for CEST which
is an absolute measure of the frequency shift, as opposed to phase maps, which
provide relative field shift from central frequency of water. However, both these
methods required the acquisition of additional images, which lengthens the CEST
protocol. These methods can be avoided by using the Z-Spectrum itself to correct
for B0 inhomogeneity. This approach is particularly efficient at high fields provided
that the Z-spectrum has enough frequency sampling and that the saturation power
is low enough (usually B1 < 2 𝜇 T) to give a sharp water peak.25,33 Additionally,
correction for B1 RF inhomogeneity is also possible but is not a common practice
as it requires CEST data at different saturation powers which considerably extends
the acquisition length.
1.5.3. Normalisation
The CEST data is then normalised to a reference value in order to define the CEST
metric and be able compare different data. However, the frequency offset for nor-
malisation is not fully standardised in the CEST field yet. The most commonly used
approach comes from the MT imaging modality in which an image with no applied
saturation is taken as the normalisation reference. In many studies this metric is
used to analyse APT data, however, as will be discussed in Chapter 3, normalisa-
tion at other frequency offsets (closer to the water resonant frequency) can be more
convenient in order to reduce effects derived from physiological noise.
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1.6. Current uses and developments in CEST
Since its presentation by Wolff and Balaban34 in 1990, CEST-MRI has gradually
increased in popularity, particularly for in vivo applications. This interest relies on
the fact that CEST can offer unique image contrast based on a signal that: a) is sen-
sitive to a number of physiological parameters, b) is sensitive to low concentration
of solutes and c) can be tuned to target specific sets of molecules. Due to its inher-
ent flexibility, CEST based methods are currently being explored in a wide range of
applications as an alternative source of useful information. Although the technique
is still not standardized for the use in the clinic, clinical trials are being conducted in
different areas of medicine. The following section will describe some of the reported
work on CEST with potential application for the clinical practice.
Probably one of the most known applications of CEST is the work on pH eval-
uation. Using amide proton transfer (APT), a CEST imaging technique where the
exchangeable sites are amide groups, researchers have reported imaging pH changes
in ischemia animal models.35,12 Using the samemethod, human studies on stroke pa-
tients have shown hypo-intense APT signal in areas affected by the insult.36
In the field of cancer research, APT-CEST has been reported to be able to dis-
tinguish between active malignant tumours and ischemic regions in the rat brain.3
Moreover, in another study presented by Zhou and co-workers it was demonstrated
that APT can discriminate between active glioma and necrotic tissue due to radio-
therapy. While structural imaging is widely used in the diagnosis of brain tumours,
it is considered to be inadequate for reliably distinguishing between treatment necro-
sis and tumour recurrence, because both lesion types display similar contrast. The
gold standard for differentiating between tumour recurrence and treatment necrosis
is currently biopsy, which is expensive and involves risks associated with surgery.37
In this context APT-CEST stands out as a promising method for the evaluation of
radiotherapy treatment response in oncology.38
Looking into CEST studies in which contrast is based on the hydroxyl protons, a
CEST modality named gagCEST focuses on the saturation of the glycosaminogly-
can chains in the knee to assess the condition of articular cartilage and has shown
promise as an early marker of osteoarthritis.39,40,41 The glycoCEST method, pre-
sented by van Zijl et al. in 2007,42 is another variation of CEST in which hydroxyl
groups in glycogen are saturated to create contrast. Researchers showed a reduc-
tion in glycoCEST signal following perfusion of glucagon in the liver, which corre-
sponds with the expected breakdown of glycogen. This type of study could help in
the screening of conditions like type 2 diabetes, insulin resistance or obesity.
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The last example of the use -OH groups is glucoCEST, which was recently pre-
sented by Walker-Samuel43 from our group. This method reports on the increased
glucose uptake in cancer tissue, making it a potential alternative to 18F-FDG-PET
with the advantage of being less costly and free from exposure to radioactive trac-
ers. This thesis is centred on the investigation of the glucoCEST technique in the
context of cancer, and specifically on its application in brain tumours, as a poten-
tial bio-marker of tumour growth. In the following chapters the concept and the
interpretation of glucoCEST contrast will be thoroughly discussed.
In a different context, the modality called paraCEST makes use of exogenous
paramagnetic agents (based on lanthanide ions) to obtain functional and molecu-
lar images. Specifically designed, these agents can be used to probe temperature,44
pH,45 specific proteins46 or enzymatic reactions.47 Because chemical shifts associ-
ated with paramagnetic agents are large (~50 ppm) compared to those observed in
diaCEST protons (~1-5 ppm) in vivo, undesired ‘signal contamination’ by endoge-
nous protons stops being an issue. This is a major asset of the modality as it allows
a more straight forward interpretation of the information present in paraCEST im-
ages.48,49
1.6.1. Developments in CEST pulse sequences
As a young MRI technique, the CEST field is very rapidly evolving. In this stage
of fast progress new pulse sequences are continuously being developed to over-
come the obstacles in specific research fields. Particularly, efforts are being made
to come up with CEST protocols that can untangle the different effects observed
in the Z-spectrum. In this sense, methods like LOVARS (Length and offset var-
ied saturation) by Xiaolei et al.,50 SAFARI (Saturation with Frequency Alternating
RF Irradiation) by Scheidegger et al.,51 or ZAPI (Z-spectroscopy using Alternating-
Phase Irradiation) by Närväinen et al.52 make use of multiple irradiation pulses and
symmetry considerations to separate contributions of MT and direct saturation (DS)
from CEST.While these methods provide a solution in certain applications, symme-
try considerations fail in the presence of aliphatic NOEs, which manifest at around
3.5 ppm from water. In the brain, where NOEs are particularly strong, alternative
methods are prone to provide more reliable results. For that matter, Zu et al.53,54
have developed a technique named CERT (Chemical Exchange Rotation Transfer),
that can distinguish CEST (APT) effects based on a dual measurement with dif-
ferent saturation schemes, which does not involve any asymmetry consideration.
However, the method requires twice the amount of data per offset frequency, which
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can lead to long protocols. A different approach that is gaining attention is FLEX
(Frequency Labeled Exchange). Developed by Yadav et al.,55 this method sepa-
rates signal contributors by studying the frequency domain of the exchange process.
Strictly speaking FLEX is not a CEST type of sequence, as it works by frequency
labelling the spins instead of saturating them, however it is included in the CEST
category, as it informs on the same exchange processes. Interestingly, FLEX has
been shown to be quite effective in the fast exchange regime, a region in which
most sequences start losing sensitivity.
New acquisition schemes and metrics can certainly be useful for different CEST
applications. Most of the analysis in this thesis, however, is based on the standard
‘saturation plus readout’ sequence and the commonly usedMTR asymmetry metric.
This approach, although it might not be able to properly separate different contribu-
tion in the Z-spectrum, is simple, efficient and can be relatively quick, depending
on the saturation length used. In the next chapter the specifics of the glucoCEST
method will be discussed.
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2. glucoCEST: imaging glucose
in tumours
Glucose plays a central role in biology. Almost all organisms, from bacteria to hu-
mans, use it as an energy and biomass source to sustain their metabolic demands. In
the human body, a single glucose molecule can provide up to 32 ATP molecules via
complete aerobic respiration, but it can also be transformed into several carbon scaf-
folds for biosynthetic reactions.1–3 Cancer cells avidly consume glucose in rates up
to 20 times faster than their healthy counterparts. The elevated glucose uptake en-
ables the cells to meet the energetic demands of fast cell proliferation and to produce
many intermediate biosynthetic precursors involved in biomass duplication.4,5
Upregulated glycolysis is arguably the single most common feature in nearly all
primary and metastatic cancers, a phenomenon known as the Warburg effect. Even
in well oxygenated conditions, cancer cells metabolise glucose via the lactate pro-
duction pathway, namely, aerobic glycolysis pathway.
The aberrant consumption of glucose by tumours has been widely exploited in the
diagnosis of cancer with the use of fluorodeoxyglucose positron emission tomogra-
phy (18F-FDG-PET) in nuclear medicine. Similarly, in glucoCEST MRI tumours
are studied by looking at the concentration of natural glucose in the tissue, which
can be detected via the chemical exchange of protons in hydroxyl groups.
In this Chapter the principles and rational behind the glucoCEST technique are
explained and a summary of the most recent developments in the field are presented.
The initial work on glucoCEST by our group6 is briefly described, highlighting the
main findings in the study. These will serve as the starting point for the discussion
of the following Chapters.
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2.1. Metabolism of Cancer
2.1.1. Introduction
In contrast to normal cells, which grow and divide under a tightly controlled bi-
ological supervision, cancer cells have the ability to elude the body’s regulatory
processes and as a result they multiply in an uncontrolled manner. This ability to
alter physiological pathways to their advantage is wired deep in the genetic code
of the cancer cells. Overall, these genetic mutations give rise to a wide range of
phenotypes, which makes both study and therapy of malignant neoplastic diseases
difficult.
2.1.2. Hallmarks of Cancer
In the year 2000 cancer researchers Douglas Hanahan and Robert Weinberg pub-
lished an article titled ’The Hallmarks of Cancer’ in which they described a list of
common traits characterising the transformation of normal cells to cancer (or ma-
lignant tumour) cells.4
Those hallmarks are: (1) self-sustained growth signals; (2) resistance to external
inhibitory growth signals to stop expansion; (3) resistance to their own programmed
cell death (apoptosis); (4) formation of new blood vessels around the tumour to sup-
ply nutrients (angiogenesis); (5) limitless replicative potential; and (6) local tissue
invasion and spread to distant sites (metastasis).
‘The Hallmarks of Cancer’ have been largely accepted by the clinical and research
community for the last decade, and have been used as guidelines to identify tumours,
becoming an important reference in the field of cancer research. Nevertheless, the
usefulness of those hallmarks has also been questioned. A notable comment in this
regard was published by Yuri Lazebnik in 2010 in Nature Reviews.7 In this article,
by comparing the characteristics of benign tumours to malignant cancerous cells,
the author argued that the true single hallmark of cancer is its metastatic ability.
Despite some critical voices, ’The Hallmarks of Cancer’remains the most cited
article in Cell.
In 2011 a revision of the original paper was published. Incorporating the knowledge
gained in the investigation of cancer over the past ten years, the authors compiled
an updated list of hallmarks. Following the impact of the original paper, the updated
manuscript has also become a key reference in the field, ranking the top cited article
since its publication.5
In addition to the original list, four new features were included which the authors
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classified under the following categories: ’enabling characteristics’ and ’emerging
hallmarks.’ The two enabling characteristics of cancer are: DNA instability and
Tumour-promoting inflammation. While these alone do not cause cancer, they assist
cell mutation from normal to oncogenic. The two emerging hallmarks are: Evasion
of the immune system andMetabolic reprogramming.
Metabolic reprogramming is understood as cancer cells’ ability to alter the syn-
thesis pathways to promote fast anabolic growth making extensive use of a range of
metabolites including fatty acids, glutamine and, in particular, glucose.
Unsure of whether the last characteristics are prevalent in all cancers, the authors
did not include them into the list of core hallmarks. Nonetheless, an increasing
number of studies acknowledge the deregulated metabolism as a ubiquitous aspect
of malignant tumours.3,8,9
In the following, the hallmark of Metabolic reprogramming of cancers will be
addressed in more depth, as it is the main characteristic which ultimately allows
glucoCEST contrast to be generated for its use in the diagnosis of cancer.
2.1.3. The Warburg effect
Towards the middle of the twentieth century Otto Warburg10 observed that tumour
cells favour the conversion of glucose into lactate as a means of energy production
instead of recurring to the much more efficient mitochondrial oxidation process.
This was odd as tumour cells need, in principle, more energy than the primitive
cells. Warburg’s opinion was that this respiratory defect, conversion of glucose into
lactate together with the cancellation of the citric acid cycle in the mitochondria, was
the most characteristic change of tumour cells. Ganapathy11 contains a beautiful de-
scription of the main differences in transport and metabolism between normal and
tumour cells. Although hypoxia in the tumoral tissue due to insufficient develop-
ment of microvasculature is sometimes referred to as a possible contributing factor
to mitochondrial malfunction, mitochondrial function is partially suppressed in most
tumours cells even in abundance of oxygen.11 Mitochondrial malfunction might be
due to an alteration in the tumoral mitochondria’s filamentation-defilamentation cy-
cle which reduces its affinity to ADP below pyruvate kinase isoenzyme’s affinity.12
Thus, in the competition for ADP between mitochondria and glycolysis the latter is
favoured.
Glycolytic transformation of glucose into lactate under normoxia conditions, a
process sometimes referred to as ‘aerobic glycolysis’, is accompanied by the release
of lactic acid to the extracellular compartment. Therefore ‘aerobic glycolysis’ in
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tumours drives extracellular pH (pHe) acidic.13 Some researchers believe that this
acidic environment promotes invasion and enhances metastasis, which offers cancer
a selective evolutionary advantage.14,15
Even though glycolysis yields only two ATP per molecule of glucose, tumours
obtain energy by enhancing the glycolysis rate to at least 25-fold higher than in
normal cells, more than compensating the glycolytic inefficiency. Obviously, this
high rate of glycolysis can not be reached with normal enzymatic levels. To get such
an extraordinary high rate of glucose conversion in ’aerobic glycolysis’ cancer cells
must coordinate glucose transport to the elevated glycolysis rate. Tumour cells must
activate not only glucose transporters but also genes encoding necessary glycolytic
enzymes to increase their expression to the required levels to enable the metabolism
of an amount of glucose 25 times higher than normal. Hence the term Metabolic
reprogramming.
Fast proliferation requires abundant energy as well as a constant supply of build-
ing blocks to enable the anabolism. As Otto Warburg himself noticed, respiration
process in tumours is small compared to their glucose consumption, but not small
relative to the respiration in normal tissues.16
During periods of rapid proliferation, many cell types ranging from microbes to
lymphocytes resort to ‘aerobic glycolysis’, which suggests that it may play a crucial
role in supporting cell growth.
Heiden et al.2,3 argue that the main function of ‘aerobic glycolysis’ is to sus-
tain high levels of glycolytic intermediates as the building blocks of the anabolic
reactions in cells. Alternative to the plain energetic considerations, this argument
provides an explanation for why increased glucose metabolism is chosen in prolif-
erating cells throughout nature.
2.2. Targeting metabolism
For over three decades, diagnosis in oncology has exploited the elevated glucose
uptake of tumours by using Positron Emission Tomography (PET) in combination
with 2-Deoxyglucose labeled with 18F radio-tracer. Based on the relative uptake of
tissues, 18F-FDG PET has enabled the distinction of areas of active tumour from
non-tumour or necrotic regions. Furthermore, 18F-FDG PET has been correlated
with tumour grade in a wide range of cancers; with an intense PET signal associated
to fast proliferating malignant cells.17–20
In the field of Nuclear Magnetic Resonance (NMR), spectroscopic techniques
have successfully identified and characterizedmostly primary brain tumors (gliomas)
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based on their increased anaerobic pathway (glycolysis) of glucose, by measuring
increases in lactate and choline concentrations together with a reduction of N-acetyl
aspartate (NAA) in cancerous areas. Again, these NMR profiles correlate with
gliomas grades, displaying high choline and lactate levels in the most common and
aggressive Grade IV gliomas, also known as Glioblastoma Multiforme (GBM).21,22
In this context glucoCEST shows up as a novel potentially promising technique
for the study of tumours by exploiting their aberrant metabolism.
It is worth pointing out that as a direct consequence of the elevated glycolysis,
increased lactate is produced. This excess of lactate is secreted from the cell, which
in turn, creates an acidic environment in the extracellular space (ECS). In this context
cancer cells present an unusual situation in which extracellular pH becomes more
acidic than the intracellular one. This anomaly, sometime referred to as ”reverse
pH gradient”, could also play an important role in CEST based experiments, as the
exchange rate is greatly influenced by the pH of the tissue. In this sense, image
contrast could be enhanced based on the local pH variances around tumours.
Furthermore, because the pH control mechanisms are largely dysregulated in tu-
mours, it is in principle possible to influence on the local pH of the cancerous tissue
using biological buffers, like sodium bicarbonate (baking soda).8,15 Dysregulation
of pH is a process which occurs in early stages of cancers to promote cell invasion.8
Combination of the exquisite pH sensitivity of CEST and the possibility of altering
local pH in tumours can lead to a new CEST-MRI modality that could prove useful
for early detection of cancer (see section 7.4 ).
2.3. glucoCEST: the concept
CEST is extremely sensitive to a number of chemical species andmetabolites present
in the body. All these species exchange magnetisation simultaneously resulting in
a combined effect that produces a complex Z-spectrum. Moreover, in vivo trans-
verse relaxation times are shorter than in aqueous solutions, which leads to broader
absorption bandwidths of the solutes and to overlapping resonant frequencies. Ac-
curate deconvolution of the Z-spectrum into its individual contributors is therefore
very difficult and a major area of research in the CEST field. Owing to these limi-
tations, exact quantification of glucose content in tissues is unrealistic at present.
The approach in glucoCEST however, is not to measure the intrinsic glucose con-
tent of tissues but rather the concentration increase following an external adminis-
tration of glucose. For that purpose, two CEST images are acquired, one before
and another after the dose of glucose. The final glucoCEST signal, namely, gluco-
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CEST enhancement (GCE), arises from the difference of the two images (see figure
2.3.1). In this way, a substantial increase of glucose following administration leads
to a strong glucoCEST signal, while no signal is observed in the absence of glucose
uptake.
Figure 2.3.1.: GlucoCEST concept diagram. Simulated Z-spectra of
three hydroxyl group resonances alongside the magnetization transfer ra-
tio asymmetry (MTRasym) before (left), and after (center) glucose admin-
istration. The signal from the hydroxyl groups resonating at 1.2, 2.1 and
2.9 ppm from water increases. The GCE is defined as the change in the
area under the MTRasym curve from baseline (right).
The approach taken in glucoCEST avoids many of the complications involved in
the interpretation of CEST data. The first pre-glucose image serves as a reference
from which changes can be measured, and therefore no deconvolution methods or
sophisticated multi-pool fittings are required in order to identify the source of the
signal. The method picks up regions of higher glucose concentration with relatively
little manipulation of the data. In this way, glucoCEST may allow the use of natural
sugar as a potential biomarker of metabolism. This makes it a very attractive and
readily applicable technique for a number of metabolic related disorders.
2.3.1. Advantages
Like all the CEST based methods, glucoCEST offers an enhanced sensitivity to la-
bile proton, glucose in this case, which allows in vivo and noninvasive imaging of
glucose distribution in tissues.
In vivo Z-spectra display complex profiles deriving from various independent
processes i.e spill-over, macromolecularMT, chemical exchange from amide, amines
and hydroxyl groups, aliphatic NOE, and distortions from B1 inhomogeneities. A
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major challenge in endogenous CEST is the lack of specificity to separate andweight
the individual contribution of each process that shape the Z-spectrum. While under
certain conditions, clever methods of data analysis can yield consistent values for
the in vivo concentration of labile protons, reliable quantification is still very prob-
lematic, particularly for those proton species resonating in a frequency range close
to water (~1ppm), as is the case of hydroxyls. Glucose administrated exogenously
alters the basal in vivo CEST profile, which allows easier determination of its spe-
cific contribution to the CEST signal by a subtraction of the baseline image acquired
prior to glucose administration.
2.3.2. Drawbacks
Currently themain limitation of glucoCEST is arguably its low SNR.As in fMRI, the
CEST contrast is generated from the difference of two quasi-identical CEST images.
Considering that these CEST images have a low signal to begin with (especially at
high saturation powers where effects of direct saturation are dominant), the final
glucoCEST image is prone to elevated noise. Hence, glucoCEST images tend to
compromise spatial resolution in favour of higher SNR.
Another hurdle associated with glucoCEST imaging arises from the potential
changes in the physiology during acquisition. As a biologically active compound,
administration of glucose can change the physiological conditions of the inspected
tissues. Altered blood flow, pH, oxygen and CO2 levels can lead to significant vari-
ations in the observed CEST profile. If not controlled, these changes can lead to
misreadings of the influence of glucose in the Z-spectrum and consequently to the
misinterpretation of the glucoCEST data.
Finally limitation on the applicable B1 power for saturation also diminishes the ef-
ficiency of glucoCEST in clinical applications. Intense and prolonged saturation RF
pulses can easily lead to SAR depositions above the regulated safe levels. This can
constrain the detection sensitivity for fast exchangeable protons in humans. Safety
considerations aside, even within the allowed SAR limits, modern clinical MRI sys-
tems have very strictly controlled B1 power levels and the use of solid-state RF
amplifiers inherently limits their duty cycle. These limitations do not always cor-
respond to technical reasons but to rather arbitrary decisions. Provided all safety
checks are passed, the scientific community should encourage the correction of ar-
bitrary constraints in order to obtain better CEST performing MRI scanners.
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2.4. glucoCEST: literature review
Over the last five years the number of studies involving CEST-MRI has largely ex-
panded due to its attractiveness for in-vivo imaging of important physiological traits.
GlucoCEST differs from endogenous CEST modalities in that it relies on the de-
tection of an exogenously administered CEST agent (or on its physiological effects).
As such the analysis of glucoCEST data becomes more straight forward, as the en-
dogenous CEST image serves as the control upon which new contrast is generated.
In the following, a brief review of the works published around the concept of
glucoCEST and the detection of glucose through chemical exchange is presented.
2.4.1. The Origins: glycoCEST
In 2007 van Zijl et al.23 published a seminal work demonstrating the feasibility of
in-vivo imaging of glycogen content in the mouse liver based on CEST-MRI. The
method, named glycoCEST, opened an opportunity to study glycogen metabolism
of any disorders with MRI.
By applying a second long RF pulse (3 𝜇𝑇 ) 1 ppm downfield from water (higher
frequency) proton in hydroxyl groups of glycogen saturate, producing a dip in the
Z-spectra as they exchange with the hydroxyls in water. While the principles in
glycoCEST are similar to other CEST methods, the publication set a precedent in
the CEST community as for the first time it was possible to image fast exchanging
-OH groups using a non-invasive technique.
The glycogen levels in the mouse liver were tracked in time by comparing CEST
images irradiated at opposite sides of the water spectrum (MTRasym(δ) = MTR(δ)
- MTR(−δ), with δ−1ppm), acquired with a [Saturation + Spin-Echo] sequence
design in a 4.7 Tesla field scanner. The progressive breakdown of glycogen was
sustained by constant infusion of glucagon and validated in parallel experiments by
13C MRS, the gold standard technique for non-invasive determination of glycogen
concentration in vivo. The CEST measurements showed a gradual reduction of the
MTRasym for a period of 2 hours from the moment of the infusion, after which the
MTRasym stabilised, which marked the glycogen depletion point. The time for de-
pletion of glycogen matched with the data found in 13C MRS.
The results were somewhat unexpected as the proton exchange rate between glyco-
gen and water hydroxyls was supposed to be too fast compared to the small chem-
ical shift (1 ppm) between the two species. While generally proton in -OH groups
exchange too rapidly for optimum CEST contrast (𝜅 > 𝛿), hydroxyls in glycogen
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Figure 2.4.1.: GlycoCEST imaging of a perfused fed-mouse liver at 4.7
T and 37° C. The first image (grey scale) marks the beginning of perfu-
sion (t = 0) with glucose-free media containing 500 pg/ml glucagon. The
liver tissue is darkened because of the CEST effect from pre-saturation
at 1.0 ppm for 1 s at 3.0 𝜇 T. Upon further perfusion with glucagon, the
liver signal increased, corresponding to a decrease in CEST effect. The
colorised glycoCEST images as a function of time during perfusion show
the relative CEST intensity [MTRasym (1 ppm)] of liver tissue as a function
of perfusion time. The colour scale shows that there are regions of liver
where the initial asymmetry difference between±1 ppm is as high as 55%
(orange pixels) and as low as 5% (blue pixels). With time, as glycogen
disappears, the CEST images become more uniformly dark blue, corre-
sponding to minimal glycogen. The corresponding glycogen depletion for
a homogeneous region of interest is quantified in the graph (n = 4). Figure
reproduced from van Zijl et al.23
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macromolecules are relatively slow (𝜅 < 1000𝐻𝑧) given their restricted mobility
and accessibility within the molecular structure.
Alternatively toMRI, a newly developed glycogen specific PET radioactive tracer
has been recently used to image aberrant glycogen metabolism in cancerous mice.24
While the sensitivity of the PET basedmodality exceeds the contrast achievable with
CEST-MRI, glycogen concentration in the liver (and its variation due to physiology)
is high enough for glycoCEST to detect it. Owing to the wide accessibility of MRI
scanners and the safety of the imagingmodality glycoCEST remains as an attractive,
purely non-invasive method of imaging liver glycogen in vivo.
Since this first study, researchers in different labs have studied ways of exploiting
the chemical exchange process to image biomolecules in the fast end of the inter-
mediate exchange regime. A notable example of this is the study of glucose and its
analogue sugars as CEST agents, fuelled by significant clinical interest due to their
central role in a number of conditions where metabolism is disrupted.
2.4.2. Cancer studies
Particularly for the field of cancer research, glucoCEST has the qualities to become
an ideal method to investigate the abnormally elevated glycolytic flux (Warburg ef-
fect) of proliferating tumours. Similar to the concept exploited in 18F-FDG-PET,
glucoCEST aims to differentiate healthy tissue from tumours based on their glucose
concentration, which may also inform on the metabolism and aggressiveness of the
tumour under study. Unlike 18F-FDG-PET, glucoCEST is free of the burdens asso-
ciated with the use of radio-tracers, i.e high production costs, limited accessibility
and the safety implications of radioactive exposure.
Currently three independent studies have been published on the use of natural
glucose as a CEST agent for the study of cancer in vivo: the work by Chan et al.25
from Johns Hopkins University, the work byWalker-Samuel et at.6 from our group at
University College London, and the study byRivlin et al.26 fromTelAvivUniversity.
The Johns Hopkins University group looked at the glucoCEST signal in two dif-
ferent human breast xenograft models (MDA-MB-231 and the less aggressiveMCF-
7 cell-lines), and compared the data with 18F-FDG-PET and Gd-DTPA contrast en-
hancedMRI scans, performed in the samemice cohort. Results of both tumour types
displayed elevated signal for glucoCEST and PETwith just partial Gd-enhancement.
Furthermore, among the three techniques explored only glucoCEST showed signif-
icant separation between cancer cell-lines, suggesting the possibility of the charac-
terisation of tumours based on their glucoCEST profile.
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Figure 2.4.2.: (a) 18F-FDG-PET/CT coronal view obtained one hour
after intravenous (i.v.) injection of 18F-FDG showing accumulation in
both tumors. (b) GlucoCEST Δ MTRasym map (Infusion – Pre-infusion).
(c) 𝑇1-weighted difference image (Injection – pre-injection) showing Gd-
enhanced regions, mainly in the edges of tumours. (d–f) Comparison of
signal intensities (n = 5) for the three modalities using ROIs comprising
the two tumours. Even though some trends appear visible for PET and
contrast-enhanced MRI, significant differences (p<0.05; paired student’s
t-test) between the tumours could be detected only in glucoCEST. (g) Bar
graph showing average glucoCEST contrast for MDA-MB-231 andMCF-
7 tumors. Figure reproduced from Chan et al.25
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Interestingly, the glucoCEST signal was found to be consistently lower in the
more aggressive phenotype tumours. These results, together with the idea that once
inside the cell glucose rapidly converts into lactate, and the fact that acidic extra-
cellular pH in tumours is likely to provide a more favourable exchange rate for the
detection of hydroxyl groups in glucose, led researchers to conclude that glucoCEST
does not directly inform on the metabolism but mainly on the interstitial glucose lev-
els.
Nonetheless, the debate of the precise source of the glucoCEST signal was far
from settled.
In the study presented by our group,6 glucoCEST technique was compared to 18F-
FDG autoradiography in twomouse models of colorectal tumour (cell lines SW1222
and LS174T) with distinct metabolic characteristics. Animals were scanned with
glucoCEST pre- and post-administration of glucose (1g/kg intra-peritoneal [IP] bo-
lus to provide a more sustained glucose delivery than intra-vascular [IV] bolus) and
24 hours later 18F-FDG autoradiography experiments were performed on the same
animal cohort. The study also included parallel Gd-enchancement MRI, carbon 13
spectroscopic analysis (using uniformly-labelled 13C glucose) aimed to track the
metabolic path of glucose in the tumours, as well as perfusion and hypoxia fluores-
cence microscopy images (using Hoechst 33342 and pimonidazole staining, respec-
tively).
In agreement with the study by Chan et al, results showed that glucoCEST is
sensitive to tumour glucose uptake and can distinguish tumour types with differing
metabolism and pathophysiologies.
13C MRS showed ratios of glucose 6-phosphate (G6P) to the glucose concentra-
tion were found to be close to 40% in both tumours (42% and 38% in SW1222 and
LS174T, respectively). In addition, glucose was observed to be metabolised into
lactate and a number of amino-acids, such as glutamine, glutamate, taurine and ala-
nine. In vitro assessment of the CEST properties of the glycolytic intermediates and
amino-acids found in the tumours suggests that intracellular stages of glycolysis can
be detected by glucoCEST, with G6P giving an approximately equal CEST contrast
as glucose.
Provided that the metabolic activity of cancer cells increases in response to a
sudden rise in glucose availability, it is expected that the glycolytic intermediates
and amino-acids from fast catabolism of glucose will contribute to the observed
glucoCEST signal.
The lack of correlation between either FDG or glucoCEST signal and perfusion
(measured with Hoechst 33342 staining and Gd-DTPA) indicates that the measured
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Figure 2.4.3.: The fluorescence microscopy images show perfused (blue)
and hypoxic (green) regions corresponding to Hoechst 33342 and pi-
monidazole staining, respectively. All CEST data in this figure were ac-
quired using the GE-CEST sequence. Figure reproduced from Walker-
Samuel et al.6
glucoCEST contrast is not limited to the vascular delivery of glucose. In fact, based
on the observed correlation between FDG and glucoCEST signal and the elevated
presence of glucose intermediates found inside the cells, the researchers argued that
a significant contribution to the glucoCEST contrast can be attributed to the intra-
cellular compartment.
In the third work published on glucoCEST in cancer, the team from Tel Aviv
University used glucose analogue molecules 2-deoxyglucose (2DG) and 2-fluoro-
deoxyglucose (FDG, non-radioactive stable isotope 19F) to study the glucoCEST re-
sponse of a poorly differentiated mammary adenocarcinoma mouse model (cell line
DA3-D1-DMBA-3). Both glucose analogues are taken into the cells by the GLUT
transporters and phosphorylated by hexokinase, after which the catabolic process
cannot continue. The molecules accumulate inside the cells until they are slowly
cleared through dephosphorylation of 2-deoxyglucose-6-phosphate (2DG6P), or though
isomerisation to 2-deoxyglucose-1-phosphate (2DG1) to form glycogen.27,28
Unlike natural glucose which quicklymetabolises, the glucoCEST signal from the
analogue molecules build up in the tumours over 2 hours after the IP administration
of FDG/2DG. This results in an increased and long lasting CEST contrast. However,
toxic effects of FDG and 2DG limit their use in clinical studies, where tolerated dose
has been shown to be around 60 mg/kg/day IV (or 250 mg/kg orally), an order of
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Figure 2.4.4.: (a) Example 1H-decoupled 13C NMR spectra from
SW1222 and LS174T tumours that were administered [U-13C]glucose fol-
lowing the protocol used in the glucoCEST experiments. The peak assign-
ments are as follows: 1, lactate C2; 2, glutamate C2; 3, glutamine C2;
4, alanine C2; 5, taurine C1; 6, taurine C2; 7, glutamate C4; 8, lactate
C3; and 9, alanine C3. An expansion of the C1𝛼 multiplet is shown that
corresponds to doublets from glucose and glucose-6-phosphate (chemi-
cally shifted by 0.13 ppm from the glucose doublet). Fitted Lorentzian
peaks are overlaid. (b) z and MTRasym spectra from glucose, glucose 6-
phosphate, fructose 6-phosphate and fructose 6,1-biphosphate. In vitro,
glucose and glucose-6-phosphate show similar CEST effects, whereas
fructose-6-phosphate and fructose 6,1-biphosphate display a smaller ef-
fect. Units on the vertical axis are signal intensity, S, normalised to a
reference measurement, S0, at 200 p.p.m. from the peak of the water res-
onance. (c) z and MTRasym spectra from glucose, lactate, glutamine, glu-
tamate, alanine and taurine. Glucose shows a strong CEST effect from
hydroxyl proton exchange, whereas the amino acids show a CEST effect
through amide proton exchange. Lactate shows a minimal effect. Figure
reproduced from Walker-Samuel et al.6
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magnitude below the dosage tested in the study.26
In a recent publication29 the team in Tel Aviv have reported the use of the non-
toxic glucose analogue 3-O-methyl-D-glucose (3OMG) as an alternative glucoCEST
agent. Once inside the cell 3OMG does not undergo phosphorylation by hexokinase
and can readily return to the blood stream (through the GLUT transporters) which
consequently is fully excreted by the kidneys.
Tested on the same cancer model as in the previous study, the researchers observed
an intense glucoCEST signal which slowly faded, retaining 70% of the maximum
contrast 1 hour after the IP injection.
While further tolerance tests are needed to assess safety dosage of the compound in
humans, initial data suggest that 3OMG can be potentially useful for the detection
of tumours and monitoring of treatment in the clinic.
2.4.3. Brain studies
Focusing on the field of neuroimaging, where traditionally MRI excels, two pub-
lished works on glucoCEST exploring the metabolism of the healthy brain can be
found.
In the first one Nasrallah et al.30 presents a thorough study of the evolution of the
glucoCEST signal in the rat brain under different conditions.
The study shows a significantly elevated glucoCEST signal following the adminis-
tration of both 2DG and natural D-glucose. Similarly to the results in other studies,
signal from 2DG was shown to be nearly twice as intense and longer lasting than
from natural D-glucose. Even with a sustained high blood D-glucose (via IV infu-
sion), signal did not reach levels observed with 2DG, which points to the accumula-
tion of 2DG6P inside the cell (rather than to the extracellular glucose concentration)
as an important contributor to the glucoCEST contrast. This observation agrees
with the similar changes observed in 2DG6P levels measured by in vivo 31P NMR,
suggesting that glucoCEST reflects the rate of glucose assimilation.
Importantly, a dramatic attenuation of signal was observed when high levels of
anaesthesia (2% isoflurane) were used, further supporting a link between gluco-
CEST contrast and the metabolic state of the brain.
Moreover, contribution from the intravascular compartment was ruled out by two
independent experiments. First, no change in glucoCEST signal was measured with
increased cerebral blood flow (CBF) under hypercapmic conditions (achieved with
1.8% CO2 in the gas mixture, which doubled basal CBF). Second, administration of
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Figure 2.4.5.: CEST MRI kinetic measurements in the tumour at different
times following injection of 3OMG, 1.5 g/kg (𝐵1 = 2.5𝜇𝑇 ,𝐵0 = 7𝑇 ). a:
A 𝑇2-weighted image before the administration of the agent. b: A CEST
image before the administration of the agent. c: A CEST image 9 min after
the injection. The marked ROI was used for the CEST calculation. d: The
time series of the %CEST for the five mice tested. Figure reproduced from
Rivlin et al.29
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L-glucose*, which does not leave the vascular compartment in the brain, produced
no glucoCEST signal.
These results let the research team conclude that glucoCEST provides a widely
availableMRImethod to image uptake and metabolism of glucose/2DG in the brain.
2.4.4. Alternative Techniques for glucose detection
The second MRI study exploring glucose uptake in the brain was published by Tao
Jin et al.32 in 2014 which strictly speaking is not a work based on CEST but on
CESL, i.e. Chemical Exchange Spin-Lock. Recently Spin-Lock sequences have
been proposed as alternative and more sensitive approach for the detection of fast
exchanging protons, like the hydroxyls in glucose. The technique relies on the mea-
surement of 𝑇1𝜌 (the spin-lattice relaxation time in the rotating frame) which as in
CEST, ultimately depends on the concentration of exchangeable pool.
Using an on-resonance spin-lock technique (spin-lock at the water Larmor’s fre-
quency) Jin et al. measured a linear glucoCESL response to the glucose dose in the
rat brain. Similar to what was reported in the study by Nasrallah et al.30 the sig-
nal measured following administration of 2DG was more intense (~2.2 times) and
prolonged in time than with natural glucose, which is consistent with the different
metabolic characteristics previously discussed.
Compared to glucoCEST technique, advantages of on-resonance glucoCESL in-
clude: a) enhanced detection sensitivity for fast exchange regimes (𝜅/𝛿 > 1), which
has been numerically demonstrated using two-pool model Bloch McConnell equa-
tions,32 b) high temporal resolution, as the duration of the spin-locking irradiation is
shorter (on the order of 𝑇1𝜌 as opposed to 𝑇1 in CEST), and c) inherent robustness
for B0 inhomogeneities with no asymmetry analysis required.
Importantly, the sensitivity enhancement of glucoCESL is expected to be higher
at low B0 field as the ratio between the exchange rate and the chemical shift (𝜅/𝛿)
is increased due to the smaller chemical shift. This makes on-resonance spin-lock
particularly interesting for clinical systems.
𝑇1𝜌 is modulated by all the simultaneously occurring chemical exchange pro-
cesses, and therefore the signal measured with on-resonance spin-lock lacks speci-
ficity to any particular type of labile proton. While in vivo studies have shown 𝑇1𝜌
to be fairly insensitive to vascular oxygenation,33 changes in vascular volume and
*L-glucose is the enantiomer (L-isomer) of the naturally occurring D-glucose. In vitro, it dis-
plays the same CEST signature as D-glucose. In vivo however, the Levo chirality prevents it from
binding to the GLUT transporter (nor it servers as substrate for glycolytic enzymes) and therefore its
permeability across the BBB is limited.31
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Figure 2.4.6.: A) Time series of glucoCEST images of rat brain under con-
stant infusion of D-glucose (top), after bolus injection of 1 g/kg D-glucose
(middle), and after bolus injection of 1 g/kg L-glucose (bottom). The im-
age intensity represents relative glucoCEST signal change from the base-
line. (B) Time courses of glucoCEST signal under the above three injec-
tion conditions in (A). The signal represents the difference of MTRasym in-
tegral around 1.0 p.p.m. from the baseline signal. (C) Arterial blood glu-
cose with constant infusion (blue) and bolus injection (red) of D-glucose.
Figure reproduced from Nasrallah et al.30
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Figure 2.4.7.: Rat-brain glucoCESL studies at 9.4T showing near-
linear contrast for intravenously administered D-glucose (Glc) doses of
0.25, 0.5, and 1.0g/kg, and robust detection for doses 0.25g/kg (in vivo
paradigm 1). (A) The t-maps for each dose for two of the animals show
highest t-values in the cortex where surface coil sensitivity is higher.
Colour scale: t-value. (B) Average of time courses for all animals (n=5,
mean±s.e.m.) clearly shows the increase in brain Δ R1𝜌 with Glc dose.
Arrows indicate time of injection. (C) The nearly linear dependence of
peak brainΔ R1𝜌 on Glc dose appears for each individual animal. CESL,
chemical exchange-sensitive spin lock. Figure reproduced from Jin et al.32
CBF are known to cause variations in 𝑇1𝜌.34,35 Therefore, in glucoCESL measure-
ments of the contribution of glucose (and its derivatives) has to be carefully weighted
against possible changes in tissue vasculature.
Although no journal publications have been documented exploring the possibil-
ities of glucoCEST for the study of brain tumors, studies from the research groups
at Johns Hopkins University and University College London have already been pre-
sented in various scientific conferences.
These ongoing studies aim to provide insight into relevant metabolic aspects of
brain tumours as well as exploring the possibility of using natural glucose for the
detection, characterisation of tumour aggressiveness and even for the monitoring of
therapy based on their glucoCEST response.
As seen in this review CEST and CESL have been shown to be promising MRI
techniques to investigate glucose uptake and metabolism in vivo, yet a more con-
ventional method has recently been proposed as a measure of glucose concentration.
Acknowledging the effect that chemical exchange processes have in the relaxation
times of water, Yadav et al.36 from Johns Hopkins University reported the in vivo
detection of changes in glucose concentration by measuring the spin-spin relaxation
constant 𝑇2.
Using standard 𝑇2-weighted images, researchers demonstrated the generation of
contrast in mouse kidneys arising at the time of a glucose infusion (a bolus of 0.15
mL of 0.5 M glucose solution). The contrast in the kidneys lasted just over a minute,
after which it returned to initial levels, within 2 minutes after the infusion.
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Figure 2.4.8.: Transverse relaxation data from a dynamic in vivo glucose
infusion experiment on a mouse. 𝑇2 weighted images of mouse kidneys
from the time of a glucose bolus infusion are displayed (time indicated
below each image). a: Effects in all regions displayed. b: Only kidney
signal displayed in colour on grayscale image to highlight effects. After
infusion, the signal in the kidneys drops by approximately 10% and then
recovers over the course of 50-100 s. Figure reproduced from Yadav et
al.36
Two of the greatest advantages of this technique is its simplicity (T2 relaxome-
try sequences are readily available on all the standard MRI systems) and the high
temporal resolution, which allows for statistical averaging of the signal in order to
boost the effective sensitivity.
However, 𝑇1𝜌 and 𝑇2 based methods become less sensitive in tissues with high
intrinsic𝑅20 (exchange independent spin-spin relaxation constant). In practice, this
might become a sensitivity limiting factor as very accurate measurements of the re-
spective relaxation times are required. See Section 4.6 for a more thorough discus-
sion on the subject.
2.5. glucoCEST: good practices
2.5.1. Drift of the main magnetic field B0
Correction for potential shifts of the water resonant frequency (B0 drifts) over the
course of the experiments are essential for reliable asymmetry analysis and mean-
ingful subtractions of the initial baseline image. Therefore special attention has to
be given to making sure every CEST image acquired during the experiment can be
adequately corrected. This can be done using different methods:
In a preclinical set-up, high field strengths produce sharp Z-spectra. Moreover,
less stringent time constraints in animal studies allows for a denser packing of the
off-resonant frequencies in the Z-spectrum. In this situation, correction of B0 inho-
mogeneities can be successfully achieved by simply interpolating the experimental
68
2.5. glucoCEST: good practices
Z-spectra (typically with a non-parametric algorithm, such as smoothing spline or
cubic interpolating spline) and repositioning the water frequency to the position of
the minimum intensity (where water is fully saturated). By doing so in a pixel basis
a map of the B0 shift is obtained which tells howmuch each pixel needs to be shifted
(in the frequency dimension) before proceeding with the asymmetry analysis.
Alternatively, one can obtain B0 maps parallel to the CEST acquisitions (using
the WASRR37 method or by a standard double TE technique) from which to correct
for B0 irregularities in the image slab.
This last approach is predominant in clinical systems where due to lower field and
shorter scan times, the Z-Spectra tend to be less defined around the water peak.
If the chosen method for B0 correction is to acquire an independent B0 map,
multiple instances of it should be run in order to track the evolution of B0 in time.
2.5.2. Timing of symmetrical offsets
It is important to avoid time delays between off-set frequencies downfield and up-
field from water. During the relatively long acquisition time of a full Z-spectrum
dataset, perceptible changes in the tissue glucose concentrations and drifts in field
homogeneity may occur. A good practise to minimise the impact of these varia-
tions in the asymmetry analysis is to sample the offset frequencies in an alternating
pattern, swapping from downfield to upfield frequencies centred at the water reso-
nance. In this way symmetrical offset data-points are acquired with the minimum
time gap between them.
2.5.3. Selection of the appropriate B1 and integration
range
Choosing the appropriate saturation parameters thatmaximise the CEST signal is not
a trivial matter. Generally, fast exchanging hydrogens (as in glucose) are expected
to produce higher CEST contrast when saturated with elevated RF power, whereas
slower exchanging molecules (like amide groups) need less power. However, the
signal to noise ratio is also affected at high B1 levels. Intense spillover effect widens
the Lorentzian absorption profile reducing the observable signal and resulting in
lower SNR close to water (see section 3.11 in Chapter 3).
Moreover, strong spillover effects shift the MTR asymmetry profile away from
water (see 3.12.1). Hence, the optimum range of offset frequencies that contain
the CEST information also depends on the applied saturation power. Precise op-
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timisation of the saturation power will depend on the characteristics of the tissue
inspected.
Figure 2.5.1.: Optimum combination of parameters (ΔΩ, Β1) for a range
of T2 values, which results in the maximum sensitivity of glucoCEST at
3T (left) and 9.4T (right). For a given set of coordinates, the colour-map
represents the required CNR (measured as the MTRasym/SEM) in order
to differentiate an increase of 10 mMolar glucose concentration with 95%
confidence interval.
Here a guide for the selection of parameters (ΔΩ,Β1) that maximise the sensi-
tivity of glucoCEST in tumours is presented. The results are based on a theoretical
glucoCEST experiment (simulated with the code introduced in Chapter 3), in which
glucose concentration was increased from 5 mMolar baseline to 15 mMolar. The
model parameters were previously fitted to in vivo and phantom data (see figures
3.6.1 and 3.7.1 in Chapter 3).
Normally distributed raw noise was introduced in the simulations from which
the mean glucoCEST signal (GCE) and its standard error (SE) were estimated for a
range of parameter values relevant to tumour physiology. Based on the combination
of parameter values which maximise GCE/SE, maps of the highest glucoCEST sen-
sitivity were defined for 3T and 9.4T field strengths. From these maps the required
contrast to noise ratio (CNR) for differentiation (CI=95%) of 10 mMolar glucose
increase was calculated.
Transverse relaxation of water, B1 saturation power and integration range were
found to alter particularly the measured GCE signal and therefore variations of these
3 variables were explored. Tissue pH has also a substantial impact on the GCE out-
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come (by changing the exchange rate) however pH was kept constant in the simula-
tions (at pH=7.1). This is probably an acceptable assumption provided a relatively
stable intracellular values across tumours38 and the fact that the intracellular space
accounts for ∼80% of the voxel volume.39
These maps should be taken as indicative values from where to start optimising a
protocol. For example, if we were to try a glucoCEST sequence on a tumour with T2
of 160 ms at 3 Tesla, and we were using an equivalent B1 saturation power of 2.7𝜇T,
then the map tells us that we should be looking around the 2.5 ppm range in order
to obtain best CEST sensitivity. It also estimates that we would need around 1500
CNR units to detect an increase of 10 mMolar glucose in the tissue (with 95% CI).
These estimations match well with the experimental data performed on phantoms.
Figure 2.5.2 shows maximum MTR asymmetry around 2.4 ppm for at B1 power of
2.3𝜇𝑇 . (Sample T2=95±7ms and pH=7.1±0.1).
These values can help in designing the imaging protocol (i.e. voxel size, number
of averages) in order to meet the estimated requirements.
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Figure 2.5.2.: Phantom experiment (0, 10, 20 and 40 mM glucose solu-
tions in 3%Agar and 0.07mMGd providing tissue like T1 and T2 at pH 7.1)
showing maximum MTR asymmetry at Δ𝜔 ≈ 2.4𝑝𝑝𝑚 with 𝐵1 = 2.3𝜇𝑇
in 3T Philips Achieva system. The results match the simulated data shown
in figure 2.5.1
.
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2.6. glucoCEST: open questions
The work presented by our team6 is tangible proof of the use of glucoCEST for the
study of cancer in vivo. The study showed both glucoCEST and 18F-FDG auto-
radiography imaging methods to offer equivalent information.
Figure 2.6.1.: Comparison of glucoCEST with 18F-FDG
Left: glucoCEST and 18F-FDG autoradiography provide equivalent information on areas
of tumour activity for both type of tumours. Right: The more aggressive phenotype of the
SW1222 model is distinguishable using either of the methods (p<0.05).
Aside from the physical principles of both imaging modalities, there is an impor-
tant difference between the glucoCEST and PET methods which lies in the marker-
molecule used. While 18F-FDG (used in PET) is an analogue of glucose that cannot
be metabolised, glucoCEST uses naturally occurring sugar that is free to go through
all the steps of the metabolic chain. Hence glucose absorbed by the cells does not
necessarily build up, as is the case for 18F-FDG. This fundamental metabolic dif-
ference raises the question of whether the glucoCEST signal originates from sugars
inside or outside the cells. Part of this work focused on the investigation of possible
sources for the observed glucoCEST signal.
To date, there is no consensus among researchers on whether the glucoCEST sig-
nal originates from glucose only, or if other sugars along glycolytic pathway con-
tribute to it as well. If glucoCEST was only sensitive to glucose, it is reasonable to
think it would predominately reflect on the blood perfusion in the tissues. On the
other hand, an intracellular origin of glucoCEST could open an exciting possibility
to study the kinetics of cancer metabolism with MRI.
To shed some light on this topic, phantom experiments were performed aiming
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to examine the CEST signal response of the first four molecules in the glycolytic
pathway, at conditions similar to the expected ones in vivo. The content of this work
is presented in Chapter 4.
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3. Computer model based
optimisation of CEST-MRI
3.1. Abstract
In this chapter the mathematical description of the CEST mechanism is laid out
which allows the construction of complex chemical exchange models. Using these
models the outcomes of different hypothetical CEST experiments will be explored
in search of the optimum combination of parameters to enhance the CEST contrast.
Computer simulations can provide an intuitive understanding of the CEST signal
expected under certain situations by providing compelling visual feedback of rele-
vant parameters evolving under complex dynamical processes in a way that is easy to
familiarise with. As well as their instructive value, these mathematical models also
provide an excellent tool for the optimisation of experimental parameters and the de-
sign of CEST sequences for different applications. In this context, the final design
of a CEST protocol is the result of an iterative feedback between the experimental
tests and the computer modelled based optimisations. Pulse sequence parameters
such as the needed RF power or the optimum saturation time can be approximated
using simulations. Moreover, effects due to tissue specific characteristics like the
pH, macro-molecule content or different relaxation times can also be incorporated
in the models and reasonable estimates about the outcome obtained for a number of
experimental situations.
All the simulations shown in this chapter are based on multi-pool exchange mod-
els constructed with the concepts described below. As part of the work in this thesis
the completed models used are provided in Matlab code form, which can be found
in the appendices E and F.
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3.2. Mathematical description of CEST:
Consider a frame of reference rotating at frequency 𝜔𝑅𝐹 around the z axis. Assum-
ing a static magnetic field 𝐵0 acting along the z direction and a constant RF pulse
applied in the x direction of the rotating frame, the Bloch equations of a set of spins
can be written as:
𝑑𝑀𝑥 (𝑡)
𝑑𝑡 = Δ𝜔𝑀𝑦 (𝑡)−𝑅2𝑀𝑥 (𝑡)
𝑑𝑀𝑦(𝑡)
𝑑𝑡 = −Δ𝜔𝑀𝑥(𝑡)−𝑅2𝑀𝑦+𝜔1𝑀𝑧 (𝑡) (3.2.1)
𝑑𝑀𝑧(𝑡)
𝑑𝑡 = −𝜔1𝑀𝑦(𝑡)−𝑅1 (𝑀𝑧 (𝑡)−𝑀0)
Where 𝜔1 = 𝛾𝐵1 represents the rotation speed of M(t) around the y axis due to
the RF irradiation, Δ𝜔 = 𝜔𝑅𝐹 −𝜔0 is the offset frequency of the RF pulse with
respect to the Larmor frequency 𝜔0 and 𝑅1 = 1/𝑇1 and 𝑅2 = 1/𝑇2 denote the
inverse of the longitudinal and transverse relaxation rates, respectively. Please refer
to Appendix A for the derivation of the Bloch equations.
In matrix form these equations can be rewritten as:
𝑑M
𝑑𝑡 = A ⋅M+B (3.2.2)
With M = [𝑀𝑥 (𝑡) , 𝑀𝑦 (𝑡) , 𝑀𝑧 (𝑡)]𝑇 ; B = (0, 0, 𝑅1𝑀0)𝑇 where 𝑇 denotes
the transposed matrix, and
A=⎛⎜⎜⎜
⎝
−𝑅2 Δ𝜔 0
−Δ𝜔 −𝑅2 𝜔1
0 −𝜔1 −𝑅1
⎞⎟⎟⎟
⎠
(3.2.3)
Another pool of spins, resonating at a slightly different frequency 𝜔𝑐0 = 𝑆𝛾𝐵0
due to a chemical shift 𝑆, would be described in a similar way as:
𝑑Mc
𝑑𝑡 = A
c ⋅Mc (3.2.4)
In this case, thematrix components𝑀𝑐𝑥 (𝑡) , 𝑀𝑐𝑦 (𝑡) , 𝑀𝑐𝑧 (𝑡),𝑅𝑐2,𝑅𝑐1,𝑀𝑐0 andΔ𝜔𝑐=
𝜔𝑅𝐹 −𝜔𝑐0 refer to the properties of the second pool c.
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In order to model the chemical exchange process, another relationship is imposed
between the two pools.
𝐸𝑥𝑐ℎ𝑎𝑛𝑔𝑒
⎧{
⎨{⎩
𝑑Ma
𝑑𝑡 = 𝑘𝑐M𝑐−𝑘𝑎M𝑎
𝑑Mc
𝑑𝑡 = 𝑘𝑎M𝑎−𝑘𝑐M𝑐
(3.2.5)
These relationships describe the influence of the exchange process on the magneti-
sation vector of each pool. Here 𝑘𝑐 represents the exchange rate from pool c to pool
a, and 𝑘𝑎 the rate from pool a to pool c. As substrate concentrations do not change in
time, these exchange rates are restricted to the mass balance between the two pools,
which imposes that 𝑘𝑎𝑀𝑎0 = 𝑘𝑐𝑀𝑐0 .
Therefore, the full dynamics of each pool including the exchange process can be
expressed as:
𝑑M𝑎
𝑑𝑡 = A
𝑎 ⋅M𝑎+B𝑎+𝑘𝑐M𝑐−𝑘𝑎M𝑎
𝑑M𝑐
𝑑𝑡 = A
𝑐 ⋅M𝑐+B𝑐+𝑘𝑎M𝑎−𝑘𝑐M𝑐 (3.2.6)
This system of differential equations, which are essentially two independent Bloch
equations coupled by the exchange mechanism, is termed the Bloch-McConnell
equation, and represents the most widely usedmathematical description of exchange
processes in the NMR field, including CEST.1,2,3,4,5
Figure 3.2.1.: Exchange diagram
For the purpose of solving this system, it is useful to synthesize the expression to
its matrix form, which can be written with the same structure as before:
𝑑M
𝑑𝑡 = A ⋅M+B (3.2.7)
where now,M, A and B include the Cartesian components of both pools:
M= [𝑀𝑎𝑥 (𝑡) , 𝑀𝑐𝑥 (𝑡) , 𝑀𝑎𝑦 (𝑡) , 𝑀𝑐𝑦 (𝑡) , 𝑀𝑎𝑧 (𝑡) , 𝑀𝑐𝑧 (𝑡)]𝑇
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B= (0, 0, 0, 0, 𝑅𝑎1𝑀𝑎0 , 𝑅𝑐1𝑀𝑐0 )𝑇
A=
⎛⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜⎜
⎝
−(𝑅𝑎2 +𝑘𝑎) 𝑘𝑐 Δ𝜔𝑎 0 0 0
𝑘𝑎 −(𝑅𝑐2+𝑘𝑐) 0 Δ𝜔𝑐 0 0
−Δ𝜔𝑎 0 −(𝑅𝑎2 +𝑘𝑎) 𝑘𝑐 𝜔1 0
0 −Δ𝜔𝑐 𝑘𝑎 −(𝑅𝑐2+𝑘𝑏) 0 𝜔1
0 0 −𝜔1 0 −(𝑅𝑎2 +𝑘𝑎) 𝑘𝑐
0 0 0 −𝜔1 𝑘𝑎 −(𝑅𝑐2+𝑘𝑐)
⎞⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟⎟
⎠
In this matrix form, it is easy to include additional pools just by adding the ex-
tra components into the matrix, following the same structure. Typically, one could
include a number pools to account for MT, NOE, amide, amine and even multiple
-OH sites.
Subsequently, the matrix equation can be solved either numerically or quasi ana-
lytically by using a matrix expansion series approach.6,7
3.3. Finding the net magnetisation: Time
evolution vs steady state solution.
Once the system of exchangeable sites (concentration and resonant frequencies of
each pool) and their interactions (exchange rates) are defined, the Bloch-McConnell
equations can be numerically integrated to obtain the value of the variable of interest,
usually the net water magnetisation along the z axis (𝑀𝑎𝑧 ), at any given time. Cal-
culation of the full evolution of the variables in time is a powerful tool which allows
visualisations and understanding of the system’s behaviour under different experi-
mental conditions. Results from these simulations can provide educated guesses for
the optimisation process of specific parameters such as the required RF power, the
saturation length or the recommended readout schemes.
Integration over time of the exchange system is however a demanding number
crunching task which can be very time consuming, especially for multiple pool sys-
tems.
Often the approach is to analyse the steady state solution which arises from the
premise that a saturation RF pulse is applied for enough time so that the net mag-
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netisation reaches a steady state equilibrium value from which it will not evolve
until conditions are changed (i.e. the saturation RF pulse stops). In steady state the
set of differential equations describing the model (the Bloch-McConnell equations)
become a system of ordinary equations, which is much easier to solve. This allows
fast inspection of the exchange process outcome over a range of parameters values.
While solving the steady state problem is a very convenient method, it does not in-
form on the status of the magnetisation during the first instances of the RF saturation
pulse, and hence it is not valid to study short saturation time schemes, nor is it useful
for the analysis of different saturation schemes other than a continuous pulse.
Both solving the entire time evolution of the Bloch-McConnell system or taking
the steady state approach to solve multi-pool system problems can be very helpful
for a number of applications. On the other hand, it is sometimes useful to simplify
the exchange system to the minimum working expression in order reduce number
of parameters involved and be able to estimate the most important parameters in the
process of maximising CEST contrast. In this context, for many situations a two
pool model can be sufficient to provide insight of the system’s general behaviour
while keeping the number of unknown parameters to the minimum. The advantage
of using simplified models is that under certain parameter conditions, it is possible
to find an analytical solution to the system, that can help elucidate the relationships
between the CEST contrast and the experimental parameters to optimise. In Chap-
ter 4 for example the reductionist approach is used to provide a simple analytical
description to describe the observed transverse relaxation time T2 as a function of
the concentration of glucose in a sample.
In the following sections the mathematical models of chemical exchange are used
extensively to evaluate and predict the expected CEST contrast in a variety of ex-
perimental situations.
3.4. Pulsed versus Continuous saturation.
Hardware limitations in the RF amplifiers prevent the use of long saturation pulses.
This limitation is usually overcome by adopting a pulsed saturation approach in
which several shorter pulses are applied instead of a single long RF pulse. Pulsed
saturation schemes allow levels of saturation comparable to the ones achieved with
continuous RF irradiation. However, peak power is higher in the pulsed saturation
scheme, as the total energy delivered is spread over periods of no irradiation. This
can become a limitation in the design of CEST pulse sequences, especially when
planning for low duty cycle saturation schemes with relatively high equivalent B1
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power,* as the peak power can quickly escalate.
Another consequence of applying pulsed saturation is related to the generated
pulse bandwidth. Short pulses will produce wide spectral bandwidths which may
be too broad to target the specific resonant frequencies of the CEST agents. There-
fore a balance has to be found between the pulse length and bandwidth that will
assure efficient labile proton saturation. In addition to the bandwidth from the main
pulse, unwanted side-bands or secondary saturation bands can be formed due to the
periodicity of the saturation train of pulses. Unexpected saturation peaks (equally
spaced in frequencies) may be symptomatic of saturation side-bands. It is useful
to analyse the Fourier transform of the entire saturation train in order to check for
potential side-bands interfering with the inspected frequency range.
The following examples shows the simulated time evolution of the magnetisa-
tion along the z axis, 𝑀𝑧, during saturation applied at the resonant frequency of
the CEST pool for both pulsed and continuous saturation schemes. The pulse and
system parameters used for the simulation are detail in the figure 3.4.1 caption. The
graph also shows the steady state value calculated for𝑀𝑎𝑧 and𝑀𝑐𝑧 . As can be ob-
served the longitudinal magnetisation evolves towards the value of the steady state
solution. In this particular case the time to reach 95% of the steady state is around 5
seconds (after which the saturation is stopped and the magnetisation returns to equi-
librium).
The optimum CEST contrast will not necessarily occur at saturation times of that
length. As discussed later in section 3.16, optimum contrast can be obtained at a
fraction of the saturation time.
*Equivalent B1, 𝐵1𝑒𝑞, is referred to the field intensity of the hard RF pulse that would deliver
the same amount of power as any given RF pulse, regardless of its shape:
𝑃 _
∫∆𝑡0 𝐵
2
1(𝑡)𝑑𝑡
∆𝑡 =𝐵
2
1𝑒𝑞
For example, the paradigm of pulsed saturation schemes, consisting of a train of Gaussian pulses
would have an equivalent B1 described by:
𝐵1𝑒𝑞 =
𝜃
2𝛾 (
√
2𝜋𝜎𝑔𝑒𝑟𝑓 (n𝜎/
√
2)(𝑡𝑔𝑎𝑢𝑠𝑠+𝑡𝑑𝑒𝑙𝑎𝑦))
−1/2
where 𝜃 is the flip angle of the Gaussian pulse, with 𝜎𝑔 its standard deviation, (𝑡𝑔𝑎𝑢𝑠𝑠 the duration
and (𝑡𝑑𝑒𝑙𝑎𝑦 the delay between each Gaussian pulse. The gyromagnetic ratio of the nucleus is repre-
sented by 𝛾, and 𝑒𝑟𝑓 (n𝜎/
√
2) accounts for the number of standard deviations contained in actual
pulse, as in practice the Gaussian shape produced by the RF coil is truncated in the edges.
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Figure 3.4.1.: Time evolution of𝑀𝑎𝑧 and𝑀𝑐𝑧 under pulsed and continu-
ous saturation. Data simulation with a two pool model with the following
parameters: Relaxation times of the water pool 𝑇𝑎1 = 2𝑠, 𝑇𝑎2 = 40𝑚𝑠.
Relaxation times of the CEST pool 𝑇 𝑐1 =1𝑠, 𝑇 𝑐2 =10𝑚𝑠. CEST offset fre-
quency relative to water (𝑝𝑝𝑚𝑐 = 1.2 ∶ 𝑝𝑝𝑚). Shown in pink continuous
B1 saturation power 2𝜇𝑇 . Shown in blue train of Gaussian pulses with
and equivalent B1 power of 2𝜇𝑇 and 98 percent duty cycle. Each of Gaus-
sian pulses has a duration of 50𝑚𝑠 and a standard deviation of 8.56𝑚𝑠,
mimicking the pulse specifications used in the Agilent 9.4T scanner. Us-
ing the same pulse but with a longer delay between them, the brown line
shows the results of a lower power (and 50% duty cycle) saturation. The
pink line corresponds to the solution for the continuous saturation scheme.
The value corresponding to steady state solution is shown in orange.
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3.5. Mz recovery time.
Each offset frequency in the Z-spectrum needs to be equally weighted, and therefore
after the readout the net magnetisation is usually let to recover fully before apply-
ing the next saturation RF pulse at a different frequency offset. This is very time
inefficient as it adds extra waiting time to an already long preparation phase (satu-
ration) for every offset point in the Z-spectrum. Although the extra waiting time for
the recovery of the net magnetisation can be invested in acquiring a different slice
of interest using a multi-slice readout approach, it is not always required or even
applicable depending on the scan protocol.
Using computer simulations it is useful to observe that the recovery time can be
avoided if sufficient saturation time is allowed. Application of a long RF irradia-
tion pulse while net magnetisation is still recovering (right after the readout) has no
impact on its final steady state, and therefore identical CEST contrast is achieved
regardless of the initial condition𝑀𝑎𝑧 (𝑡 = 0). This knowledge can be used to con-
siderably shorten scan times, reducing the duration for full Z-spectrum acquisition
to half of the time in some cases.
3.6. Simulation of glucose CEST profile
Simulation of multiple CEST pools. Exchange rates of different pools can
be estimated by fitting the experimental data to the mathematical model. In the
following case, figure 3.6.1, the three exchange sites of glucose were simulated and
compared with experimental data, which provided an estimation of the exchange
rate of each -OH pool.
Values found comparing the simulated data to the phantom data represent a good
starting point for the parameters in glucose, which is useful when running simu-
lations in vivo conditions. Although it is expected that the exchange rates of each
of the hydroxyls in glucose will vary (mostly depending on pH, phosphate concen-
tration and the higher temperature in vivo), their resonant frequencies and even the
approximate values of the exchange rates provide valuable information.
Assessment of saturation status. In the work published byWalker-Samuel8
described in section 2.4.2, the two pool mathematical model was used to establish
enough saturation was provided by the used pulse sequence (see figure 3.6.2).
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Figure 3.5.1.: Time evolution of the net water magnetisation𝑀𝑎𝑧 starting
from different initial conditions. Both at 5 and 20mMolar glucose concen-
tration the𝑀𝑎𝑧 reaches the same steady state value after the application
of the irradiation pulse, independently of the initial condition𝑀𝑎𝑧 (𝑡 = 0).
For all four cases, a simple 2-pool model (water-glucose) was simulated
with a hard 1.3 𝜇𝑇 B1 RF pulse applied on resonance with glucose at 1.2
ppm from water.
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Figure 3.6.1.: CEST effect of glucose
a) Z-spectra and MTRasym of in vitro measurements with glucose solutions at 0, 125,
250 and 500 mMolar concentrations. b) Simulations of the Z-spectrum of glucose at the
same concentrations as in vitro. Simulation parameters: 𝐵1 = 1.2𝜇𝑇 , 𝑇1𝑤𝑎𝑡𝑒𝑟 = 2𝑠,
𝑇1𝑔𝑙𝑢𝑐𝑜𝑠𝑒 = 0.17𝑠, 𝑇2𝑤𝑎𝑡𝑒𝑟 = 500𝑚𝑠, 𝑇2𝑔𝑙𝑢𝑐𝑜𝑠𝑒 = 10𝑚𝑠, ∆𝜔𝑎 = 2.9𝑝𝑝𝑚,
𝑘𝑎𝑤=1275𝐻𝑧,∆𝜔𝑏=2.0𝑝𝑝𝑚, 𝑘𝑏𝑤=1700𝐻𝑧,∆𝜔𝑐=1.3𝑝𝑝𝑚, 𝑘𝑐𝑤=935𝐻𝑧.
c) Schematic diagram of a glucose molecule showing the location of hydroxyl groups sus-
ceptible for CEST. d) Image of the scanned phantoms showing the glucoCEST effect (pH
= 7.2, 37°C). The image was produced by integration of MTRasym spectra between 0.75
and 4 ppm for each pixel. An enhanced CEST effect is observed for increasing glucose
concentrations, both in in vitro and simulated data.
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Figure 3.6.2.: Simulation of approximation to steady state
Simulations of the longitudinal magnetisation of glucose and water pools during a gradient
echo CEST acquisition, for both 5 and 20 mM glucose solutions. Sets of 3 Gaussian off-
resonance saturation pulses are simulated prior to a 20∘ readout pulse, for every k-space
line. These simulations show that, for glucose concentrations of 5 and 20 mM, a steady
state condition is reached within 3 seconds, which corresponds to 19 k-space acquisitions.
For the 128 phase encoding steps used in the GE-CEST sequence, this suggests that only
the outer 13% of k-space is acquired before the steady condition is met. Figure published
in Nature Medicine Journal8
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3.7. Simulating in vivo conditions
Unlike in phantoms where the Z-spectrum is formed by the interaction of water
and the CEST agents of interest alone, in vivo spectra are shaped by a multitude of
different parameters and exchanging pools.
In this section the impact of some of these parameters on the Z-spectrum will be
analysed. The data produced are based on multi-pool exchange models for which
the model parameters have been chosen to mimic as accurately as possible the ex-
perimental data obtained from in vivo CEST acquisitions.
Model variables: The model used for the CEST simulation of in vivo conditions
is composed of eight sets of Bloch equations corresponding to the different type of
protons in chemical exchange. The labile proton groups, each associated with a set
of Bloch equations, are linked by a pseudo first order exchange mechanism to the
set of Bloch equations associated with the water pool. The eight pools contained
in the model represent: the macromolecular pool (MT pool), the amides and amine
molecules, the aliphatic molecules responsible for the Nuclear Overhauser Effect
(NOE), three pools for the hydroxyl groups in glucose and finally the water pool.
Each of these pool has five associated parameters that can be adjusted. These are:
the concentration or pool size, 𝑇1 and 𝑇2 relaxation times, the exchange rate and
resonant frequency with respect to the water pool.
The exchange rates of amides and amines are modelled by the environment pH
(which needs to be entered in the model) by the relationships presented in Chapter
1, section 1.4.5. The system also needs to be provided with the specific B1 RF
pulse profile over the integration time (or just intensity for the case of the steady
state model). Optionally one can include additional pools and relationships between
them. The model included in Appendix E contains an extra ninth exchangeable pool
which can be used to fit more complicated profiles such a double NOE pool or other
external agents that may need to be considered.
The model also allows for the possibility of connecting pools to each other in
order to simulate processes of magnetisation exchange between them, such as the
likely transfer of magnetic label from protein amides to amines and vice versa, for
example.
By adjusting the parameters in the model it is possible to obtain a reliable Z-
spectrum that fits well with the in vivo experimental data. Figure 3.7.1 shows the
averaged Z-spectrum of mouse brain at two different powers. Once the parameters
are fitted in the first power, the model can accurately fit the experimental data of the
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second power, and provide an estimate of the in vivo CEST parameters.
Figure 3.7.1.: Z-spectra of the mouse brain acquired with𝐵1𝑒𝑞 = 0.9𝜇𝑇
on the left and𝐵1𝑒𝑞=1.3𝜇𝑇 on the right. Shaded lines correspond to the
standard deviation of the Z profile across the brain. The blue lines that ex-
tend over±4.5𝑝𝑝𝑚 are simulated data. The parameter values used in the
simulation which mimic the experimental result in vivo are listed below.
Labile proton pool sizes in mmolar: 𝑀𝑎0 = 55 for water,𝑀𝑏0 = 5 for the
macromolecular (MT) pool, 𝑀𝑐0 = 0.9 and 𝑀𝑑0 = 12×10−3 for amine
and amide groups. Glucose levels set at 5 mMolar with𝑀𝑒0 = 27×10−3,
𝑀𝑔0 =9×10−4 and𝑀ℎ0 =1.8×10−4 for each hydroxyl group in glucose.
𝑀𝑓0 =3.2×10−2 for the aliphatic proton pool. Transfer rates (Hz): Value
of pH was set at 7.2 and the pH dependent exchange rate relations de-
fined as,𝐴𝑚𝑖𝑛𝑒𝑠𝐸𝑥=0.5.10(𝑝𝐻−4.5),𝐴𝑚𝑖𝑑𝑒𝑠𝐸𝑥=5.57.10(𝑝𝐻−6.4).
For the rest of the pools the exchange rates are: Re=1870; Rg=3400;
Rh=2500; Exb=50; Exf=5. T1 relaxation times (s): T1a=1.85; T1b=1;
T1c=1.1; T1d=1.1; T1f=1; T1e=1.2; T1g=1.2; T1h=1.2; T2 relax-
ation times (s): T2a=0.04; T2b=0.00001; T2c=0.0006; T2d=0.0018;
T2f=0.00042; T2e=0.017; T2g=0.017; T2h=0.01. Resonant frequen-
cies (ppm): ppmb=0; ppmc=+2.1; ppmd=3.5; ppmf=-3.15; ppme=1.1
ppmg=2; ppmh=2.9;
3.8. Normalisation
The MTR (and MTRasym) measure was originally defined as the variation between
irradiated and non-irradiated signal ( +𝛿𝜔 and −𝛿𝜔 for MTRasym) divided by the
non-irradiated signal.5,9 The non-irradiated signal, 𝑀0, is a logical reference for
normalisation as it produces values of Z-spectra bound from 0 to 1 in the entire fre-
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quency range. However, due to physiological noise* during in vivo acquisitions,
normalisation at 𝑀0 is not recommended. As physiological noise scales linearly
with the signal intensity, variations in 𝑀0 values can be large compared to the Z-
spectrum intensity close to water. This has a serious impact on the stability of the
signal and it is particularly harmful for exogenous CEST experiment, such as gluco-
CEST, in which information is obtained from small differences in the CEST images
acquired over the time-course of a generally lengthy experiment. Signal intensity
jumps between different acquisitions can completely ruin an exogenous CEST ex-
periment.
Use of a normalisation reference closer to the off-resonance frequencies of interest
(where the signal strength is lower) can reduce the noise variability of physiological
nature, which is crucial for CEST experiments where data has to be acquired several
times. For that reason the in vivo data in this study has been normalised to the aver-
age signal level in the range between ±4.3 and ±4.5 ppm from the water resonant
frequency.
Figure 3.8.1.: Normalisation approach. Two sets of Z-spectra at varying
saturation powers are shown. On the left, normalisation is defined as the
averaged signal intensity with no saturation,𝑀𝑟𝑒𝑓 =∑𝑀𝑖0×𝑒𝑇𝐸/𝑇
𝑖
2 .
On the right the reference is taken as the mean value of the Z-spectrum
between ± 4.3 and ± 4.5 ppm.
*The image noise in MRI can be described as: 𝜎 = √𝜎20+𝜎2𝑝 with 𝜎𝑝 = 𝜆𝑆 where 𝜎0 de-
scribes the electronics and other system noise that includes drift and imperfections in RF, gradient,
and shims. 𝜎0 is considered the raw noise and has been shown to be proportional to B0, but inde-
pendent of the signal strength. The term 𝜎𝑝 describes the physiological noise, which arises from
fluctuations in the basal cerebral metabolism, blood flow, and blood volume and also from cardiac
and respiratory functions that cause oscillations in the vascular system, motion from subtle brain
pulsatility, and magnetic field modulations. In contrast to the raw noise, the physiological noise is
signal-dependent. See10 for more information on physiological noise.
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Similar to the approach taken in this work, the research group lead by R. Reddy
in Pennsylvania, have used the negative offset frequency as the reference for nor-
malisation.11–13
𝐶𝐸𝑆𝑇𝑎𝑠𝑦𝑚(Δ𝜔) =
𝑀𝑠𝑎𝑡(−Δ𝜔)−𝑀𝑠𝑎𝑡(+Δ𝜔)
𝑀𝑠𝑎𝑡(−Δ𝜔)
(3.8.1)
As a generalisation of the close reference normalisation approach, an alternative
measure of the Z-spectrum asymmetry could be proposed as the ratio between the
asymmetric and the symmetric components of the Z profile, ie:
𝑍𝐴𝑅 = 𝑎𝑠𝑦𝑚𝑚𝑒𝑡𝑟𝑖𝑐𝑝𝑎𝑟𝑡𝑠𝑦𝑚𝑒𝑡𝑟𝑖𝑐𝑝𝑎𝑟𝑡 =
𝑀𝑠𝑎𝑡(−Δ𝜔)−𝑀𝑠𝑎𝑡(+Δ𝜔)
𝑀𝑠𝑎𝑡(−Δ𝜔)+𝑀𝑠𝑎𝑡(+Δ𝜔)
(3.8.2)
The Z asymmetry ratio, ZAR, is by definition a normalised measure, and as such
not susceptible to variation due to the selection of a different normalisation refer-
ence (a common issue in the reported CEST values across different labs). ZAR
provides similar information as 𝐶𝐸𝑆𝑇𝑎𝑠𝑦𝑚, however it weights both sides of the
Z-Spectrum equally and in the author’s opinion it is conceptually more elegant.
3.9. Effect of pH in vivo
As mentioned before in Chapter 1, pH plays an important role in CEST, particularly
for endogenous measurements where the peak intensities from amide and amine
groups depend on the specific tissue pH. The simulation in figure 3.9.1 shows the
extent and directionality of the change in the amide and amine peaks in relation to the
pH. The exchange rate dependence of both amide and amine pools have been sim-
ulated according to the experimental pH relationship reported in the literature14,15
and detailed in section 1.4.5.
The amide peak displays a clear monotonic relationship with pH, showing a pro-
nounced peak at the normal pH values of 7.2 found in the brain tissue, to a complete
disappearance of the peak at acidic pH values of around 6.6. The amine peak at 2
ppm has a less defined pattern, displaying similar intensities at different pH values.
It is worth noting however, that in the depression formed between 0 and 2 ppm, sig-
nal appears to be modulated strongly by the pH, showing the same response as the
one observed in the amide peak.
The intense effect of pH on the CEST outcome is the motivation behind all APT
based pH weighted imaging methods.16–20 While the models alone have so far failed
to provide a reliable quantitative measure of pH, different approaches have been
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Figure 3.9.1.: Effect of pH on amide and amine groups. The monotonic
relation of amide peaks with pH is the principle of pH weighted imaging
with CEST MRI.
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suggested to overcome this limitation. One possibility is the so called “radiomet-
ric approach” in which the pH can be deduced from the relationship of both amine
and amide peaks. However, the method requires prior knowledge of the concentra-
tion of both pools21 or alternatively the use of exogenous pH sensitive agents.22,23
Alternatively semi-quatitative pH maps can be obtained from CEST images, prior
calibration of the pH using 31P NMR spectroscopy. Using this method the team
in our lab has recently been able to image the local pH change caused by hypoxia-
ischaemia in the piglet brain.24
3.10. Effect of the Macromolecular pool
It has been shown both experimentally and theoretically that for many biological tis-
sues, a Lorentzian function (which naturally arises from the Bloch equations) does
not adequately describe the RF absorption line-shape of the protons in the hydrated
layer of macromolecules. Dipole interactions in a rigid system have been accurately
described with Gaussian line-shapes as opposed to the Lorentzian shapes suitable for
the description of liquid samples.4,25,26 In the intermediate exchange regime such as
in biological tissues, the super-Lorentzian function, which includes the integration
over all the dipolar orientations in the macromolecule, is found to be most appropri-
ate.27,28 The super-Lorentzian absorption line-shape can be written as:
￿𝑏(2𝜋Δ) =∫
𝜋
2
0
𝑑𝜃 sin𝜃√2𝜋
𝑇 𝑏2
|3cos2 𝜃−1|𝑒
−2( 2𝜋∆𝑇
𝑏
2
|3cos2𝜃−1|
)
2
whereΔ is the RF resonant frequency relative to water and 𝜃 the dipole orientation
angle relative to the main magnetic field B0.
In the current simulations the semi-solid water pool is modelled with the above
super Lorentzian absorption line-shape, and pool size of 11% bound to free water
fraction, in agreement with values available in the literature.25,29
In ppm range close to the water resonant frequency, the exchange between the
MT pool and water has a moderate effect on the Z-spectrum profile, which scales
with saturation power. As shown in figure 3.10.1 theMT shifts the signal up slightly
(this is due to the lower normalisation value) but without significantly affecting the
sensitivity to detect CEST peaks. The effect of MT gets reduced to zero as the
saturation offset gets closer to the water frequency. However, it should be said that
in reality, the MT pool has a larger impact on the CEST outcome than shown by the
simulations in Figure 3.10.1.
The dipolar exchange between the bound water (MT) and free water pool signifi-
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Figure 3.10.1.: Effect of the macromolecular pool on the sensitivity of
CEST. At the narrow frequency range relevant for endogenous CEST and
usual power levels, the direct effect of MT exchange is not critically detri-
mental for the detection sensitivity of CEST. However the shortening of the
spin-spin relaxation time T2 of water in the presence of macromolecules
(not shown here) has a strong broadening effect in the Z-spectra, and thus
the capacity to resolve CEST peaks is severely affected.
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cantly reduces the transverse relaxation time of the free water, which in turn widens
the Z-spectrum and flattens the CEST peaks out, with the consequent loss in sensi-
tivity. The model can be easily adapted to couple the water relaxation time to the
MT concentration, with a proportionality relation, i.e. 𝑇2𝑎 = 𝑓 (𝑀0𝑏). For the cur-
rent simulation however, the 𝑇2𝑎 time was deliberately fixed at the experimentally
measured value. The purpose of it was to assess only the pure exchange effect, as
it is studied in MT and qMT experiments, without accounting for the shortening in
the water the relaxation time attributed to the macromolecular pool.
At far offset frequencies and at high power saturation schemes particularly, the
effect of the macromolecular pool is much more evident, as shown in figure 3.10.2.
Figure 3.10.2.: Comparison of the Z-spectrum shape with and without
the macromolecular pool contribution. At elevated B1 powers and offsets
above 3 to 5 ppm, the MT pool drags the signal intensity down up to 75%
compared to the same power in absence of MT.
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3.11. Saturation power and noise
As a rule of thumb, fast exchanging hydrogens will produce better CEST contrast
when saturated with high B1 powers. Defining the precise optimum saturation
power however is still a controversial subject.
It is generally accepted that an estimate for the optimum B1 power for a given
CEST agent can be deduced from the saturation efficiency equation, first introduced
by Snoussi et al in 2003:5,9,30
𝑀𝑇𝑅 ∝ 𝑘𝛼
where the saturation efficiency constant 𝛼 is defined as
𝛼 ≈ (𝛾𝐵1)
2
(𝛾𝐵1)2+𝑘2
For an exchange rate on the order of 1000Hz, as in the case of hydroxyl groups
in glucose, the equation predicts an optimum saturation power of above 10𝜇𝑇 . See
figure 3.11.1.
While the equation may provide a good estimate for labile protons resonating
away from the water frequency such as paraCEST agents, it fails to predict the op-
timum power of many endogenous CEST molecules.
For endogenous CEST agents resonating at frequencies close to water, the largest
source of signal loss comes from the spillover or direct saturation effect. Yet the sat-
uration efficiency equation does not take into account the consequence of spillover.
First, higher extent of spillover produces a proportionally smaller contrast, as
the MTR does not scale linearly with signal.31,32 Secondly, CEST labile protons
with small offsets 𝛿𝜔 are susceptible to secondary saturation effects. Excessive RF
power applied at the −𝛿𝜔 frequency (needed for asymmetry analysis) will not only
saturate the water but also the CEST agent itself, situated at 2𝛿𝜔 away from the RF
frequency. This partial saturation of the CEST pool from both sides of the water
spectrum, further reduces the achievable CEST contrast, as the MTR asymmetry is
reduced.
Lastly, the signal to noise ratio (SNR) is affected at high B1 powers. Spillover
effects reduce the availablewater signal and hides the CEST label. The characteristic
Lorentzian absorption profile (super-Lorentzian in semi-solid like organic tissues),
limits the strength of the observable signal which inherently worsens the raw SNR
of the measurement.
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Figure 3.11.1.: Saturation efficiency profile.9 Dependence of the product
of saturation transfer efficiency and exchange rate (k) on B1 and k. The
graph shows an increased CEST efficiency at power levels up to 10 𝜇𝑇
for labile proton with exchange rate k of ~1000 Hz. However, the effect of
direct saturation is not taken into account.
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The multi-pool exchange model developed here allows the introduction of ran-
dom noise* in the system to evaluate the effects of noise propagation on the quality
of CESTmeasures. Simulation with different noise levels were run to asses the opti-
mum B1 power and also inform on the ppm integration range † that would maximise
the CEST contrast.
Figure 3.11.2 illustrates the deterioration of the signal due to noise as a conse-
quence of increasing B1 power. Raw noise, which is independent of signal strength,
becomes proportionally larger when intense direct saturation reduces the available
signal. Note that all the Z-spectra are normalised to the same values, however the
noise scales up with high powers. To see the actual reduction of available signal by
the spillover effect refer to Figure 3.10.2.
These results reflect the importance of finely tuning the B1 power in a trade-off
between SNR and saturation efficiency.
These simulations also reveal the need of pre-processing techniques aimed to re-
duce the noise before evaluating the CEST data. Spatial smoothing techniques, fre-
quency filtering or other kind of data manipulationmethod that increase the effective
SNR are crucial in order to confidently detect the subtle CEST changes encountered
in vivo.
*It is known that the raw noise in MRI follows a Rician distribution, which for values of SNR
larger than two approximates to a Gaussian distribution.33 The model can simulate the presence
of noise in the system. Raw (or thermal) noise 𝜎0 is simulated by adding a normally distributed
random noise to the Z-spectrum before normalisation. Physiological noise in the data is simulated
by giving every offset point in the spectrum a probability of being noisy and a normally distributed
noise variance proportional to the Z-spectrum amplitude. 𝑍𝑛𝑜𝑖𝑠𝑦 = 𝜎0+𝜎𝑝|𝑍𝑝𝑢𝑟𝑒| The noise
level is defined as the ratio between the variance and the mean signal intensity at the reference offset
point. Please refer the Matlab code in Appendix F for the full derivation of the noise parameters.
†The MTR asymmetry is usually defined as a point-wise function in this form:
MTRasym(𝛿𝜔) =
M(−𝛿𝜔)−M(𝛿𝜔)
𝑀𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒
The expression requires the input of only two images, acquired with saturation at +𝛿𝜔 and −𝛿𝜔
(plus a reference image if the far away normalisation approach is to be used). This is convenient
in terms of reducing scan time and has been commonly used in the clinic as Amide Proton Transfer
(APT) imaging technique. 𝐴𝑃𝑇 = 𝑀𝑇𝑅𝑎𝑠𝑦𝑚(3.5𝑝𝑝𝑚). The acquisition of multiple points
in the Z-spectrum on the other hand allows for integration over a range of frequencies, aimed to
achieve higher confidence in the measurement by sampling more than a single experimental point.
Moreover, data from a rage of frequencies can be post-processed to minimise the harmful effects of
B0 inhomogeneities across the image.
MTRasym(∆𝛿𝜔) =∫
𝛿𝜔2
𝛿𝜔1
M(−𝛿𝜔)−M(𝛿𝜔)
𝑀𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒
𝑑𝛿𝜔
Ideally the frequency range should be centred around the highest Z-asymmetry produced by the CEST
agent of interest.
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Figure 3.11.2.: Propagation of noise with different saturation power.
Normalised Z-spectra (top) and MTR asymmetry (bottom) at different lev-
els of raw noise in the data (columns). Reduction of available signal due
to direct saturation makes the noise increasingly more evident at high B1
powers.
3.12. Measuring glucose increase in vivo
conditions
In the following section a theoretical glucoCEST experiment is modelled, in which
glucose concentration is increased from a baseline of 5 mMolar to 15 and 25mMolar
respectively. Model parameters are set to the values found by fitting the in vivo
data with pH values set at 7.2 in agreement with the reported pH in normal brain
tissue.34–36
The results of these simulations give a good estimation of the expected increase in
CEST signal in an in vivo glucoCEST experiment at 9.4T.
Figure 3.12.1 shows simulations run with equivalent B1 powers of 1, 3 and 10
𝜇T from left to right respectively. The Z-Spectra, the MTR asymmetry, and the
increment in MTR asymmetry for the different glucose concentrations are displayed
from top to bottom.
It is important to realise that the intensity of final glucoCEST image will be de-
termined by the area under theΔ𝑀𝑇𝑅𝑎𝑠𝑦𝑚 curves (bottom figures), on a pixel by
pixel basis.
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The area under theΔ𝑀𝑇𝑅𝑎𝑠𝑦𝑚 curve, which will also be referred to as the glu-
coCEST enhancement signal (GCE), is clearly dependent on the saturation power
used, and generally for fast exchanging hydroxyls groups, amplitudes of a few𝜇Tesla
produce the largest contrast.
Interestingly, the GCE will also depend on the integration range in which the area
is calculated. For example, in the range of frequencies from 0 to 1 ppm, the GCE is
larger at 1𝜇𝑇 than at 10𝜇𝑇 .
The flexibility in the selection of the integration range allows optimisation of
the CEST data analysis according to the B1 power used in the acquisition, which
usually falls shorter than the ideal one, especially in a clinical set up, where due to
SAR limitations, B1 power is restricted to around 2 𝜇 Tesla.
Figure 3.12.1.: Detection of glucose increase in ideal in vivo conditions.
Simulation of glucoCEST experiment for 5, 15 and 25 mMolar glucose
concentration at different B1 irradiation powers, 1, 3 and 10 𝜇𝑇 , in
columns respectively. Z-spectra, %MTR asymmetry and change in the
%MTR asymmetry due to glucose, in rows respectively. In ideal conditions
high saturation powers (above 3 𝜇𝑇 ) offers an intense overall increase in
the MTR asymmetry.
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3.13. GCE in noisy data
The sensitivity of CEST is very much limited to the noise level in the data, as pre-
viously discussed. After re-running the same simulations as in previous section
with an added raw noise level of 0.5 percent (SNR=200), the picture changes dras-
tically. TheΔ𝑀𝑇𝑅𝑎𝑠𝑦𝑚 is no longer a smooth curve and the signal enhancement
is masked by the noise. In this context, measurement of the GCE becomes progres-
sively less accurate as the intensity of the B1 increases. At very large powers the
Δ𝑀𝑇𝑅𝑎𝑠𝑦𝑚 becomes too noisy to confidently observe any change due to the rise
in glucose concentration. Figure 3.13.1 visually demonstrates the damaging conse-
quences of applying an excessive B1 power.
Figure 3.13.1.: Detection of glucose increase in in vivo conditions with
noise. Contrary to the results in Figure 3.12.1 elevated B1 powers de-
teriorate the glucoCEST signal due to the magnification of noise at high
saturation fields.
The average noise level per voxel in the in vivo experiments included in this
study ranged between one and two percent (SNR between 50 and 100), before pre-
processing of the data. Therefore in the light of the results in these simulations, for
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most of the in vivo cases strong smoothing of the data was required at the expense
of some loss in spatial resolution, to achieve SNR ratios above 250 units.
In the next section the relationship between the reliability of the GCE, B1 power
and the chosen integration range will be further analysed.
3.14. Quality of the GCE data at different offset
frequencies and saturation powers
Following the discussion above, a more in depth analysis of the interaction between
power and observed signal is presented here. Using the in vivo parameters in the
multi-pool simulator, themeanGCE signal and the standard error of themean (SEM)
are estimated for a range of saturation powers, varying noise levels and different fre-
quency ranges. Figure 3.14.1 contains the results of the simulations at four different
integration ranges: In figure 3.14.1a GCE is integrated in a very narrow range from
1 to 1.1 ppm. In figure 3.14.1b GCE is integrated from 1 to 2 ppm. In figure 3.14.1c
from 0.1 to 2 ppm and in 3.14.1d from 0.1 to 4 ppm. The blue line in the centre of
each figure represents the value of the GCE in an ideal noise-free situation. Shaded
colours represent the spread of the standard error for different values of SNR.
The first point to emphasise is again the impact of noise in the GCE, and CEST
the general. The adverse effect is exacerbated at higher powers which results in a
rapid increase of the SEM along the ‘saturation power’ axis.
The error in the GCE measurement can be reduced by including more exper-
imental points in the calculation. Comparison between figure 3.14.1a and 3.14.1b
illustrates the advantage of calculating the GCE over a range of experimental offsets
rather than sampling a single point in order to increase confidence about the mea-
surement (see section 3.11). The narrow sampling range in figure 3.14.1a (equiva-
lent of 1 experimental point in a typical scan) yields large SEM. On the other hand
integration over 1 to 2 ppm in figure 3.14.1b provides a significantly lower uncer-
tainty in the measurement.
It is clear from graphs 3.14.1b to 3.14.1d that the integration range can be opti-
mised to the saturation power used in order to achieve better contrast. For the case
of irradiation power of around 2 𝜇T the frequency offsets which provide the highest
signal lie around the 1 ppm range. To help minimise the standard error in the mea-
surement and yet obtain high contrast from glucose, a range of frequency offsets
close to one ppm should be considered for the calculation of the GCE signal.
The predicted noise-free signal (blue line) rapidly increases within the first few
106
3.14. Quality of the GCE data at different offset frequencies and saturation powers
Figure 3.14.1.: Predicted in vivo GCE signal at different B1 power and
integration range. The blue line represents the value of the GCE in an
ideal noise free situation. Shaded colors represent spread of the standard
error of the mean. Integration range used is specified in each figures title.
Given a particular B1 power and noise level, an optimised integration
range can be chosen that increases the sensitivity of CEST.
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𝜇T, after which it stabilises or reduces its amplitude. The SEM on the other hand
increases fast with power. Based on these results it is fair to conclude that, saturation
powers above 4𝜇T are unlikely to provide any advantage for the detection of glucose
in vivo.
This conclusion is contrary to a common belief in the CEST field, that fast ex-
changing hydroxyls groups in glucose require far more intense saturation power for
optimum contrast (see saturation efficiency in figure 3.11.1). This point is certainly
debatable as large variations in the exchange rate of glucose could change the out-
come of these simulations. For example at an average exchange rate of around 5000
Hz (twice as fast as in previous case) the optimum B1 power seems to shift towards
higher intensities (see figure 3.14.2). However, the ability to select an optimum in-
tegration range can help mitigate the lack of powerful irradiation. Here, a sampling
range from 1 to 2 ppm yields contrast close to the one achieved with larger B1 fields.
Figure 3.14.2.: GCEwith faster glucose exchange rate. Integration range
from 1 to 2 ppm, figure on the left, shows the GCE signal to increase
quicker at lower values of B1 compared to signal integrated from 0 to 4
ppm, on the right.
3.15. Translation to the clinic
As a last point in the discussion of this chapter, it interesting from the point of view of
the translation to the clinic, to assess the results of the same hypothetical glucoCEST
experiment at 3 Tesla magnetic field. To do so certain parameters in the model had
to be modified. Besides the B0which was changed from 9.4T to 3T, relaxation times
of each pool had to be adjusted to match experimental values at 3T, while chemical
108
3.16. Saturation length
exchange rate and relative resonant frequencies were assumed to be independent
of the B0 field strength and therefore left untouched. Two different tissue types,
grey and white matter, are considered in the simulations of which values of T1,
T2 and M0b (size of the MT pool) were taken from Stanisz et al..37 With these
new parameter values the simulation results summarised in figure 3.15.1 show a
significantly higher GCE signal in the grey matter compared to the white matter
for the same glucose increase. Concerningly, for a 10 mMolar increase in glucose
concentration, the expected magnitude of the GCE signal at 3T (and 2 𝜇𝑇 power)
falls below the 0.3% mark. These limited levels of signal, require values of SNR
in the CEST data of at least 250 units in order to be reliably detected. The analysis
stresses the need of high quality data for reliable glucoCEST results at 3T. Multiple
CEST acquisitions with moderate spatial resolution would probably be needed, as
well as intense preprocessing of the data to reduce noise and achieve sufficient SNR
levels.
Figure 3.15.1.: Sensitivity of GCE at 3T. Figure on the left shows the
predicted signal for grey matter and on the right for white matter. Values
of relaxation time and macromolecular pool content of each tissues were
taken from the literature.37
3.16. Saturation length
So far in the discussion of the hypothetical glucoCEST experiment the steady state
solution of the system has been analysed, which assumed that a long RF irradiation
was applied for the acquisition of the CEST data.
In this section the same hypothetical experiment will be studied, but now the focus
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will be set on the evolution of the𝑀𝑇𝑅𝑎𝑠𝑦𝑚 over the time of saturation, instead
of the steady state solution.
The simulation parameters are set to the same values as previously except for the
saturation irradiation scheme which in this case is defined as a train of 80 Gaussian
pulses. Each Gaussian pulse is 50 ms long and it is followed by a 1 ms delay before
the application of the next pulse. The overall equivalent B1 power accounting for
the pulses and delays is set at 2 𝜇T.
Figure 3.16.1 shows the time evolution of the𝑀𝑇𝑅𝑎𝑠𝑦𝑚 (with its contour plot
on the right), of the simulation with 5 and 20 mMolar glucose concentration and the
difference of the twoΔ𝑀𝑇𝑅𝑎𝑠𝑦𝑚.
As can be deduced from the plots in figure 3.16.1, the time evolution of the
𝑀𝑇𝑅𝑎𝑠𝑦𝑚 is governed by the rate of chemical exchange (𝜅) of each type of labile
proton. For example, the fast exchanging amine group at 2 ppm rapidly stabilises
(in less than 2 seconds) while the effect of the slow aliphatic pool, which makes
the MTR asymmetry negative, is still building up 4 seconds after beginning of sat-
uration (see maximum and minimum levels in contour plots). From that moment
onwards saturation pulse is deliberately stopped and consequently the MTR asym-
metry evolves towards zero (the thermal equilibrium state) with T1 relaxation time
constant.
Taking a close look at the shape of the𝑀𝑇𝑅𝑎𝑠𝑦𝑚 in figure 3.16.2, the emergence
of a wavy pattern can be observed. This oscillating profile is a consequence of the
pulsed irradiation, as was also seen in the example of figure 3.4.1. This can easily
be verified by acknowledging that the number of oscillations match the periodicity
of the saturation pulses train; one oscillation every 51 ms, in this case. While one
could consider the existence of this wavy pattern as a problem for the stability of
the CEST measurement, in practice it is not a concerning issue as the sampling of
the data (the readout) is always done after an integer number of saturation loops,
e.g. after 80 iterations of ‘Gaussian pulse plus delay’ blocks, but never after 80.5
iterations.
Only in the case of amore complicated saturation scheme, in which onewould like
to sample the data at a different phase of the saturation loop, the oscillations would
have to be carefully taken into account in order get reliable CEST measurements.
Bringing attention back to theΔ𝑀𝑇𝑅𝑎𝑠𝑦𝑚 in figure 3.16.1, it is noticeable that
the surface reaches its maximum height within the first second of saturation irradi-
ation, after which it approximates to a lower steady state value.
The different shapes ofΔ𝑀𝑇𝑅𝑎𝑠𝑦𝑚 curve at the first 6 seconds in the simulation
are shown in figure 3.16.3.
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Figure 3.16.1.: Time evolution of the𝑀𝑇𝑅𝑎𝑠𝑦𝑚 and GCE in vivo con-
ditions. The figure shows the MTR asymmetry in time for the case of 20
mMolar glucose content, 5 mMolar and the difference between the two,
which gives rise to the GCE signal. Figure on the right shows the contour
plots in each case. Notice how the GCE signal peaks in less than a second
around the 1.2 ppm range. After about 3.5 seconds of saturation, the sys-
tem approaches steady state where barely no changes are observed. After
4 seconds, the saturation pulse is stopped and the magnetisations evolves
towards the thermal equilibrium value.
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Figure 3.16.2.: Oscillations due to pulsed saturation. The amplitude of
the MTR asymmetry oscillates with the same periodicity as the Gaussian
pulses, according to the variations in the instantaneous supply of power.
In practice these oscillations are not observable as the data acquisition
occurs always in the same phase, after an integer number of Gaussian
pulses.
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Saturation length of as short as 1 second yields a higher glucoCEST contrast pro-
vided that the integration of theΔ𝑀𝑇𝑅𝑎𝑠𝑦𝑚 signal is performed around 1.2 ppm.
It is clear from the graphs that achieving steady state (with ~4 second saturation)
does not necessarily provide the largest CEST signal. The significance of this result
is that shorter saturation times can be used without compromising the quality of the
signal. This has the advantage of shorter scan times (although time savings would
be moderate as sufficient time between readouts has to be allowed for the recovery
of the magnetisation), and more importantly the advantage of lower SAR values.
Figure 3.16.3.: GCE profile at different saturation length. GCE build up
quickly for fast exchanging hydroxyl groups, providing maximum signal at
short saturation times. Long saturation stabilises the signal in the steady
state with lower maximum asymmetry. After saturation is stopped GCE
relaxes towards zero with T1.
At 3 Tesla the reduction of the signal close to water due to direct saturation is
more severe than at 9.4 Tesla (because the chemical shift is proportional to B0 while
the absorption lineshape remains constant). Furthermore, commonly clinical MRI
scanner manufacturers limit the maximum duty cycle for long RF pulses to 50%.
This produces peaks of high saturation power which aggravate the effect of direct
saturation for a given equivalent B1. As a consequence the GCE at 3T reaches
its maximum amplitude around 2 ppm, in contrast to the 1 ppm range observed at
9.4T. Figure 3.16.4 shows the peak of the GCE signal to move away from the water
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frequency as the slow MT effect builds up. The maximum intensity is achieved
around the 2 ppm range for B1 power of 2 𝜇𝑇 .
Figure 3.16.4.: Saturation time optimisation at 3T. The GCE signal peaks
at around 2 ppm and saturation length below 1 second. At steady steady
state signal stabilises close to 3 ppm but with lower intensity than at
shorter saturation times.
3.17. Conclusion
The exchange principle behind CEST can be easily expressed in a mathematical
form. Ranging from the most simple two-pool system to more complex multi-pool
interactions, the dynamics of CEST can be accurately described using computer
simulations.
This allows the inspection of each parameter’s effect on the final CEST signal and
helps form an intuitive understanding of the expected experimental result, before
testing it in a real setting.
With this information, the process of optimising a CEST sequence for a particular
application becomes more guided and efficient rather than a blind trial and error
process.
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3.17. Conclusion
In this chapter the behaviour of the CEST contrast under several conditions has
been analysed. The CEST profile of glucose in different concentrations has been
accurately modelled as well as the general Z-spectra of a mouse brain in vivo, which
included the contributions of amides, amines, and aliphatic protons, as well as MT.
The impact of different macromolecular pool content and pH levels on the MTR
asymmetry have been assessed.
For cases where physiological noise is present, the benefits of taking a normalisa-
tion reference close to water has been explained. Along the same lines an alternative
measure of CEST asymmetry has been proposed which is inherently normalised by
its definition. As for the raw noise, the relationship between the saturation power,
reliability of CEST contrast and the level of noise in data has been shown. The anal-
ysis indicated that for investigating glucose, B1 power levels of around 3 to 4 𝜇𝑇
yields good CEST contrast in most situations and that an increase of power above
that level is likely to increase uncertainty in the measurement due to loss in SNR.
The expected signal in an in vivo glucoCEST experiment is generally small. This
is particularly true at low B0 fields and poses a big challenge for glucoCEST in
the clinic where current standard strength is 3 Tesla and only a few centres in the
world have access to 7 Tesla human scanners. Efforts to increase SNR are therefore
necessary. Repeated acquisitions aimed to average noise out and sacrifices in spatial
resolution may be required in order to confidently measure the glucoCEST signal.
On the other hand, optimisation of the scanned offset frequencies and the sat-
uration length can yield increases in the GCE signal. The simulations show that
at B0 field of 9.4 Tesla integration range around the 1.2 ppm offset provides the
maximum glucoCEST contrast while at 3 Tesla and saturation with 50% duty cycle
the optimum integration range appears to be around the 2 ppm range from water.
At both fields short saturation times (below 1 second) offer superior signal than at
steady state, which also helps reduce the acquisition time as well as the SAR of the
glucoCEST protocol.
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4. Chemical exchange properties
of glycolytic sugars
4.1. Abstract
In this chapter the CEST properties of the first four sugars along the glycolytic path-
way (glucose, glucose 6-phosphate (G6P), fructose 6-phosphate (F6P) and fructose
1,6-biphosphate (F16bP)) are explored under different conditions. Glucose and the
first three glycolytic intermediate molecules will be tested as potential CEST agents
which may be exploited as markers of increased metabolic activity in cancer and
other conditions in which the metabolism is disturbed. With the obtained results the
possibility of intracellular origin of glucoCEST signal is discussed.
As the second part of the study, the influence of glucose on the observed relaxation
rate R2 is investigated. Themethod has been recently proposed byYadav et al.1 as an
alternative method to glucoCEST for the detection of small concentration of glucose
with MRI. Results of the 𝑇2 relaxivity due to glucose are compared to the contrast
obtained from CEST.
4.2. Introduction
GlucoCEST has been shown to be sensitive to distinguish elevated glucose uptake
in tumours.2 However, to this date, it is not clear whether the glucoCEST signal
comes from glucose molecules only, or if other sugars from the break down process
of glucose contribute to the signal as well.
Initial reports in the literature revealed a sceptical opinion about the possibility of
intracellular signal detection. However, more recent reports consider the source of
glucoCEST signal as being intracellular.2–5
If shown to be the case, the detection of intracellular glucoCEST signal could open
an exciting possibility to study the kinetics of cellular glucose uptake and utilisation
with MRI. This kind of dynamic analysis can be useful for the characterisation of
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several conditions associated with dis-regulated glucose metabolism including dia-
betes, neurological disorders such as epilepsy and cancer.
4.2.1. Bioenergetic pathways background
4.2.1.1. Cellular Respiration
Cellular catabolic reactions convert biochemical energy from nutrients into adeno-
sine triphosphate (ATP), the energy ‘currency’ of living organisms. The chemical
energy stored* in ATP is used to drive energy hungry processes including cell sig-
nalling, biosynthesis, locomotion or transportation of molecules across cell mem-
branes.6,7 The process of converting organic matter into small energy packages able
to generate work is generally called cellular respiration.
Across nearly all living organisms, glucose is the primary fuel molecule used
to harvest energy through cellular respiration. Overall, the metabolism of glucose
inside the cell consists of the oxidation of glucose to𝐶𝑂2 and𝐻2𝑂. In the process,
through a complex path of enzymatic chemical reactions, more than 30 molecules of
high energy ATP are synthesized from adenosine diphosphate (ADP) and inorganic
phosphate Pi.8 Overall the process of harvesting energy from glucose can be divided
into three stages namely, glycolysis, citric acid cycle and the electron transport chain.
For conciseness and relevance to this work, the process of glycolysis will be ex-
plained in the following and only a brief mention of the citric acid cycle and the
electron transport chain will be made for completeness. To obtain more information
about the metabolism of carbohydrates specificity please see reference Lodish et al.9
in the bibliography.
4.2.1.2. Glycolysis
Glucose is transferred into the cytosol of the cell by the GLUT† transporters where
the process of glycolysis takes place. In the glycolytic process, also known as the
Embden-Meyerhof pathway, glucose is split into two molecules of pyruvate with a
resulting net production of two molecules of ATP per molecule of glucose.
The chain of glycolytic reactions is constituted by the following 10 steps:
*Theweakly bonded phosphate groups in ATPmolecules are easy to brake which allows stronger
bonds to form, effectively transferring energy from one molecule to another.
†GLUT or glucose transporters are a group of membrane proteins that facilitate the transport of
glucose across plasma membranes. Each GLUT isoform plays a precise role in the metabolism of
glucose, which is determined by its specificity to substrates, the transport kinetics, and their regula-
tion under different physiological conditions.10,11
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1.
G→G6P (−ATP)
Phosphorylation of glucose (G) into glucose-6-phosphate (G6P). The hydro-
gen on the alcohol on carbon 6 of glucose is replaced by a phosphate group
from the ATP by hexokinase enzyme.
2.
G6P→ F6P
Phosphoglucose isomerase changes the glucose structure to fructose by swap-
ping the C=O and alcohol groups on carbons 1&2 to form fructose-6-phosphate
(F6P).
3.
F6P→ F16biP (−ATP)
Phosphofructokinase replaces the hydrogen on the alcohol group of C1 with
another phosphate group to produce fructose-1,6-bisphosphate (F16biP).
4.
F16biP→GLAP+DHAP
Aldolase splits F16biP into two 3 carbonmolecules, glyceraldehyde 3-phosphate
(GLAP) and dihydroxyacetone phosphate (DHAP).
5.
DHAP→GLAP
Triose phosphate isomerase converts DHAP intoGLAP by changing the struc-
tural configuration. From this step onwards there are two molecules per one
of glucose.
6.
2𝑥 {GLAP→ 13biPG (−Pi) (+NADH)}
Glyceraldehyde 3-phosphate dehydrogenase replaces hydrogen on C1 with
oxygen and a phosphate group to produces 1,3-bisphosphoglycerate (13biPG)
and a reduced nicotinamide adenine dinucleotide molecule (NADH).
7.
2𝑥 {13biPG→ 3PG (+ATP)}
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Phosphoglycerate kinase removes the phosphate group from C1 from 13biPG
to give 3-phosphoglycerate (3PG) and adenosine triphosphate (ATP).
8.
2𝑥 {3PG→ 2PG}
Phosphoglyceratemutase swaps C2&C3 to create 2-phosphoglycerate (2PG).
9.
2𝑥 {2PG→ 2PEP (+H2O)}
Enolase removes the alcohol on C3 forming a C=C between C2 & C3 and
produces phosphoenolpyruvate (PEP) and water.
10.
2𝑥 {2PEP→ Pyruvate (+ATP)}
Pyruvate kinase removes the phosphate group from C2 in 2PG to yield in
pyruvate and another ATP molecule.
Glycolysis alone brings just about 5% of all the biochemical energy in glucose.
However, it is a very rapid reaction and most importantly it does not rely on oxygen.
During step 6 of the intermediates glycolytic reactions the coenzyme nicotinamide
adenine dinucleotide NAD+ is reduced to NADH. This coenzyme is essential for
glycolysis and the reaction cannot continue in its absence, which is why a constant
replenishment of NAD+ in the cytosol is required. In normal oxygen conditions
(normoxia) the regeneration occurs via the mitochondrial oxidation of NADH in the
electron transport chain.
In the absence of oxygen, the cell resorts to an emergency procedure. In this
situation, glycolysis does not end in pyruvate but in lactate instead mediated by one
last reaction.
2𝑥 {Pyruvate+NADH+H+→ Lactate+NAD+}
The NADH is re-oxidized by reducing pyruvate to produce lactate. The produc-
tion of lactate from glucose is known as anaerobic glycolysis and is a rapid process
that allows glycolysis to proceed at a fast rate*
*In cancer cells the anaerobic glycolysis pathway is active even in the presence of oxygen, a
phenomenon known in the cancer research field as the ’Warburg effect’ or somewhat confusingly as
’aerobic glycolysis’, to emphasise the fact that the fermentative (lactic acid) process occurs despite the
abundance of oxygen. The over-expression of the ’aerobic glycolysis’ in tumour cells is considered
a Hallmark of Cancer which is further analysed in Chapter 5.
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4.3. Aim of the study
The net production ofATP by glycolysis (in the absence of oxygen) is twomolecules
of ATP per molecule of glucose. But as a fast reaction it can provide energy and the
necessary glycolytic intermediates at an elevated rate. Despite an inefficient ratio
of ATP generation per glucose consumed, glycolysis can produce ATP molecules at
a rate 100 times faster than the aerobic respiration.12 This is part of the reason why
during short periods of intense exercise, when oxygen supply cannot cope with the
demand, muscle cells switch to anaerobic glycolysis.
It is important to be reminded that the cellular membrane is not permeable to
the sugars produced in the glycolytic chain, and unlike glucose which is abundant
outside the cell, the glycolytic intermediates are only present inside the cell.
4.2.1.3. Citric acid cycle and electron transport chain
A protein transport system takes the pyruvate from the cytoplasm into the mitochon-
dria. In the mitochondria the pyruvate formed during glycolysis gets converted to
acetyl CoA. Enzymatic reactions known as the citric acid cycle, Kreb’s Cycle or
Tricarboxylic Acid Cycle, breakdown the acetyl CoA into CO2 and H2O with the
release of energy in the form of ATP, NADH and FADH2.
In the electron transport chain the electron carriers in the inner mitochondrial
membrane are organized in such a way that each transport steps reduces the free
energy of the biochemical system. The released energy in these reactions is used
to generate ATP from ADP and 𝑃𝑖. Overall, thirty molecules of ATP are synthe-
sized per one molecule of glucose. In the process NADH formed in glycolysis gets
re-oxidized to NAD+ which keeps the glycolytic metabolic cycle going in the cyto-
plasm.
4.3. Aim of the study
4.3.1. Parameter optimisation
A number of parameters influence the CEST signal. As such part of this study aims
to explore which of these parameter and under which conditions the CEST contrast
could be maximised. The dependence of CEST data on sugar levels, concentration
of phosphates, pH values, temperature and B1 saturation power will be explored in
each of the glycolytic intermediate molecules.
To shed some light on whether intracellular sugars could contribute to the ob-
served CEST signal, a phantom experiment was planned, aiming to investigate the
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CEST signal response of the first four molecules in the glycolytic pathway, at con-
ditions similar to the expected ones in vivo.
Figure 4.3.1.: The monosaccharides involved in the first 3 steps of the
glycolytic pathway. Among them only glucose is present outside the cells.
4.3.2. Spatial reproducibility check
When dealing with small signals any variations in the setup can yield to significant
changes in the experiment outcome. One possible variation is the performance of the
transmitter coil to produce an homogenous irradiation field inside the coil. Spatial
variations of the B1 field could result in important signal drifts. To address this
concern a study was planned to measure the robustness of the CEST measurement
by scanning sugar samples at two positions inside the RF coil. Simply enough the
second setting was obtained by rotating the sample 90°clockwise from the original
position (see Figure 4.5.13).
4.3.3. Relaxation time
Chemical exchange processes in a solution are known to alter the observed relax-
ation time of the solvent. In a second part of the study, the effect of glucose on
the relaxation properties of water is analysed. Comparison between CEST data, 𝑇1
and 𝑇2 maps are performed in order to check possible relationships between the two
contrast mechanisms and obtain more information on potential confounding factors
affecting CEST imaging technique.
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4.3.4. Correlation of 𝑇2 with Z-spectrum width
Lastly, the relationship between the 𝑇2 relaxation time of the sample and the width
of the Z-spectrumwill be explored as an alternativemethod to estimate𝑇2 relaxation
times.
4.4. Experimental procedure
4.4.1. Sample preparation
Two groups of phantoms were prepared. The first set comprised 64 liquid phantoms,
combining concentration of sugars and pH in a range of physiological values. A
second set of 16 solid phantoms was prepared with relaxation times matching the
ones in vivo. Specifics for each set are described below.
4.4.2. Liquid samples
Glucose, glucose 6-phosphate (G6P), fructose 6-phosphate (F6P) and fructose 1,6-
biphosphate (F16biP) were chosen as they contain the largest number of exchange-
able -OH groups, 5, 4, 4 and 3, respectively. Solution of these compounds were
prepared in 1% PBS at the chosen concentrations of 5, 10, 20 and 40 mMolar. An
initial highly concentrated sample was also prepared to be able to distinguish the res-
onance frequencies of the labile molecules from the marked peaks produced at high
levels of CEST agent. Values for pHwere calibrated at 6.8, 7.0, 7.2 and 7.4 using hy-
drochloric acid (HCl) and sodium hydroxide (NaOH). All phantoms were prepared
and scanned within the same day to avoid potential pH drifts and consumption of
glucose by bacteria. The samples were scanned at 23°, 29°, 33°and 37°Celsius,
allowing a 30 minute gap between scans to guarantee constant temperature.
4.4.3. Solid samples
Solutions of glucose and glucose 6-phosphate were prepared with 3% agar and 0.07
mMolar gadolinium in 0.2X PBS solution, in order to achieve the consistency and
relaxation times similar to the observed ones in the brain; 𝑇1 of 1800 ms and 𝑇2 of
40 ms (at 9.4 Tesla).
Solutions were prepared in gadolinium doped water to the specific concentrations
and pH. The same amount of agar was added to all samples prior heating them in
a microwave at low power setting. Calibration of pH was checked before and after
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the cooking process to ensure stability of the pH. The different sugar concentrations
were prepared ranging from 5 to 20 mMolar in steps of 5 mMolar. The pH was
titrated at 4 different values; 7.3, 7.0, 6.7 and 6.4 using HCl and NaOH.
4.4.4. Temperature control
Temperature in the scanner wasmonitored by a thermocouple temperature probe and
controlled by the flow of warm air though the scanner bore (Small Animal Instru-
ment). For large sized phantoms, even when the mean temperature of the samples
is stable, circulation of water due to convection is unavoidable. These water move-
ments produce inhomogeneities which cannot be fixed by a standard B0 correction
as the magnetic field variation is dynamic in time. As a consequence the satura-
tion profile is less homogeneous and the quality of the CEST data gets affected.
An effective way to reduce the harm is to make the phantoms smaller (particularly
along the direction of the temperature gradient) and if possible to make more vis-
cous phantoms that would resist the fast movements of mass. In practice the eroding
effect of the convection phenomenon is not too concerning. The analysis of these
type of phantoms usually requires information on the averaged CEST value for a
particular sample, which leaves spatial information from a pixel by pixel analysis in
a second place. Furthermore, for in vivo studies convection effects are minimal as
the biological tissues are mostly semi-solids, have no large volumes of liquid around
(CSF could be an exception, but no structural information is expected) and do not
experience significant temperature gradients.
4.4.5. MRI Sequence
The phantomswere scanned in a horizontal 9.4TMR scanner (Agilent Technologies)
with a volume receive/transmit RF coil with a 33millimetre internal diameter (Rapid
Biomedical). Prior the scan all phantoms were shimmed to a linewidth below 20 Hz
(an average of 17±3 Hz).
4.4.5.1. CEST
The sequence used to acquire the CEST data was a modified Turbo-FLASH (64x64,
FOV=19x19x4mm, TR=3.5s, TE=1.52ms) for the readout part, with the inclusion
of a 4.5 second duration pre-saturation train of pulses. Each pulse consisted of 50
millisecond Gaussian (standard deviation of 8.55 ms) RF shape followed by 5 ms
delay to reduce the stress on the amplifier by lowering the duty cycle (91%). The Z-
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spectrum was sampled at 59 equally distributed offsets over a 10 ppm range centred
at the water frequency.
During the readout the data matrix was filled starting from the centre of the K-
space and expanding towards the edges (inverse centric), in order to maximize the
contrast in the low frequencies, at the expense of a higher definition in the images.
This was done assuming the contrast in the CEST images changes smoothly, as
would be the case inside each phantom.
A set of radiation powers were used, equivalent of a constant B1 RF pulse of 0.9,
1.28, 1.6, 1.92, 2.56 and 3.2 𝜇T.
4.4.6. CEST analysis
Calculation of the CEST signal was done by fitting a Lorentzian curve to the Z-
spectra in a pixel by pixel basis. To avoid any asymmetry errors when fitting the
Lorentzian, data on the negative side of the spectrum (from -1 ppm to 0 ppm) were
fitted. Subsequently, any B0 shifts found in the images were corrected by setting
the frequency of water to minimum point of the Lorentzian fitted curve. Finally the
CEST values were calculated by integrating the difference between the experimental
Z-spectra and the fitted Lorentzian between 0 and 4 ppm.
It has to be noted that in the absence of aliphatic peaks, MTR asymmetry analysis
produced the same outcomes as the Lorentzian fitting approach. Therefore, when
referring to the CEST signal the term MTRasym will be used indistinctively.
Results and discussion
Part I:
4.5. CEST properties of sugars
4.5.1. CEST contrast in all the sugars
The first clear result is that all four molecules generate significant CEST signal.
This is an important outcome because it confirms a necessary condition for the hy-
pothesis of intracellular origin of CEST, that is, sugars formed inside the cell can
generate CEST signal. For the case of G6P in particular, the averaged magnitude
of the observed CEST is consistently within the same range as in glucose. There
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are even certain conditions, discussed below, in which G6P appears to exceed the
CEST contrast capacity of glucose.
Figure 4.5.1.: Reprinted from Walker-Samuel et al.2 Left: Z- and MTRasym
spectra from glucose, glucose 6-phosphate, fructose 6-phosphate and fructose
1,6-biphosphate, at 100 mM concentration and 37°C. Right: Averaged signal
(integration of the MTRasym) from the same sugars at different concentrations.
The two pentoses, fructose 6-phosphate and fructose 1,6-biphosphate, give con-
siderably less CEST signal.
It is also worth noting at the signal discrepancies between the hexoses and the
pentoses. At the same conditions, both hexoses (glucose and G6P) produce signif-
icantly higher signal than the pentoses (F6P and F16bP). The average signal ratios
relative to glucose are 0.93 ± 0.11, 0.61 ± 0.09 and 0.54 ± 0.13 for G6F, F6P and
F16bP respectively.
As a first guess one would expect the CEST signal to be proportional to the num-
ber of exchangeable sites in the molecule. The total number of hydroxyl groups
in each of these monosaccharides is 5, 4, 4 and 3 for G, G6P, F6P and F16biP re-
spectively. It is clear that this relationship does not match with the signal intensity
observed experimentally.
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4.5.1.1. CEST contributing protons in monosaccharides.
It is a well known fact in biochemistry that the anomeric * hydroxyls in the first
carbonC1 are known to be very reactive; in fact they are the first natural link between
monosaccharides to form disaccharides and polysaccharides.9 Hence, the exchange
of the protons in the anomeric hydroxyl is likely in a too fast regime for CEST, and
will not have a significant contribution to the overall signal.
Furthermore, a closer look at the molecular structure of these sugars reveals 2
hydroxyl groups outside the ring structure (linked to C6 in G and to C1 in F6P and
circled in red in figure 4.5.2).
Figure 4.5.2.: Molecular structure of G, G6P, F6P and F16biP. Hydroxyl
groups in the cyclic structure are circled in green and blue, the last one
being the anomeric site. Hydroxyls circled in orange are not part of the
ring structure of the molecule and have little contribution in the CEST
contrast.
The enzymatic phosphorylation in glycolysis occurs at precisely these hydroxyls,
which have a higher degree of mobility due to their position in the molecules. Not
surprisingly, the NMR relaxation rate (dipolar relaxation) of hydroxyls groups in C6
has been reported to bemore than twice as fast as other hydroxyls in the ring structure
(excluding the fast exchange found in the anomeric hydroxyl).13 This suggests that
*Carbohydrates dissolved in water usually exists in cyclic form. In its formation the linear
aldehyde is bended to the side, taking the C5 hydroxyl close to the C1 aldehyde carbon. Once
bonded C1 carbon atom becomes a new stereocenter, referred to as the anomeric center, and the
𝛼 and 𝛽 isomers are called anomers. The anomeric center is a site of enhanced reactivity in the
sugar, in terms of substitution of the carbonyl. The anomeric hydroxyl group and a hydroxyl
group of another sugar can join together, releasing a water molecule to form a glycosidic bond.
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the chemical exchange rate for this particular hydrogen will also be enhanced and
as a matter of fact, the second branch in polysaccharide such as starch or glycogen
is formed through a link at the C6. See figure 4.5.3.
Figure 4.5.3.: Molecular branched structure of glycogen. Glucose molecules
are linked together linearly by 𝛼(1→ 4) glycosidic bonds (shown in blue). Side
branches are linked to the main chains by 𝛼(1 → 6) glycosidic bonds, formed
between hydrogens in C1 and C6 carbons (in orange).
In this situation, the revised number of protons that would actually produce signif-
icant CEST signal would be 3, 3, 2 and 2, for G, G6P, F6P and F16bP respectively.
These numbers match reasonably well with the signal ratios observed in the exper-
iments.
These ratios alone cannot explain the subtle signal variations seen betweenmolecules,
which probably arise from conformational differences. However, it is reasonable to
think, given the similar CEST magnitudes within hexoses and pentoses, that the hy-
droxyls outside the cyclic structure do not contribute significantly to the production
of the CEST contrast.
4.5.2. Concentration
Blood glucose level in healthy humans ranges between 4 and 6 mMolar before
meals and rises temporarily up to 8 mMolar shortly after eating. An example of
the glycemic response in two healthy volunteers is shown in figure 4.5.3.
Under the right medical supervision these levels can be safely increased up to
15-20 mMolar by a venous infusion of glucose.14
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Figure 4.5.4.: Blood glucose level test of two healthy volunteers.
Glycemia rises from a basal level of 4.3 mMolar to a peak of 6.8 mMolar
around an hour after food ingestion.
For the glucoCEST technique to be useful in the clinic one should be able to detect
changes in glucose concentration similar to those occurring in vivo. In practical
words this means that a sample at 10 mMolar glucose concentration should provide
significantly higher CEST signal than a 5 mMolar one.
It can be observed from figure 4.5.5 that at 5 mMolar concentration the CEST is
significantly lower than at any of the higher concentrations. The increase in signal
is biggest for glucose with a 2.1±0.3 enhancement ratio from 5 to 10 mMolar. In
the case of the other 3 sugars the signal increase is not as drastic, however it is still
very significant (p<0.05). This result arises from liquid solution scanned at pH 7.0
and equivalent B1 power of 1.92 𝜇T.
It should be noted however, that the signal enhancement due to the concentration
of glucose (and the rest of the sugars) will be very much dependent on the specific
conditions of the environment in which the scan is performed. Different pH values,
saturation power, and crucially 𝑇2 relaxation times will yield to completely differ-
ent enhancement ratios for the same glucose increase. In general fast relaxing media
will produce less signal enhancement as the CEST peaks become less defined due
to spectral broadening at short 𝑇2 relaxation times. For this reason the investiga-
tion of CEST effects at specific conditions for each application is important before
predictions of expected signals can be made.
Figure 4.5.6 shows the CEST signal from phantoms in 3% agar. In contrast to the
liquid sample, here the signal enhancement is 1.6 ± 0.2 at best, when moving from
from 5 mMolar to 10 mMolar.
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Figure 4.5.5.: CEST concentration dependence of G, G6P, F6P and
F16biP at pH 7.0 and equivalent B1 power of 1.92 𝜇 T. A monotonic in-
crease of the MTR asymmetry with concentration is manifested in all 4
sugars, with significant signal differences between the low and high con-
centrations.
Figure 4.5.6.: CEST signal of G andG6P solutions in 3% agar at different
pH and concentrations. Equivalent B1 saturation power of 1.92 𝜇 T. At
these conditions and ranges, the signal enhancement due to pH variation
exceeds the contrast due to concentration change.
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Figure 4.5.6 also demonstrates the extent to which pH modulates the CEST out-
come, even exceeding the effect due to concentration at these ranges.
[Note: The disproportionately elevated signal of glucose at pH 6.4 is likely a fluke
due to inaccurate pH calibration]
4.5.3. pH
As can be seen in figures 4.5.6 and 4.5.7 the pH of the solutions has a profound
impact on CEST.
The elevated signal observed at the lowest pH values agrees with the notion of fast
exchange rates in the sugars, as when the medium acidifies the exchange rate slows
down to a more optimum regime for CEST, therefore producing more contrast. For
a discussion on the effect of pH in CEST please refer to 1.4.5.
As in the previous case the observed signal ratios vary from samples in liquid and
solid state (agar phantoms). In liquid samples (figure 4.5.7), the pH seems to affect
glucose the most while the rest of the sugars appear to have a less acute response
to variations in pH. Nonetheless, it can be inferred with no loss in generality that
across the physiological range tested, the signal is lowest in basic environments and
it increases as the medium acidifies.
4.5.4. Concentration vs pH
Tissues at different pH will have an unequal response to the same amount of glu-
cose delivery. Acidic media, for example the extracellular space of tumours, will
display higher glucoCEST enhancement, while a more basic region will have a less
pronounced signal increase.
During an in vivo glucoCEST experiment glycemia level may vary between 4 and
20 mMolar (it will depend on the glucose administration route). On the other hand
the pH level in healthy and cancerous tissue could vary between 7.3 and 6.7 respec-
tively.15,16 For this physiologically relevant range, the CEST signal gradient along
the concentration and pH axis are both within the same order and it can be argued
that glucoCEST alone will not be able to separate what percentage of the measured
signal is caused by an increase in glucose concentration and what percentage of it
arises from the enhanced effect of being in a more acidic medium.
Considering the agar phantom as the one closer to in vivo conditions and the B1
saturation power of 1.6 𝜇 T adequate for clinical use (due to SAR limitations, values
around 2 𝜇 T tend to be the maximum allowed saturation power on 3 Tesla clinical
scanners), the relation of CEST with concentration and pH is summarised in Figure
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Figure 4.5.7.: CEST dependence on pH for G, G6P, F6P and F16biP at 20
mmMolar and equivalent B1 power of 1.92 𝜇 T. Acid environment favors
the CEST contrast by slowing the exchange rate towards the intermediate
exchange regime.
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Figure 4.5.8.: Comparison of the influence of pH and concentration on
CEST. The lines show the observed CEST signal in G and G6P at different
pH values. The 2 lines on top represent samples at concentration of 20
mMolar, the 2 lines on the bottom at 5 mMolar. Signal intensity from
concentrated samples overlap with signal from more diluted but acidic
samples.
4.5.8. Except for the edge cases (in the extreme limits of any physiological rele-
vance), it is not possible to distinguish whether the magnitude of the signal is due to
a particular sugar concentration or due to different pH in the sample.
Moving from an environment with pH 7.2 to another with pH 6.7, the observed
increase in the mean signal from both sugar together is 0.015±0.003 units of MTR
asymmetry. On the other hand the signal increase due to concentration going from
5 to 20 mMolar is 0.010±0.003 units. These results show the variation in pH to
be 50 percent more effective in producing the CEST contrast than changes in the
concentration.
Although the above ratio will certainly vary depending on the saturation power
and tissue parameters, it is fair to conclude that pH variations within the physiolog-
ical range could alter significantly the results of glucoCEST experiments.
Although only G and G6P are shown here, the same conclusions apply to F6P and
F16biP.
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4.5.5. Temperature
Contrary to what was reported for glycogen with glycoCEST,17 CEST signal from
the hydroxyl groups in the monosaccharides decreases as temperature increases to-
wards 37°C (see Figure 4.5.9). This effect, although possibly counter-intuitive as
the exchange rate speeds up with temperature, demonstrates that each of these sug-
ars at 23°C are already close to the fast exchange rate regime, which is not the ideal
condition for CEST (see section 1.4.5 in Chapter 1). Any increase in temperature
takes the exchange rate further away from the optimum intermediate exchange rate
best suited for CEST.17–19 Hence the signal is lower at 37°C than at 23°C.
Figure 4.5.9.: CEST temperature dependence of G, G6P, F6P and F16biP
at pH 7.0 and equivalent B1 power of 1.92 𝜇 T. A linear decrease of the
MTR asymmetry is observed in all 4 molecules as the temperature raises.
The observation fits with the assumption of exchange rates being very
rapid in these molecules.
Generally, exchangeable sites from small molecules, tend to exhibit very fast ex-
change rates due to their fast tumbling motion (low correlation times). Large macro-
molecules like glycogen are less mobile and less accessible to the free water, thus
their -OH groups have a slower exchange rate. Due to their small size, the signal
decrease associated with an increase in temperature is an effect that applies to all the
sugar in the study (all monosaccharides). This is a rather unfortunate circumstance
for in vivo glucoCEST applications which limits the CEST contrast from OH groups
in small sized molecules.
As a remark, G6P appears to be less sensitive to variations in temperature as it
can be observed from the smaller gradient in Figure 4.5.10. Glucose displays a more
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Figure 4.5.10.: Mean values of CEST signal in G and G6P phantoms at
varying temperature and concentration. Left: glucose presents a strong
gradient in concentration and temperature. Right: G6P is less sensitive
to temperature and offers same signal levels as glucose at 37°C.
pronounced signal drop, which at 37°Cmakes the signal of G6P very similar or even
higher than glucose.
4.5.6. PBS vs Saline solutions
Controlled preparation of phantoms requires the use of pH buffering salts which
allow the titration of the samples to specific pH values. A commonly used concen-
tration (1x PBS) would contain 10 mM 𝑃𝑂3−4 , 137 mM NaCl, and 2.7 mM KCl in
pure water. The phosphates in the buffered solution act as exchange catalysers by
enhancing the dissociation rate of hydroxyl protons (the reader is referred to section
1.4.5 for more information on exchange catalysers). The data in figure 4.5.11 shows
a reduced CEST effect in the sample with PBS solution as compared to the one in
saline solution. The boost in chemical activity, in this case due to the addition of
phosphates, takes the exchange rate above the regime in which the CEST mecha-
nism is efficient, above the intermediate exchange regime. As in the case of high
temperatures, sugars dissolved in high amounts of phosphates produce less MTR
asymmetry and their potential to produce CEST contrast is reduced.
An exchange rate strongly dependant on phosphates could have profound impli-
cations for CEST in vivo. As different compartments in the tissues have distinct
phosphate contents, it is to be expected that their CEST response will vary from one
to another. Incorporating that information in the CEST analysis could help clarify
important questions regarding the source of the glucoCEST signal and its variation
across different tissue characteristics.
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Figure 4.5.11.: Z-Spectra of 40 mMolar glucose solutions in saline and
1x PBS. Scanned at 37°C and pH 7.4. Exchange catalysis effect of phos-
phates in PBS reduces the CEST contrast of glucose. This is yet another
indication of the fast chemical exchange between glucose hydroxyl pro-
tons and water.
4.5.7. Power
The saturation preparation is essential in CEST experiments as it is during this pro-
cess that the magnetic labelling takes place before is exchanged with water. As such,
the B1 irradiation power is a critical parameter that can enhance or ruin the CEST
contrast if used inadequately. In this study a relatively narrow range of power has
been explored, which already makes a considerable difference in the intensity of the
MTR asymmetry.
Overall, the highest B1 powers used in the study yielded the biggest CEST signal
across all phantoms. This is consistent with substances in fast exchange rate for
which elevated powers increase the labelling effectiveness.
Nevertheless, using higher powers does not always improve the CEST signal. A
good estimate for the optimumpower is usually accepted to be𝐵1=𝜅/2𝜋where𝜅 is
the exchange rate of the CEST pool. This relationship, predicted byWoessner et al.20
was introduced for paramagnetic CEST agents which resonate a few tens of ppm
away from water. Accordingly, the reduction of available water signal caused by
direct saturation and MT is not taken into consideration and the predicted optimum
B1 power tends to be too high for diamagnetic CEST agents like sugars. This fact is
already acknowledged in a study by Desmond et al.21 where they report lower than
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Figure 4.5.12.: Dependence of 𝐵1 saturation power on observed CEST
contrast in G, G6P, F6P and F16biP at 20 mMolar concentration in
PBS solution. Generally largest MTR asymmetries are obtained when the
molecules are saturated at high powers.
the predicted values of B1 power to produce the highest CEST contrast.
Besides the SAR considerations, using very elevated powers has the drawback
of producing noisier CEST measurements close to water. As the power increases
the total magnetization available to produce signal reduces considerably, yielding to
noisy data well below the numerically estimated optimumpower. This is particularly
relevant in non aqueous samples for which saturation profile becomes especially
broad due to the short 𝑇2 relaxation rate. In Chapter 3 the relationship between B1
power and resulting CEST signal is discussed for a range of in vivo situations.
Owing to the multiple factors involved in the production of CEST contrast, opti-
mum B1 power is approximated using computer simulations (as shown in Chapter
3), and later tested experimentally for each application according to hardware and
SAR limitations.
4.5.8. Spatial reproducibility
Two CEST scans were performed for the same phantom where the location of the
solutions within the coil was changed. As illustrated in figure 4.5.13 in experiment
B the sample was rotated 90 clockwise relative to the position in experiment A.
The results from both experiments show that phantoms at same concentration give
141
Chapter 4. Chemical exchange properties of glycolytic sugars
Figure 4.5.13.: Image of showing the position of each phantom in the first
experiment A and in the rotated experiment B.
Figure 4.5.14.: Comparison of the CEST signal obtained for each phan-
tom in experiment A and experimant B. Reproducibility in the measure-
ments demonstrate that CEST contrast is invariant to the position of the
coil.
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the same level of CEST regardless of the position in the coil. Comparison between
experiments lead to no significant differences between samples in experiment A and
B. Only the 5 mMolar solution scanned at 1.3 𝜇 T showed a significant change in
signal intensity when rotating the sample (p<0.05). Nevertheless, the variation ob-
served in this phantom did not significantly impinge the spatial reproducibility of
CEST in this coil. Other factors like small drifts in pH, circulation of water due to
a temperature gradient or amount of agar used had generally a bigger impact in the
stability of the CEST signal. In this context it is worth noticing that measurements
of the phantom at 10 mMolar produced some inconsistent results compared to the
pattern observed from the rest of the samples (see Figure 4.5.14 ). The odd values
obtained, which were likely caused by an abrupt field inhomogeneity due the for-
mation of an air bubble in the sample, were reproduced in both the experiment A
and B. This test confirmed that the position of the samples within the coil did not
have a significant impact in the obtained CEST signal.
Study part 2
4.6. Relaxation in the presence of chemical
exchange.
4.6.0.1. Transverse relaxation
Higher sugar concentration phantoms tend to produce wider Z-spectra. The domi-
nating parameter in the widening effect of the Z-spectrum is the transverse relaxation
time 𝑇2; shorter relaxation times leading to broader water profiles. One could log-
ically question the cause of the shortening in the measured 𝑇2 value (or increase
in relaxation rate 𝑅2) when sugar is diluted in water. In the case of a static solu-
tion of sugar and water there are two main reasons that explain the enhancement of
relaxation rate 𝑅2.
On one side the sugar content in the sample increases the viscosity of the solu-
tion. Viscous solutions contain larger amount of ‘bound water’ than liquid ones22
which slows down the molecular rotational correlation time. Long correlation time
leads to efficient transverse relaxation (non-efficient ‘motional narrowing’), hence
the shortening of 𝑇2. At low concentrations of sugar however, the viscosity of the
solution does not change significantly,1 which excludes the viscosity as the cause
of enhanced transverse relaxation. This argument can be experimentally verified by
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Figure 4.6.1.: Z-spectra and MTR asymmetry corresponding to PBS and
glucose solutions at 3 concentrations. The Z-spectra become wider as the
sugar concentration increases.
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measuring 𝑇1 relaxation time (see 4.6.0.2), which is not influenced by the exchange
process but does vary with viscosity. The longitudinal relaxation time 𝑇1 is relevant
to the final contrast obtained with CEST. However, the influence of the chemical
exchange process does not alter 𝑇1 relaxation time itself. Unlike 𝑇2 which can vary
significantly, 𝑇1 remains constant for a wide range of exchange rates (see section
4.6.0.2 below).
The second mechanism for enhanced transverse relaxation is the proton exchange
process between the hydroxyl group in sugar and free water. The consequence of
the increased 𝑅2 relaxation is inherent to the dynamics of the Bloch-McConnell
equations, and will be addressed in the following section.
Figure 4.6.2.: Measured transverse relaxation rate 𝑅2 of glucose solu-
tions as concentration varies. The relaxation rate increases linearly with
glucose concentration in both tested temperatures.
Note: Variations in temperature will also change the transverse relaxation rate.
The predictions from the Bloembergen-Purcell-Pound (BPP) theory* is that an in-
*According to the Bloembergen-Purcell-Pound (BPP) theory the relaxation times of pure sub-
stances can be expressed in terms of their correlation time 𝜏𝑐 and 𝜔0 Larmour frequency as:
1
𝑇1
=𝐾[ 𝜏𝑐1+𝜔20𝜏2𝑐
+ 4𝜏𝑐1+4𝜔20𝜏2𝑐
]
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crease in temperature should make the 𝑇2 relaxation time longer, as the correlation
time 𝜏𝑐 reduces. The experimental observations contradict the theoretical predic-
tion. This discrepancymay have arisen from the way the samples were heated. Tem-
perature gradients inside the phantoms would originate convection currents which
could have resulted in a more efficient transverse relaxation rate due to incoherent
motion of spins inside the magnetic field.
4.6.0.2. Longitudinal relaxation 𝑇1 in CEST
At concentrations such as the ones used in the phantom study, the effect of the labile
pool on the longitudinal relaxation time of water is negligible. The simulated 𝑇1
variation is less than 0.01%, which would be masked by the experimental error.
On the other hand, the 𝑇1 (and 𝑇2) relaxation time will be influenced by the
viscosity 𝜂 of the sample through a change in the correlation time 𝜏𝑐. The rotational
correlation time of a molecule can be estimated by Stoke’s law (using a spherical
molecule approximation) as:
𝜏𝑐 =
4𝜋𝜂𝑟3
3𝑘𝑇
Where 𝜂 is the viscosity of the solvent, 𝑟 the effective hydrodynamic radius of the
molecule, 𝑘 the Boltzmann constant and 𝑇 the temperature. According to the BPP
theory, a change in viscosity implies a variation in relaxation times, both transverse
and longitudinal.
It is fair to conclude from the lack of variation in the observed 𝑇1 (Figure 4.6.3),
that at the range of concentration used in the study the viscosity of the glucose so-
lutions remains, for all intends and purposes, constant.
4.6.1. Exchange mediated 𝑇2 relaxation
The chemical exchange process between sugars and water is a complex process in
which multiple pools interact with each other.
As in any modelling approach, simplifying the complexity of the problem can
help analyse its general behaviour. In this case the minimal working description of
,
1
𝑇2
= 𝐾2 [3𝜏𝑐+
5𝜏𝑐
1+𝜔20𝜏2𝑐
+ 2𝜏𝑐1+4𝜔20𝜏2𝑐
]
with𝐾= 3𝜇20160𝜋2
ℏ2𝛾4
𝑟6 being 𝜇0 the magnetic permeability in empty space, ℏ the reduced Planck
constant, 𝛾 the gyromagnetic ratio of the nuclei, and 𝑟 the distance between the nuclei with magnetic
dipole moment.23
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Figure 4.6.3.: Measured longitudinal relaxation rate 𝑅1 of glucose so-
lutions with concentration. The longitudinal relaxation rate remains con-
stant in the range of glucose concentration tested.
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the chemical exchange process can be described by a two pool exchange model, in
which the first exchanging pool represents water and the second one the averaged
effect of the hydroxyls protons in glucose molecules. Using this simplified model
of chemical exchange, inferences about the system’s behaviour can be made.
Based on the Swift-Connick* equation, by substituting the inverse of the lifetime
with the chemical exchange rate, the observed transverse relaxation rate R2obs can
be described as:
𝑅2𝑜𝑏𝑠 =𝑅20+𝑅2𝑒𝑥 (4.6.1)
Where R20 is the water relaxation rate in the absence of exchange and R2ex is the
exchange mediated relaxation rate defined as:
R2ex = 𝜌𝜅
R22b+𝜅R22b+𝛿2
(R2b+𝜅)2+𝛿2
(4.6.2)
where 𝜅 is the exchange rate between pools in 𝐻𝑧, 𝜌 the labile to water proton
ratio, R2b the transverse relaxation rate of the CEST pool in𝐻𝑧 and 𝛿 the chemical
shift difference in 𝑟𝑎𝑑.𝑠−1.
For the case where 𝛿 ≫ R2b this equation can be further simplified to:
R2ex = 𝜌𝜅
𝛿2
𝜅2+𝛿2 (4.6.3)
The slope obtained by fitting equation 4.6.1 to the experimental R2 values gives
the relationships between the chemical shift 𝛿 and the exchange rate k of glucose.
Assuming that the mean chemical shift for the hydrogen in glucose is the same at all
temperatures, it can be deduced that the minimum combined shift 𝛿 in glucose lies
around 1.09 ppm (see horizontal line in figure 4.6.4).
With a chemical shift of 1.09 ppm, the mean exchange rate k for glucose stands
at 1400 Hz at 21∘𝐶 and increases to 2800 Hz at 37∘𝐶 (Figure 4.6.4). In the study
by Yadav et al. values of 1.44 ppm offset and 2200 Hz were reported for glucose
at 22∘𝐶. The discrepancies between both results might be due to the different PBS
concentration used in the solutions. In this study samples were dissolved in 0.2x
PBS as compared to the 1x PBS used by Yadav et al. As previously discussed,
high concentration of PBS reduces the CEST signal, which can be explained by an
increase in the exchange rate. This is in good agreement with the obtained results.
The potential of glucose as a natural transverse relaxation agent has been recently
*Swift and Connick in 1962 developed an equation that relates the bandwidth of the NMR signal
to the mole fractions of each pool containing paramagnetic molecules interacting with water.24
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Figure 4.6.4.: Combined averaged resonant frequency of hydroxyls in
glucose in relationship to the mean exchange rate. Data obtained from
fitting 𝑅2 and concentration at 23∘ and 37∘ C. The predicted minimum
resonant frequency of glucose lies around 1.09 ppm from water, granted
that the relative resonant frequency 𝛿 is independent of the temperature.
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proposed by Yadav et al..1 This is a very interesting approach for the use of ex-
ogenous glucose which has the virtue of being very attractive for clinical use due
to its extreme simplicity; just measurements of the transverse relaxation of water
while infusing glucose. The acquisition of 𝑇2 maps is fast and based on well estab-
lished protocols. While the sensitivity of this method is good in liquid samples, it
gets compromised as the 𝑇2 of water shortens, as the exchange related relaxation
𝑅2𝑒𝑥 becomes small compared to 𝑅20. This poses a serious practical challenge
as it would require precise measurement of 𝑇2 relaxation time with the millisecond
accuracy, to be able to detect 20 mMolar concentration in a 3 Tesla scanner.
Numerical simulations demonstrate the small reduction of the transverse relax-
ation at short 𝑇2 values.
Figure 4.6.5.: Simulated relation of 𝑇2 relaxation time and concentra-
tion of glucose. A two-pool exchange model was used to calculate trans-
verse magnetization in time and then fitted to a mono-exponential recov-
ery, which yielded to the effective values of 𝑇2𝑜𝑏𝑠 at different glucose
concentration. Left: simulation run with 𝑇20 of water set a 2 seconds.
Right: simulation run with 𝑇20 of set at 80 milliseconds. While the short-
ening of the observed 𝑇2 is notorious at long 𝑇20 values (on the left), the
same concentration of glucose at shorter 𝑇20 (on the right) results in less
than 3 millisecond reduction in optimum exchange rate conditions at 3T.
In media in which the 𝑇2 relaxation time is mostly conditioned by other factors
other than the concentration of sugar, the sensitivity of 𝑇2 measurements to detect
variation in sugar content appears to be limited. The example in figure 4.6.6 shows
a comparison of 𝑇2 and CEST. It can be observed how while 𝑇2 measurement is
insensitive to concentration changes, CEST can still differentiate samples with dif-
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ferent content of glucose.
Figure 4.6.6.: Comparison of 𝑇2 relaxation and CEST at different con-
centration of glucose in a semi-solid environment. In tissues with short
𝑇2 relaxation times (tens of millisecond), the exchange mediated trans-
verse relaxation 𝑅2𝑒𝑥 is imperceptible compared to fast self-relaxation
rate 𝑅20, resulting in a lack of contrast between phantoms. CEST mea-
surements on the other hand still provide enough contrast to separate sam-
ples according to their glucose concentration.
4.6.2. Correlation of 𝑇2 with Z-spectrum width.
As mentioned in the previous section the transverse relaxation influences the width
of the Z-spectrum. The relationship between the two parameters can be clearly ob-
served in the scatter plot in figure 4.6.7. At both temperatures (21∘ C and 37∘ C)
the observed relaxation rate R2 correlates well with the measured width of the Z-
spectrum (calculated as the full width at 3𝑟𝑑 maximum). Considering the asymme-
try due to the exchange is small compared to the water-profile width, the analyti-
cal relationship for the 𝐹𝑊3𝑟𝑑𝑀 can be approximated from the Bloch-McConnell
equations as:
𝐹𝑊3𝑟𝑑𝑀 = 2𝑅2√
𝜔21
2𝑅1𝑅2
−1 (4.6.4)
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For the range of 𝜔1 in which saturation can be achieved the expression can be
further reduced to:
𝑅2 = 0.5𝑅1(
𝐹𝑊3𝑟𝑑𝑀
𝜔1
)
2
(4.6.5)
The expression can be fitted to the experimental data yielding to estimate values of
𝜔1=0.96𝜇𝑇 (41 Hz) at both temperatures and effective 𝑇1 of 3.1𝑠;(𝑅1=0.32𝐻𝑧)
at 21∘𝐶 and 𝑇1 of 4.3 s ;(𝑅1 = 0.23𝐻𝑧) at 37∘𝐶.
Figure 4.6.7.: Scatter plot showing measured 𝑅2 versus 𝐹𝑊3𝑟𝑑𝑀 at
varying concentration of glucose. The theoretical derivation predicts a
quadratic relationship between the two parameters, which fits very accu-
rately with the data collected at 23∘𝐶 (in blue). Measurements at 37∘𝐶
(in red) appear less consistent, which could be related to distortions from
convection currents formed while heating the sample.
The gap observed in the values of the 𝐹𝑊3𝑟𝑑𝑀 at different temperatures cannot
be explained by this model and requires fitting an additional additive constant. In
the same way as in the 𝑇2 measurement (Figure 4.6.2), the motion from convection
currents might be the source of the discrepancies between the predicted and the
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experimental data. Therefore, results obtained from this approximation should be
interpreted with care.
4.7. Conclusion
Results and analysis of the data in this study can be summarised in the following
conclusions.
All four molecules scanned in this study are capable of producing CEST contrast.
This result supports the hypothesis of the intracellular origin of glucoCEST, particu-
larly considering that the CEST magnitude from G6P is very similar to the observed
in glucose. Same levels of signal intensity observed between hexoses and pentoses
suggest that the hydroxyl outside the cyclic structure do not contribute significantly
to the CEST contrast.
The CEST signal from all four sugars, while different in intensity, are alike in
terms of the MTR asymmetry shape and therefore it is not possible to identify a
specific molecule from the asymmetry profile. This limits the possibility of tracking
the CEST signal through the metabolic process.
The diminished intensity observed at 37∘𝐶 confirms the notion of very fast ex-
change rates involved in the exchange process with monosaccharides. The same
conclusion can be deduced from the pH analysis, as well as from the enhanced ex-
change rates due to the presence of phosphates.
Results in the study indicate that the tissue pH can be a key parameter for the effi-
cient generation of contrast in glucoCEST imaging. The pH of the tissue influences
the CEST signal, in most cases to a larger extent than what the expected change in
glucose concentration would. The signal intensifies in acid environments and mod-
erates it in more basic media, making quantification of glucose increase particularly
difficult in a heterogeneous pH environment.
Along the same lines, the phosphate content of tissues may play an important role
too, enhancing or reducing the contrast in certain regions based on the phosphate
levels of those tissues.
Having demonstrated the CEST efficiency of these molecules, determination of
the signal origin and its relative proportions will depend on parameters such as pH,
phosphate concentrations, sugar concentration and volume ratio of each compart-
ment (vascular, interstitial or intracellular). This is an open field of study that can
provide useful information for a better understanding of the CEST contrast in vivo
and its potential applications.
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The 𝑇2 relaxivity properties of monosaccharides open up an attractive way of us-
ing glucose as perfusion and even metabolic MRI agent, by looking at 𝑇2 variations
after administration of glucose. The major advantage of this approach is its simplic-
ity which makes it readily available in any clinical scanner. The question remains on
whether the sensitivity of the method is enough to be useful in real clinical applica-
tions. In the current study the CEST technique demonstrated an improved sensitivity
over 𝑇2 mapping for the detection of small concentration of sugar, particularly in
semi-solid tissue where short transverse relaxation time limits the sensitivity to de-
tect variations in 𝑇2.
The CEST technique has a number of drawbacks of its own too. Limitations
on B1 power due to SAR and comparatively long scan times are some of the most
important for translation to the clinic.
Each of these methods provides an alternative solution for imaging small concen-
trations of glucose with MRI. The choice of the technique should be decided upon
by comparison of both in specific applications, and by considering whether the re-
quirement is the speed and robustness of 𝑇2 mapping or the higher sensitivity of
CEST imaging.
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5. Modelling the source of
glucoCEST signal
5.1. Contrast in glucoCEST: The rationale
Unlike FDG-PETwhich reports on the uptake and utilisation of glucose, glucoCEST
is sensitive to the concentration of sugar in the tissue. However, detection of endoge-
nous sugars is not feasible as their CEST signature is hidden under stronger effects
(i.e B1 inhomogeneities, relaxation times, other exchanging molecules) which vary
throughout tissues and scans.
Moreover, the steady state concentration of glucose in cancer cells tends to be 3-
to 10-fold lower than in normal cells (but not so the glycolytic intermediates which
are usually over-expressed1). This is likely a consequence of a deficient vasculature
in the tumour combined with uncontrolled glycolysis.2 While in healthy tissues,
energy metabolism and blood delivery are tightly coupled through a variety of auto-
regulatory mechanisms,3 cancerous tissues generally display an abnormally high
metabolic-rate to blood-perfusion ratio.4
In order to generate contrast, ‘chemical exchange’ basedmethods like glucoCEST
(or exchange dependent T2 variations) rely on the assumption that sugar concentra-
tion is heterogeneous in tissues, and more importantly that it varies in time. As such
glucoCEST does not measure the amount of sugar in the tissues but rather its vari-
ation over a short period of time. (Note the word ‘sugar’ was specifically chosen,
because glucose is not the only substrate that can contribute to the CEST signal.
Other substrates in the glycolytic path (G6P, F6P, F16biP, etc) can also add to the
net CEST effect, as was shown in Chapter 4. This is a reasonable assumption con-
sidering that cancer cells have an aberrant metabolism, with a particularly elevated
glycolytic flux.
Provided that the nutrient supply to the tumour cells is scarce to fully meet their
metabolic demand and that the auto-regulatory mechanisms are disrupted, a sudden
increase in the glucose supply is likely to produce a larger variation of the homoeo-
static sugar levels in cancer than in the tightly regulated healthy tissue. The ability
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to detect those variations would result in image contrast with intense glucoCEST
signal coming from the tumour areas.
Knowledge of whether the observed signal is extracellular, or alternatively it orig-
inates from sugars inside the cells, is important in order understand the information
provided by the technique. If shown to be intracellular, glucoCEST could offer
the possibility of assessing tumour metabolism, which could be useful for the char-
acterization of malignancy. On the contrary if proven to be mostly extracellular,
glucoCEST could be informing on blood perfusion in tissues. The study of the pos-
sible scenarios in glycolytic dynamics could shed light on the origin of the measured
glucoCEST signal. To do so, a mathematical model of glycolysis was built which
explores the dynamics and distribution of the different sugars along the glycolytic
pathway.
5.2. System Dynamics model of glucose in the
tissue.
Most biochemical processes form complex network systems for which intuition
alone is not sufficient to fully grasp their dynamical behaviour. In SystemDynamics
an explicit mathematical description of the network and its interaction allows testing
and prediction of the general system’s behaviour using computer simulations.
Modulation of the glycolytic rate can lead to different transient state levels of
the intermediate sugar. The dynamic study of the transformation of sugar in tissues
could help estimate the expected CEST signals, under different physiological con-
ditions. In this context, a compartmental model of glucose delivery in the tissues
and its dissociation through glycolysis was built, aimed to obtain a more analytical
understanding of the dynamics of glucose and the potential CEST signal associated
with it.
The model hereby presented is initially intended to describe the dynamics of glu-
cose entering the brain cells. However, it can also simulate the delivery of glucose to
a body cell (not brain) by bypassing the step accounting for the Blood Brain Barrier
(BBB).
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Figure 5.2.1.: Diagram of the cross-section of capillaries in the body (left)
and in the brain (right). The BBB surrounding the brain capillaries exerts
a tight control over the passage of metabolites to the cells.
5.3. A mathematical model of glucose entering
the brain
Tumours require large amounts of glucose to support their metabolism. The most
important upregulator of glucose entering the brain is the glucose transporter pro-
tein GLUT1.5,6 Dense networks of tangled capillaries, the microvasculature, perfuse
all brain regions including tumour tissues. Long endothelial cells joined together by
tight junctions form a barrier that prevents glucose from entering the interstitial fluid
uncontrolled. Glucose uses GLUT1 to cross both the luminal and abluminal mem-
branes and emerge in the interstitium. GLUT1 is a rate limiting equilibrative glucose
transporter, i.e, glucose concentration in the interstitial fluid will tend to equalise
with the blood glucose levels in the capillaries, provided a sufficiently large num-
ber of transporter molecules is available. Under normal physiological conditions
the density of GLUT1 transporters in endothelial cells is low enough to maintain
the interstitium glucose concentration well below its corresponding blood concen-
tration. To keep up with the metabolic demands, expression levels of GLUT1 are
dynamically increased by reduced availability of glucose and decreased by increased
glucose levels.
Glucose from the interstitial fluid, or directly from the capillaries, enters into the
cytoplasm by crossing the cell membrane; mediated by the GLUT1 in astrocytes and
mediated by the GLUT3 transporter in neurons. The kinetic parameters of these two
transporter proteins affect the local distribution of glucose in tissues. In this study
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it is assumed the dynamics follow a Michaelis-Menten* type of kinetics.7,1 Normal
GLUT1 density maintains interstitial glucose levels below the blood glucose con-
centration, and so at glia and neuron levels. GLUT3 has a high affinity for glucose
(Km = 1.5 mM) ensuring efficient uptake of glucose by neurons so that neurons can
rapidly equilibrate their cytoplasmic glucose concentration with its milieu concen-
tration.8
Once inside the cell, free glucose is rapidly converted to glucose-6-phosphate by
phosphorylation (mediated via Hexokinase) which reduces glucose concentration
in the cytoplasm enabling additional influx of glucose along the concentration gra-
dient. New phosphorylated compounds are produced in subsequent glycolytic reac-
tions (see Chapter 4).
5.4. Outline of the model
Following the above conceptualization a mathematical model was developed that
puts together and quantifies some of the regulatory processes controlling glucose
dynamics in the brain. Diagrams showing which biochemical processes have been
considered in the simulation together with their mutual relationships are displayed
in Figures 5.4.1 and 5.4.4. Detailed mathematical equations quantifying these rela-
tionships can be consulted in the Matlab code in Appendix G.
The model consists of a set of ordinary differential equations describing the in-
teraction between parameters in different steps of the glycolytic pathway. Equa-
tions have been written so that metabolite concentrations equilibrate following a
Michaelis-Menten type of kinetics, usually assumed for biochemical models. Pa-
rameter values for the transporter kinetics and the enzymatic reactions (Vmax and
Km) have been chosen in accordance with the values found in literature, and espe-
cially in Simpson et al.9,8 Themodel describes a basal glucose income from nutrients
that keeps the cell alive and glucose levels stationary under normal metabolic condi-
tions. This represents the normal energy supply by food. In addition, three possible
*Michaelis–Menten kinetics is one of the best-known models of enzyme kinetics. The model
takes the form of an equation describing the rate of enzymatic reactions, by relating the reaction rate
𝑉 to the concentration of a substrate 𝑆:
𝑉 = 𝑑[𝑃 ]𝑑𝑡 =
𝑉𝑚𝑎𝑥[𝑆]
𝐾M+[𝑆]
Where 𝑉𝑚𝑎𝑥 represents the maximum rate achieved by the system, at maximum (saturating) sub-
strate concentrations. TheMichaelis constant𝐾M is the substrate concentration at which the reaction
rate is half of 𝑉𝑚𝑎𝑥. Biochemical reactions involving a single substrate are often assumed to follow
Michaelis–Menten kinetics.
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Figure 5.4.1.: Diagram of the first part of the compartment model illus-
trating the variables and their relationships in the process of glucose en-
tering the cells. Glucose flux through the four compartments in the model
(blood in the main circulatory system, capillaries, interstitial and intra-
cellular space) is modelled by the parameters associated to Glut proteins.
From the circulatory blood (where glycaemia is measured), glucose flux
evolves differently depending on the characteristics of the tissue: tumour
in orange and healthy tissue in green.
entries of glucose have been implemented in order to analyse the dynamics of the
glucose in different scenarios. Extra glucose uptake can be simulated by 1) a single
bolus administration via the intravascular route or 2) intraperitoneal route, or 3) by
a continuous intravascular infusion of glucose. The continuous intravascular infu-
sion reproduces a glucose clamp experiment in which blood glucose is intended to
be kept constant at a specified desired value. In the model the infusion of glucose
stops or continues depending on the blood glucose concentration, which is measured
every 2 minutes.
Intravascular and intraperitoneal injections have been respectively modelled as
a first and third order exponential delay responses to a glucose impulse placed at
time=0 minute. Thirty minutes of pre-glucose dosing running of the model permits
relevant variables, to reach stationary values so that the glucose administration dy-
namics is not distorted by transient behaviours. Average delay values for the rise
of blood glucose concentration following glucose injections have been adjusted to
emulate the glycemic patterns observed in vivo.12,10,11
Pancreatic 𝛽 cells respond to high blood glucose concentration by secreting in-
sulin. Insulin activates the synthesis of glycogen which is stored in the liver and
muscle which reduces glucose blood concentration. Insulin continues to be secreted
until the blood sugar level has been lowered to normal levels. The expected insulin
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Figure 5.4.2.: Intra-peritoneal (IP) and intra-venous (IV) glucose toler-
ance tests performed in fasted mice. Glucose concentration was measured
in the tail vein blood after IP and IV injection of filter-sterilized glucose
in PBS (2.0 mg glucose/g body weight for IP and bolus dose of 0.5 mg
glucose/g of body weight for IV case). Figures reproduces from Tweedie
et al. and Lim et al.10,11
control time for the recovery to basal levels seems to be shorter for abrupt increases
of glucose (intravascular delivery) than for smoother increases induced by intraperi-
toneal injections. In the model we have used 50 and 180 minutes for the expected
insulin control times for the intravascular and intraperitoneal respectively injections
what is roughly compatible with published data in the literature. Figure 5.4.2 il-
lustrates the different time response of blood sugar levels using either the IP or IV
route for the administration of glucose. Figure 5.4.3 shows the simulated glycemic
response in the model.
Brain is perfused by micro-vessels that facilitate the flow of blood from the global
circulation into tissue. Microvasculature glucose concentration is replenished from
the global circulation, reaching equilibrium values that may differ from those of the
main blood glycaemia. In normal tissue the capillary recovery time is short, allow-
ing fast equilibrium between the microvascular glucose level and the glycaemia in
the main circulation. Tumour tissue might have an impaired microvasculature struc-
ture hindering its refreshment and perfusion capacity. In this circumstance tumoral
microvasculature might reach a glucose concentration equilibrium that is below the
main circulatory blood glucose concentration. In the model, normal tissue’s refresh-
ment capacity has been modelled assuming that its microvasculature is able to re-
cover up to sixty percent of its glucose concentration discrepancy with main blood
circulation in only 1 minute. Larger recovery times can be used to model different
degrees of tumour microvasculature impairment if required.
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Figure 5.4.3.: Simulated blood glucose levels following the administra-
tion of glucose via an IP bolus, IV bolus and IV infusion. A first and third
order impulse functions were used to emulate the IV and IP glucose ad-
ministration cases respectively, which yield to blood glucose responses
similar to the observed in real glucose tolerance tests.
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Figure 5.4.4.: Flow diagram of the model illustrating glycolytic reactions
occurring in the cytoplasm of the cells.
Glucose entering the extracellular milieu across the blood-brain barrier (BBB)
has been modelled mediated by GLUT1 transporters. From the extracellular mi-
lieu glucose crosses the cell membranes into the cytoplasm mediated by GLUT1 in
astrocytes and by GLUT3 in neurons. In the model both entries have been aver-
aged and represented by a single entry, with a one to one neuron to astrocyte ratio.
Once in the cell glucose quickly undergoes metabolic transformation through the
glycolytic pathway which has been generically represented in the model by a flow
of glucose through the metabolism of tumour and normal tissues. This reaction is
catalysed by the enzyme hexokinase which quickly reduces the concentration of free
glucose inside the cell facilitating its continuous entry mediated by the equilibrative
transporters GLUT1 and GLUT3. In successive steps glucose-6-phosphate is iso-
merized to fructose-6 phosphate which after a new phosphorylation yields fructose-
1,6-bisphosphate. Modelling is stopped here with the condensation of this aldol to
dihydroxyacetone phosphate.
The above described processes have been represented for both tumoral and healthy
tissue with parallel structures although with different appropriate parameter values.
Control over glycolytic flux is believed to reside primarily in the transport and phos-
phorylation steps,13,14 and therefore to simulate conditions in cancer, expressions of
GLUT1 and HK have been significantly increased (by rising the Vmax of these two
proteins more than the rest of the enzymes).
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Glucose and glycolytic intermediate levels are expressed in millimolar which is
not an additive unit. In order to quantify the contribution of each compound to the
CEST contrast, their concentrations have been weighted with the volume ratio of
each compartment, i.e vasculature, interstitial and intracellular milieu. The volume
fractions set to 0.03 for the microvasculature, 0.15 for the interstitium and 0.82 for
the cell volume, in agreement with values reported for tumour microstructure.15,16,17
Finally, the total intracellular signal is calculated by adding the effect of the different
glycolytic sugars which are present inside the cell.
5.5. Simulation results and discussion
5.5.1. Increased glycolysis
The overexpression of Glut transporters (notably GLUT1 and GLUT3) and hexoki-
nase (HK) I and II enzymes14,18,19 leads to basal glycolic rates up to 20 times larger
in metastatic cells compared to those in their normals counterparts. In our model
tumour basal glycolitic flux is ∼12 times the rate of normal tissue.
Figure 5.5.1.: Glycolytic flux and its change caused by an abrupt increase
in blood glucose concentration, through healthy and cancerous cells.
While the activity of other catalytic enzymes are also unregulated, GLUT1 and
Hexokinase2 have been reported to exert the main control over the glycolytic flux
in tumoral cells, regulating up to 71% of the total glucose uptake rate.20,21
Importantly, following a rise in glycaemia the transient glucose uptake in tumours
is also enhanced beyond the normal physiological values, resulting in significant
variations of the glycolytic rate over time. As shown in figure 5.5.1 the glycolytic
flux in cancer cells increases by 0.21mMolar/min (from 0.59 to 0.8 mMolar/min) as
the result of an IP bolus of glucose. Meanwhile normal tissue sustains a rate increase
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of just 0.024 mMolar/min.
5.5.2. Sugar distribution
Compared to healthy tissues, neoplasms display a different distribution of the glu-
cose intermediate concentrations.
Over-expression of Glut transporters and HK in neoplasic cells induces fast deple-
tion of the interstitial and intracellular glucose in conjunction with an accumulation
of glycolytic intermediates inside the cells. This phenomenon, illustrated by the
simulations in figure 5.5.2 has also been shown in in vitro cell studies,1,22 where
levels of intracellular sugars have been measured to be higher than tissue glucose
concentration itself.
Figure 5.5.2.: Concentration of glucose and its derivatives in the vascu-
lar, interstitial and intracellular spaces following an IP bolus injection of
glucose. Dashed lines represent the relative CEST signal intensity in each
compartment ⟮∑[𝑠𝑢𝑔𝑎𝑟𝑠] ∗𝑉 𝑜𝑙𝑢𝑚𝑒⟯.
The contribution of each compartment to the total glucoCEST signal can be es-
timated from the relative metabolite concentration and the volume of the compart-
ment. For that purpose the strength of CEST signal has been assumed to be propor-
tional to the volume and sugar concentration but independent of the compartment
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itself*.
The graphs in figure 5.5.3 show the relative signal contribution of each compart-
ment (normalised to the maximum GCE). Using the same parameter setting as in
figure 5.5.2, the model predicts an overwhelming intracellular contribution in tu-
mours† compared to the mostly vascular component in healthy tissue.
Perhaps the most remarkable lesson to be learnt from these simulations is the
importance of timing in the acquisition of CEST images. For instance, in the case
of IV bolus the model predicts that 20 minutes after the administration of glucose,
more than 80% of the signal in the tumour would be of intracellular origin.
While the model is possibly not accurate enough as to give exact timings, it is
possibly robust enough to provide insight about the importance of deciding an ap-
propriate time-frame of the experiment for different glucose inputs.
5.5.3. Estimation of the glucoCEST signal
Based on the phantom study described in Chapter 4 a relation of the expected GCE
signal and the sugar concentration increase in the tissue was approximated as 0.2%
GCE per mmolar (hexoses were weighted twice as much as the pentoses because of
their higher signal).
The millimolar concentrations in each compartment can now be translated into GCE
signal and the total expected glucoCEST estimated.
Figure 5.5.4 shows the predicted glucoCEST signal for each of the routes of glu-
cose administration. The fast insulin response in the case of the IV bolus, quickly
reduces the amount of glucose in blood and avoids a substantial increase in the tran-
sient state concentration of the glycolytic intermediates inside the cell. The result
is a lower intensity GCE using the IV bolus route compared to the IP route for the
same dose of glucose.
The IV infusion method produces the most intense GCE signal as hyperglycaemia
is kept for a prolonged period of time. For these simulations the volume ratio of each
compartment was set to be the same for both tumours and healthy tissue. However,
the effect of enlarged vascular fraction in tumoral regions can be also simulated.
*The author acknowledges that different physiological conditions in the model compartments
(pH, phosphates levels, viscosity) would lead to the modulation of the signal intensity. However
these simulations do not account for such effects and treats the compartments indistinctively.
†For this simulation the BBB in the tumour tissue has been assumed to be intact and as such it
prevents large glucose leakages to the interstitial space.
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Figure 5.5.3.: Relative GCE signal in each compartment for healthy and
tumour tissues. Each raw represents different routes of glucose adminis-
tration.
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Figure 5.5.4.: Total estimated glucoCEST signal in tumour and healthy
tissue with different methods for glucose administration.
5.5.4. Comparisons of LS174T and SW1222 tumour cell
lines
In our initial glucoCEST study12 two cancer cell-lines with distinct phenotypes were
studied. The LS174T cells are poorly differentiated, whereas the SW1222 display a
well-differentiated glandular structure.23
To simulate the glucoCEST profile of these distinct tumours, their compartment
volume ratios were adjusted in the model to match the experimental values found in
a separate study by Panagiotaki et al24 (see figure 5.5.5).
Comparison of the 18F-FDG measurements in both tumours revealed 1.7 fold
higher uptake in SW1222 than in LS174T tumours. The disparity in the metabolic
rate between the two cell-lines was simulated by a parameter (aggressiveness) which
controls the Vmax values of Hexokinase and GLUT1 in the model. The aggressive-
ness value was set to 10 for SW1222 cells and 6 for the LS174T, which gave a
glycolytic flux ratio close to the 1.7 (see figure 5.5.6).
Additionally, in order to describe the glucose dynamics outside the brain (where
no BBB is present), parameters that controls the endothelial GLUT1 transport were
bypassed.
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Figure 5.5.5.: Vascular, interstitial (EEC) and intracellular volume frac-
tion of LS174T and SW1222 tumours measured with VERDICT MRI. Fig-
ure modified from.24
Figure 5.5.6.: Comparison of LS174T and SW122s metabolic traits. GCE
(a), FDG uptake (b) and simulated rate of glycolysis (c).
172
5.5. Simulation results and discussion
Figure 5.5.7.: Comparison of the expectedGCE signal in healthy, LS174T
and SW1222 tumours. Different colours illustrate the contribution of each
compartment to the total signal.
Figure 5.5.7 shows the simulated GCE measurement in normal tissue and both
tumours. The most intense GCE signal (0.64% of the𝑀𝑇𝑅𝑎𝑠𝑦𝑚𝑒𝑡𝑟𝑦) is predicted
to arise from the highly glycolytic SW1222 cell line, followed by the signal from
LS174T cancer cells (0.4%) and healthy tissue (0.27%). Notably the interstitial
contribution is dominant in the normalmuscle tissue. This is understandable as in the
absence of BBB, the interstitial glucose concentration closely follows the glucose
blood level,25,26 which scaled up by the interstitial volume produced a significant
GCE signal.
In the case of aggressive tumours however, the interstitial contribution reduces
dramatically as over-expressed glucose carriers quickly move glucose into the cell.
While glucose is depleted from the extracellular space, fast HK activity generates
large amounts of glycolitic intermediates which rise the intracellular concentration.
Even a moderate increase brings up the estimated GCE, as most of the tissue volume
is comprised of cells.
5.5.5. Source of GCE in LS174T and SW122 tumours
The ratio between the vascular volume fraction of the two cancer cell lines matches
remarkablywell with the ratio between the observedGCE signal. This would strongly
suggest that most of the GCE signal comes from the blood compartment. However,
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Figure 5.5.8.: Median %GCE and compartment volume fractions mea-
sured in SW1222 and LS174T cell line tumours and in muscle tissue (left).
Model prediction for the total %GCE and the contribution of each com-
partment for the same tissues (right). Best fit calculated as the minimum
of√⟮𝑆𝑊1222𝐿𝑆174𝑇 ⟯2+⟮ 𝑆𝑊1222𝐻𝑒𝑎𝑡𝑙ℎ𝑦 ⟯2 .
looking at the same ratio between SW1222 and healthy tissue it would appear that
the contribution from the vascular compartment is overestimated. Furthermore, it is
not clear why the interstitial space, which has high concentration of sugar and larger
volume than the vascular one, would not contribute to the GCE contrast. Values for
these ratios can be found in the table of figure 5.5.8.
For intracellular CEST contribution to be compatible with the measured %GCE
ratios, signal from inside the cell is required to be larger in the SW1222 cell line
in order to compensate for its smaller intracellular volume ratio. Our simulations
prove that this is certainly a possibility and in fact, the inclusion of the CEST contri-
bution from all three compartment (predicted by the simulation) seems to give the
best fit to the experimental results, rather than just considering the vascular contribu-
tion. However, this is quite coincidental as small variations in the model parameters
can significantly change the final output. Hence a dominant vascular component
remains as a strong possibility to explain the observed glucoCEST in these experi-
ments.
5.6. Consequences of amino-acid production
A notable result from the 13C-NMR (carbon 13 nuclear magnetic resonance) spec-
troscopy presented in the first glucoCEST study12 is the high concentration of sev-
eral amino-acids in the tumour tissue. In the two cancer cell-lines analysed (SW1222
and LS174T) taurine, alanine and glutamine amino-acid peaks were particularly in-
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tense, together accompanied by over-expressed lactate from anaerobic glycolysis*.
It is known that pyruvate, the end product of glycolysis, can undergo transami-
nation to alanine mediated by the alanine transaminase (ALT), or serum glutamate-
pyruvate transaminase (SGPT).27 The rate of alanine synthesis is proportional to the
intracellular pyruvate concentration, thus an increased glycolysis in tumours could
promote alanine production.
On the other hand, glutamine synthesis from glucose has been shown to be a
prominent feature of primary gliomas.28
Inspection of the CEST capabilities of these amino-acids showed defined peaks
around 3ppm in the Z-spectra, demonstrating the potential of these amino-acid in the
production of glucoCEST contrast. For details about the preparation of the phantoms
shown in figure 5.6.1 please refer to Appendix C.
Figure 5.6.1.: Z- and MTRasym spectra from glucose, lactate, glu-
tamine,glutamate, alanine and taurine. While lactate shows negligible
signal, amino acids show distinct CEST peaks centred at 3 ppm from the
water frequency.
Therefore, provided the amino-acids turn-over is enhanced as the result of an
elevation in glucose level, amino-acids produced inside the cells could add towards
the observed glucoCEST signal.
*Despite being an anaerobic process (no oxygen is consumed), some authors use the misleading
term aerobic glycolysys to express the the fact that tumour cells undergo anaerobic production of
lactate even in abundance of oxygen availability.
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5.7. Conclusion
The model presented in this work is an oversimplified description of the full dy-
namics in glycolysis. More elaborate biochemical systems can certainly help un-
derstanding particular pathways or specific key question researchers might want to
investigate. An example of this can be seen in figure 5.7.1 which illustrates a model
built to account for the influence of the ATP charge (ATP to AMP ratio) in the net
glycolytic flux. Another possibility would be to incorporate the anabolic role of glu-
cose e.g. by coupling the glycolysis to the pentose phosphate pathway (ppp), and
account for the synthesis of amino acids.
Figure 5.7.1.: Example of an extended model of glycolysis developed to
investigate the influence of the ATP charge [ATP to AMP ratio] in the
glycolytic flux of cancer cells.
However, modelling higher complexity systems inevitably comes with the draw-
back of increasingly larger number of unknown parameters to deal with. Too many
parameters often blur the purpose of the simulation, which should serve to stimulate
new insights about the dynamics of the system under study. As such, the purpose of
this work was to give a reasonable representation of the processes that might govern
the creation of glucoCEST contrast.
Despite its simplicity the model successfully illustrates how variations in the
metabolic profile of tumours could dramatically change the observed glucoCEST
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signal.
These type of models can also serve as an argument to challenge the notion that
glucoCEST cannot give metabolic information because of the dynamics of glycol-
ysis is too fast to be captured. The simulations show how fast glycolytic rate is
compatible with high levels of glycolytic intermediates, and therefore inspection of
intracellular metabolism with glucoCEST may be possible.
Figure 5.7.2.: Simulated steady-state values of elevated glycolytic inter-
mediates in a glucose clamp experiment (glycemia 20mMolar) for healthy
and cancer tissue. Concentration of intracellular sugars in cancer rise to
above 10 mmolar, as docummented in Marín-Hernández et al.1,22 Simu-
lation done using the model in Figure 5.7.1.
It has been shown that values of the glycolytic intermediates in certain cancers
cells can reach extremely high values, to concentrations above the normal blood
glycaemia, in some cases.1,22 In tumours with similar characteristics, maintaining a
high blood glucose level (with an IV infusion of glucose for instance), could induce
build up of intracellular sugars up to values that should be easily detectable with
glucoCEST. Simulations in figure 5.7.2 illustrate this effect.
The question still remainswhether high intracellular phosphate levels wouldmake
detection of CEST signal from cellular sugars impossible.
Examination of the effects of cellular phosphate levels and other physiological buffers
on the chemical exchange rate and hence on the CEST signal in vivo is an interesting
subject for further study.
In a scenario in which detection of intracellular glucoCEST proves to be unreal-
istic (either because of high phosphate or low glycolytic-sugar levels), glucose in
combination with glucoCEST could potentially be used as a natural contrast agent
to measure perfusion.
On the other hand, assuming there is a good chance of detecting glucoCEST sig-
nal from the intracellular space, discrimination capacity between each compartment
could be improved by scanning at the right time or by designing a clever pulse se-
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quence aimed to avoid blood contribution, e.g. an ASL-CEST protocol. In fact the
beauty and power of the model is indeed to give an alternative perspective on the
processes governing the glucoCEST contrast and hopefully trigger creative thinking
to improve it.
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6. glucoCEST in glioblastoma
6.1. Introduction
As was demonstrated in the work published by Walker-Samuel1 glucoCEST is able
to detect high signal in cancers and can successfully differentiate between twometabol-
ically distinct human xenograft flank tumours. These results gave a strong motiva-
tion to continue research on the application of the technique in other types of cancers.
From a technical perspective, assessing brain tumours with glucoCEST is a nat-
ural decision as imaging the brain reduces many of the complications involved in
scanning other parts of the body, ie artefacts from fat, large magnetic susceptibility
gradients or movement artefacts. More importantly, the gold standard method for
the detection of tumours, fludeoxyglucose positron emission tomography (18F-FDG-
PET), does not provide sufficient contrast to depict the majority of brain gliomas.
The high glucose background in brain makes the technique inefficient in identifying
the highly metabolic cancer nodes. As such, amino-acid based radio-labels are be-
coming increasingly popular in neuro-oncology imaging as opposed to the glucose
analogue FDG.2,3,4,5
It is logical to think that the same reasons that render 18F-FDG-PET ineffec-
tive would make glucoCEST also inadequate for the detection of brain tumours.
Nonetheless, due to the fact that FDG and natural glucose do not share the same
metabolic path and that glucoCEST could be sensitive to sugars in the glycolytic
pathway, it is possible that the two modalities would offer different information.
As such glucoCEST could prove to be more valuable than 18F-FDG-PET for the
evaluation of brain tumours.
On these premises, in this chapter a feasibility study of using glucoCEST for the
assessment of brain tumours is presented.
6.2. Glioblastoma multiforme
Glioblastoma multiforme (GBM) is the most prevalent and most aggressive malig-
nant primary brain tumour in humans. It accounts formore than 50%of all malignant
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brain tumours with about 2200 new cases diagnosed each year in England alone.6
GBM has an extremely poor prognosis with a median survival time of 6 months.
Accurate diagnosis is important to confirm a primary or secondary GBM and to
differentiate from other type of brain lesions.
In MRI images, glioblastomas often appear as ring-enhancing lesions, but the
structural features are not specific enough and definitive diagnosis of suspected
GBM usually requires a biopsy. Due to the tissue heterogeneity across most tu-
mours, even biopsy samples can yield inaccurate tumour grading.
The development of new imaging methods to assist in the precise grading of brain
tumours is of great clinical interest. With this goal in mind, in this work various
GBM mouse models are investigated using glucoCEST as a potential new method
for the assessment of brain cancers.
6.3. Study design
A study was planned with the objective of testing the possibility of using glucoCEST
for the assessment of brain tumours.
Three main goals were set. The first one was to investigate the feasibility of de-
tecting signal in the brain as the result of an injection of glucose. Secondly to eval-
uate whether glucoCEST contrast between tumours and contra-lateral areas could
be observed. And lastly to investigate whether different tumour types could be
identified from the pattern of their glucoCEST signature over the time of tumour
development.
For these purpose mice bearing GBM from different cell lines were scanned in a
longitudinal study, allowing screening of the progression of the tumours at different
time points.
6.3.1. Cancer cell lines
Five different human primary glioblastoma cell lines were studied. Cancer cells had
been extracted from four different patient biopsies and cultured in the laboratory*
for research purposes. The xenograft tumours from these cells generally showed a
diffuse phenotype, which is commonly observed in humans too. Additionally, well
characterised U87 cancer cells were included in the study, which are know to form
solid tumours.
*All the cell grafting and histochemistry analysis for this study was performed by the team in
the histopathology laboratory led by Prof. Sebastian Brander, at the National Hospital for Neurology
and Neurosurgery.
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Figure 6.3.1.: Study plan layout. Mice bearing GBM from five different
cell lines were scanned longitudinally with MRI and culled at late stage of
cancer for histological analysis. High resolution structural T2 weighted
SE images, T1 and T2 maps and glucoCEST were acquired at different
stages during the development of GBM tumour.
Inoculation of cancer cells Human glioblastoma cells were injected intracra-
nially in immune suppressed (NOD-SCID)micewith a slow injection of 5𝜇𝑙 solution
containing between 1.8×105 and 6×105 free cells depending on the cell line.
The time until the formation of tumours varied for individual cell lines, and ranged
between 2 weeks, for the most aggressive (U87), to around 12 weeks for the slow
growing ones.
6.4. Experimental procedures
6.4.1. Animal preparation
Mice were fasted for 12 hours prior the experiments in order to reduce and stabilize
blood glucose levels. Anaesthesia was induced with 3% isoflurane and once animals
were asleep the level of anaesthetic was reduced to around 1.3% for the duration of
the experiment. A pressure pad placed under the animal’s chest was used to monitor
the respiration rate. If needed, the level of anaesthetic was adjusted to keep the
respiration between 60-90 breaths per minute. Body temperature was monitored
with a probe placed on top of the animal and maintained at 37°with a flow of warm
air controlled by a SA Instruments Inc. monitoring system (Model 1030). Mice
were cannulated via the intra peritoneal (IP) route for the administration of glucose
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while in the scanner. A dose of 1g/kg D-glucose was given from a solution of 10%
glucose in saline, respectively .
At the late stage of tumour development, animals were culled and brains were
extracted for post-mortem histological analysis.
All the procedures were conducted according to protocols approved by the Home
Office.
6.4.2. MRI protocols
All scans were performed on a horizontal 9.4T MRI scanner (Agilent Technolo-
gies) with a receive-transmit volume coil with an internal diameter of 33mm (Rapid
Biomedical).
High resolution structural images (74𝜇𝑚×0.5𝑚) were acquired using a T2weighted
Spin Echo sequence (T2wSE with TR=3s and TE=20ms).
Maps of the longitudinal and transverse relaxation times T1, T2 were also ac-
quired at the beginning and at the end of each experiment. Details for all the se-
quences used can be found in Appendix B.
Quantification of T1, T2 per pixel was done using Matlab.
CEST sequence Z spectra were acquired using a saturation train of 80 Gaus-
sian pulses prior to a Turbo-FLASH readout. Each Gaussian pulse was 50ms long
with flip angle of 540°C and 91% duty cycle, providing an equivalent of 0.9 𝜇𝑇
B1 power and 4 second saturation length. Saturation was applied at 57 frequency
offsets ranging from -4.5 to 4.5 ppm in a linearly spaced pattern. The total temporal
resolution was 4 minutes per block Z spectra. Readout parameters were 2.73ms TR,
1.52ms TE and 20°excitation angle. The K-space was sampled from low to high
frequencies for a matrix size of 64 by 64 voxels per slice and a field of view of
20mm by 20mm, with 1.3mm slice thickness. Three parallel slices of the brain were
scanned for each saturation train length.
6.4.3. glucoCEST protocol
The animals were first acclimatised to the scanner until a regular respiration pattern
was observed. A minimum of three CEST baselines were scanned before the infu-
sion of glucose IP, after which another nine CEST measurement were taken. The
glucoCEST signal was calculated as the subtraction of the mean MTR asymmetry
between the first and last three CEST images (post minus pre glucose administra-
tion). Z-spectra were fitted to a smoothing spline and corrected for B0 drifts on
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a pixel by pixel basis. GlucoCEST enhancement maps (GCE) were obtained by
integration of MTR asymmetry between 0.75 and 1.5 ppm.
6.4.4. ROI data analysis
Figure 6.4.1.: ROIs selection method. In every slice three ROIs present-
ing different degrees of tumor affection were chosen. The selection was
based upon inspection of the structural image at the last scan. In case of
no visible tumour, two ROIs were selected, one in each hemisphere.
From the last scan of every animal, three ROIs were selected from each CEST
slice. The ROIs represented the core of the tumour, the area adjacent to the tumour
(named as proliferating region) and visually unaffected areas (usually contra-lateral
region). The selection of these ROI was done upon inspection of T2wSE images at
the last scan time. Regions with intense T2 contrast (excluding the ventricles) were
assigned the core label. If at the last scan-time, an animal had no apparent tumour,
two ROIs were selected, one on the right (cell inoculation side) and another one on
the left. An example of the ROI selection method can be seen in figure 6.4.1. Once
the regions were selected, the same ROIs per mouse where tracked back for all the
previous scan, in order to evaluate the progression of the same volume of tissue.
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Data from all the acquired scans were translated to a chart and classified into the
different categories i.e. ROI number, animal, cell line, scan time, etc. The analysis
of these data was done using SPSS software.
6.5. glucoCEST results
Results have been split in to different section. The first section contains the overall
statistical analysis of the data in the ROIs selected. The second section is a summary
of the most relevant results observed in individual animal cases.
6.5.1. General results
Figure 6.5.1 shows the median GCE signal measured from all the mice in the same
cell line group (in rows). Non-inoculated and sham groups represent mice which
had no intracranial injection and intracranial injection of saline (not cancer cells).
The rest of the groups are defined by the inoculated cell line. Combined weekly
data is displayed in the abscissa, which gives an overview of the growth rate of each
cancer cell line. Colour bars represent the different ROIs analysed per group. The
initial number of animals per measurement is n=4, except for case of U87 where n=5
mice were scanned. However these numbers reduce at late stages, as some animals
had to be culled due to their poor health condition. For every animal results from
three CEST slices are counted.
From the presented data, the lack of well defined patterns in the observed GCE
signal is probably the first conclusion to make. Variation in the signal appears to be
quite random and generalised to all animal groups.
Contrary to what was observed in Amide Proton Transfer (APT) measurements*
the overall time evolution of the GCE signal does not seem to correlate with the
stage of tumour development.
However, some underlying trends can be highlighted for specific cases. Quite
consistently an increase of MTR asymmetry is observed in the core of solid tumours
(U87) and a significant decrease in non-affected areas (contra-lateral and adjacent
to the tumour centre).
On the other hand, diffuse tumours show a very variable signal. Among them only
the 10-1123 cell line group displays a positive glucoCEST intensity, particularly in
*As part of this work the endogenous APT-CEST and relaxation times were analysed for the
same animals and ROIs. A summary of these data can be found in Appendix D.
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Figure 6.5.1.: Evolution of the glucoCEST signal for different glioblas-
toma models. Colour-bars represent the median %GCE value in the spe-
cific ROIs. Horizontal axis represents weeks after inoculation of cancer
cells.
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Figure 6.5.2.: Overall glucoCEST signal for the different GBM cell lines.
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the centre of the tumours, which appears significantly elevated from the rest of the
ROIs. This can be better observed in figure 6.5.2.
Overall the data presented does not give enough evidence to conclude whether
glucoCEST in brain tumours is significantly enhanced or reduced. While in some
cases the results seem to follow a consistent trend, other cases show random varia-
tions in the signal.
An issue often encountered during the analysis of individual cases is that the mean
GCE signal varied considerably from one scan to the other. On occasion the contrast
between two different brain regions would remain very similar, as if the entire signal
had been scaled. This type of fluctuations may suggest that the baseline CEST scans
(pre-glucose) may have been unstable, resulting in a different normalisation value
(please refer to section 3.8 for a discussion on issues with the selection of the nor-
malisation parameter). Other times, the contrast between ROIs would have changed
with no apparent pattern, which may be indicative of random signal fluctuations,
and a sign of insufficient contrast to noise ratio (CNR).
When dealing with the low signals intensities expected in glucoCEST, the hard-
ware SNR can certainly be a limiting factor for good CNR. However the physiolog-
ical noise is probably the biggest source of signal instability in this case.
Movement due to irregular respiration (gasping from anaesthesia) can result in se-
vere signal changes. Additionally, the animals’ physiology is known to drastically
affect the glucoCEST outcome and therefore it is difficult to track the evolution of a
small GCE signal through different scans. For instance, a change in the anaesthesia
level from 1% to 2%was shown to reduce the observed GCE signal to less than 40%
of the baseline value.7 In this regard, a persistent issue during the glucoCEST scans
was to keep the animals under a relatively low anaesthesia so that metabolism of the
brain would not be suppressed but still be able to maintain an adequate level of seda-
tion. Often the dose of isoflurane would have to be adjusted during the experiment
in order to avoid animals wakening up. This could have changed the glucoCEST
signal and compromise the results.
Heterogeneity between tumours, even within the same cell line, can also obscure
possible trends in the signal. However, doing the analysis on an individual case basis
does not provide any conclusive result either.
Another reason, perhaps an important one, for the inconsistency of the statistical
results is the method chosen for the selection of the ROIs used in the analysis. The
selected ROIs do not encompass homogeneous regions but rather heterogeneous
areas comprised by both tumour and healthy tissues, which results in multi-modal
or skewed distributions. This is apparent when looking at the histogram of the same
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Figure 6.5.3.: Histograms of the %GCE signal in 10-1123 cell line over
three consecutive weeks. As the tumour evolves, the initially normally
distributed data splits into a bimodal distribution during the transition
towards a higher mean value.
animal over time (see figure 6.5.3). Perhaps smaller sized and more anatomically
shapedROIs could have producedmore robust trends. However, this was not an easy
task. Firstly because tumour morphology and consistency changes fast over time,
and secondly because smaller ROIs are very difficult to co-register in a longitudinal
study. The method used aimed to guarantee that at least a considerable volume of
tissue in the ROIswould be the same from one experiment to the other. Nevertheless,
the endogenous data from the same ROIs displayed consistent results, suggesting
that for broad signal variations the selection of the ROIs is probably adequate (see
Appendix D). However, heterogeneous signal variations in regions within the ROIs,
run the risk of being averaged out and going unnoticed.
As such, the presented statistical analysis may not capture the full picture. It is
worth looking at the particular cases to have a more complete view of what gluco-
CEST can offer.
6.5.2. Control results
Figure 6.5.4.: GlucoCEST on control mice. Although some GCE signal is
present, control mice tend to display a relatively flat glucoCEST response.
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Control mice tend to exhibit a relatively flat glucoCEST signal response to the
administration compared to the tumour cases. Nonetheless, some control animal
did show areas of intense glucoCEST contrast, likely as result of the low CNR and
high physiological noise. The examples in figure 6.5.4 illustrate the glucoCEST
profiles expected from a normal control animal (not the cleanest nor the noisiest
examples obtained).
6.5.3. Detection of tumours
Scan of the first animal cohort inoculated with U87 cells only showed significant
glucoCEST contrast in one out of four mice. Structural T2wSE images failed to
show tumour growth in any of the mice. In the absence of tumour signs, animals
were culled for histological analysis and the entire batch was regarded as ‘failed
inoculation’ (A second cohort (n=5) injected with U87 cells was used in the study,
from which all animals developed tumours).
Surprisingly inmunohistochemistry results revealed a small nucleus of proliferat-
ing cancer cells in the same animal that had an elevated glucoCEST contrast, while
the rest three animals were free of cancer cells.
Figure 6.5.5.: Comparison of the four animals in the ‘failed inoculation’
cohort. GlucoCEST contrast (1st column) shows contrast enhancement
only in the animal with confirmed cancer cell under histological analy-
sis (right column). Second column shows the time-evolution of the mean
GCE signal after glucose injection; left hemisphere in blue and right hemi-
sphere in red. In the third column T2wSE images show no sign of tumour.
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6.5.4. Tracking tumour progression
Results in figure 6.5.6 illustrate the case of an animal injected with cell line 10-
1127, which displayed a distinct regional GCE signal that evolved over the time of
the experiment’s length. Histology of the animal (in figure 6.5.7) demonstrated the
existence of infiltrated cancer cells, with highest concentrations in the thalamic re-
gion where the intracranial inoculation was done.
The density of malignant cells gradually reduces from the original source in the
thalamus to the corpus-callosum, from where the cancer cells invade the left hemi-
sphere. Figure 6.5.7 illustrates the pattern described. Arguably the time-course of
the tumour growth can be linked to the gradient in cancer cell density. It is remark-
able that glucoCEST contrast appears to follows a similar pattern, which suggests
the possibility that the method might be sensitive to tumour progression.
Note that in none of the time-points the T2w images gave any indication of tumor
presence, which is expected from early stages of diffuse carcinomas.
Figure 6.5.6.: GlucoCEST contrast of the same animal at different scans
over the course of the experiment (left). Mean GCE signal after glucose
administration from left (blue) and right (red) hemispheres. T2wSe in mid-
dle.
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Figure 6.5.7.: Inmunohistochemistry staining (Vimentin and Haema-
toxylin counterstain) of the same animal as in figure 6.5.6 showing a re-
gions of different cancer cell density.
6.5.5. Contrast at early stage of cancer
In all the presented cases, comparison between the GCE maps and the anatomical
images seem to suggest that glucoCEST can identify the presence of tumours in an
earlier phase than conventional MRI. A paradigmatic example of this is presented
in figure (6.5.8), which illustrates the case of an animal injected with 10-1123 cells,
scanned at two separate timepoints. GlucoCEST at the first time point displays a
larger extension of the tumour than the T2wSE at the same time. However, the
structural image acquired 15 day later shows an expanded tumour with similarities
with the previously acquired glucoCEST images. In fact the GCE image correlates
better with the T2wSE image acquired 2 weeks later (R2=0.13) than with the one at
the same time–point (R2=0.027)*.
Cases with similar characteristics can be seen across the different cell lines stud-
ied. Example in figure 6.5.9 shows the case of an animal injected with U87 cancer
cells that displays a hyperintense signal in the right side of the cortical region from
where the tumour grows at a later stage.
*Correlations were calculated based on intensity maps. The author acknowledges a measure of
correlation based on mutual information would be preferable to compare data acquired with different
imaging techniques.
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Figure 6.5.8.: Comparison between glucoCEST, spin echo and histology.
At day 220 post tumour inoculation , the SE image does not show the full
spread of the tumour, while glucoCEST already displays features that will
be detectable 15 days later by T2w SE. The overlay of MR and histology
slice shows tumour cells highlighted in brown by a human specific stain
(Vimentin), whereas the host brain is shown in blue (Haematoxylin coun-
terstain).
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Figure 6.5.9.: GlucoCEST in U87 cancer cell line showing intense signal
in the top of the cortical region from where the tumour grows in a later
stage.
This same effect is manifested, clearer perhaps, in animals with diffuse phenotype
tumours. The following examples illustrated two cases of animals bearing diffuse
GBM from the 10-987 cell line (see figure 6.5.10). In the set of images scanned
at week 8 after inoculation of cancer cells, glucoCEST displays an intense signal
in the top right hand side of the brain where the tumour will grow. At this stage
T2wSE does not provide signs of any anomaly. At a later stage a normointense
signal is observed in areas where cancer has developed but a hyperintense signal
around the tumour area, conceivably indicating further expanse of tumour towards
the hyperintense regions.
Figure 6.5.10.: GlucoCEST profile in 10-987 GBM cell line. At week 8,
when T2wSE shows no apparent signs of tumour, glucoCEST shows an
intense signal in regions of the brain where tumours will start developing.
In a later stage a normointense signal is observed in areas where cancer
has consolidated and a hyperintense signal around the tumour.
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6.5.5.1. No GCE in areas with consolidated tumour
It is worth emphasising the fact that in most of these cases the GCE images dis-
played no significant contrast in the regions where the cancer cell had been well
consolidated. This was especially true at late stage of tumour development when
GCE showed normo-intense signal in the cancer but hyper-intense in areas in which
the spread of the cancer was not complete. Figure 6.5.11 shows another example of
this effect on a mouse inoculated with 10-1123 cell line and scanned at late stage.
Figure 6.5.11.: GlucoCEST in advanced stage of GBM, in animal inocu-
lated with cell line 10-1123. Contrast across the brain slice is produced by
hyperintense glucoCEST signal in areas with lower density of cancer cells
compared to a flat glucoCEST response in highly invaded regions. T2wSe
and histology show the extension of the areas most affected by cancer.
6.6. Changes in relaxation times
As discussed in chapter 4 the transverse relaxation time is susceptible to the con-
centration of glucose via a chemical exchange mechanism. Using the same ROIs as
in the analysis of the glucoCEST data, the median change in the T2 relaxation time
were measured in all the experiments performed. The results of theses measure-
ments are summarised in figure 6.6.1, which shows variation of T2 in each animal
group per week, and in figure 6.6.2, which presents the combined change of T2
throughout all the scans.
As a general basis T2 relaxation time appears to decrease an average of two mil-
liseconds during the glucoCEST experiment. The effect is overall quite consistent
and independent of the cancer cell line studied. The reduction happens across the
entire brain (except in the cerebrospinal fluid) and in all phases of the study, which
might be indicative of dehydration rather than an effect of the chemical exchange
effect from glucose. However, control mice seem to experience a lower reduction
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Figure 6.6.1.: Change in T2 relaxation time after glucose administra-
tion for different glioblastoma models. Colour-bars represent the median
Δ𝑇2 value in the specific ROIs. Horizontal axis represents weeks after
inoculation of cancer cells. 199
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Figure 6.6.2.: Overall median Δ𝑇2 per cell line group.
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(average of 0.5 ms) compared to the sick animals. Moreover, tumour affected areas
appear to display the largest amounts of variation in T2, particularly at late stage of
cancer.
Figure 6.6.3.: Reduced T2 is observed mostly in region affected by tu-
mour. GlucoCEST at the same time display a less define pattern.
Figure 6.6.3 illustrates two examples from different cell lines in which T2 of the
tumour area is decreased after the injection of glucose. Contrary to what might have
been suspected from a theoretical argument, glucoCEST and change in T2 do not
seem to correlate. Compared to the glucoCEST signal, the T2 change appears to be
more localised in the regions affected by the tumour.
The significance of these results is unclear, as standard T2 weighted images al-
ready provide the same information in much higher detail. Nonetheless, in solid
phenotype tumours, the observed pattern in the variation of the relaxation time is
more interesting. Figure 6.6.4 shows the evolution of a solid tumour (U87 cell line)
over a three week time period. In the first scan (at week 3 after inoculation of cancer
cells), relaxation times appear relatively even across the three brain slices. Scans of
the same animal a week later starts showing regions with largely reduced T2 in the
anterior and posterior slices of the brain where tumour onset is visible. The same
scan shows another cancer node in the middle of the brain with an increase in T2.
The magnitude of these changes reach up to ±20𝑚𝑠, which account for roughly
15% of the transverse relaxation in those areas. Longitudinal relaxation time T1
shows a similar trend.
In our first analysis these changes were suspected to be a result of the animal
moving during the experiment. After cautious inspection of the raw images it was
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Figure 6.6.4.: Extreme variations in the relaxation times in U87 solid
tumour. At late stage the change in T2 shows an over-intense ringing
pattern surrounding the tumour node (on the right hemisphere), while the
more centred node displays a hypo-intense signal.
concluded that the animal remained stable in the same position (less than 1 voxel
displacement was measured between pre- and post- glucose administration). More-
over, images from the next scan at week 5 post injection show the same pattern with
enhanced contrast.
While the amount of glucose concentration can reduce the observed T2 via chem-
ical exchange mediated relaxation, T1 variations cannot be explained by this mech-
anism. One way in which such intense changes could be understood, would be by
a variation in the water content of the tissue by either a leak from blood vessels
or extreme vasoconstriction. The fact that T1 and T2 appear to change in opposite
directions (last time point) and witch such a large magnitude, eludes the author’s
comprehension.
6.7. Conclusion
In this chapter the effects of glucose administration in mice bearing brain gliomas
have been studied via glucoCEST and changes in relaxation times (both T1 and
T2). Transverse relaxation time T2 was found to reduce in areas affected by diffuse
cancer. Solid tumours were found to display marked changes in relaxation times,
both longitudinal and transverse.
Unfortunately, the lack of sufficient control data on mice bearing solid tumours
(given saline instead of glucose) renders these result inconclusive in order to at-
tribute variation in the relaxation time exclusively to the administration of glucose.
The variety of cancer cell lines studied resulted in relatively low numbers per group,
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limiting the possibility of solid statistical inference. Arguably this is one of the
biggest flaws of this study.
Nevertheless, the extent and cause of the variations in relaxation time of solid
tumours, although unclear, appear too evident to be ignored. More research could
help understand the physiological reasons behind these observations which might
yield information relevant to the study of cancer.
Regarding the results on glucoCEST, the initial hyper intense signal observed
in early phases of cancer, followed by a normointense signal in regions with fully
developed tumour is a pattern that can be observed in around 40% of the animals
studied.
In the presented cases glucoCEST seems to highlight the cancer-affected areas
before the appearance of significant changes in the tissue structure, suggesting the
possibility that glucoCEST may be sensitive to early phases of cancer. A possible
explanation for it is that at early stages of cancer, while brain structures are still
undisrupted and the T2 relaxation time is unaffected, tumours cells already prolif-
erate at higher rates demanding more glucose.
Figure 6.7.1.: Comparison between glucoCEST, IBA1 and Vimentin in-
munohistochemistry staining. CEST image corresponds to a volume in
between the two histological slices.
Inflammation signal in areas invaded by malignant cells could also cause ele-
vated metabolic activity and hence an increased glucoCEST signal. As a matter of
fact, when animals were culled in early stage of cancer development, the contrast
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provided by glucoCEST was found to better match with IBA1* staining than with
cancer cell density(see figure 6.7.1).
The cases presented reflect the bright side of the story. The author recognises
that given the variability in the observed signal these results could be regarded as
mere coincidences. Given the lack of reproducibility and the low contrast to noise
in the results, the hypothesis that glucoCEST might be informing on early brain
tumour stage is little more than speculation with the current evidence. However, the
significance of this hypothesis being true, supported by some very intriguing cases,
leaves room for the excitement and encourages more research on the topic.
*IBA1 protein (ionized calcium-binding adapter molecule 1) is present in activated macrophages
which are found in tissues with inflammation. IBA1 levels in healthy humans have been found to
positively correlate with metabolism and with fasting plasma glucose levels.8
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7. Future work in exogenous
CEST
This last chapter outlines the projects that are currently ongoing or planned for the
future as continuation of the work done in this thesis. Three projects are described
which relate to different application of exogenous CEST methods. The first sec-
tion contains a brief discussion about the challenges involved in the translation of
glucoCEST to the clinic. The second section, describes the application of CEST
in combination with the administration of 2DG as a potential method for the con-
trol of epileptic seizures and identification of the seizure-onset zones. Lastly, in the
third section, a new application of exogenous CEST is explored in which bicarbon-
ate is used as a potential contrast agent to provide alternative information regarding
dis-regulation of pH in tumours.
7.1. Translation of glucoCEST to the clinic
GlucoCEST could offer an attractive alternative to 18F-FDG-PET for the diagnosis
of cancer and metabolic related disorders. The use of natural glucose as the contrast
agent in glucoCEST makes the technique safe which allows human studies to be
readily approved. The lack of toxicity in glucoCEST allows examination of specific
patient populations like children and pregnant women for which nuclear medicine is
contraindicated. Additionally glucoCEST would be ideal for longitudinal studies on
patients, which could eventually be useful for the assessment of response to therapy
and general clinical research.
The translation of glucoCEST to the clinical setting however poses some technical
challenges that need to be addressed.
Lower field strengths of humanMRI scanners compared to preclinical systems re-
sults in smaller chemical shift between water and labile protons, which makes peaks
harder to resolve. As a consequence of the reduced chemical shift, spillover (direct
saturation) effects are also more pronounced. Thus, the power needed for effective
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glucose labelling considerably reduces the net MR signal with the consequent loss
of SNR.
Standard MRI imaging sequences seldom make use of RF pulses longer than a
few milliseconds. As such clinical scanners have a limited energy capacity in the
RF amplifiers which can limit the length of the saturation pulse below the optimum
one for CEST. Moreover, due to strict SAR regulations the highest B1 power al-
lowed for scanning patients is lower than the one typically used in preclinical stud-
ies, especially for the detection of fast exchanging protons. In these conditions,
the detection of the glucoCEST signal becomes extremely challenging. However
most of these limitations can be partially overcome by choosing a shorter saturation
scheme (without aiming for steady state magnetisation) and an optimum integration
range (see suggested guidelines in Figure 2.5.1 and discussion on the selection of
appropriate power in section 3.14).
On the bright side, field inhomogeneity is more controlled at low field which re-
duces the hampering effects of large B0 variations across the image. Transverse
relaxation time T2 of tissues increases with reduced field, making the peaks in the
Z-spectrum more defined which should compensate for some of the negative con-
sequences of the small chemical shift. From the physiological point of view, gluco-
CEST performed on humans does not require anaesthesia, hence reducing the risk
of low brain metabolic activity found in animal studies using isoflurane.1
7.1.1. Suggested approach for clinical glucoCEST
Because of the time constraints in the clinical environment and the low SNR ex-
pected from the measurements, it is sensible to target the acquisition on just the
offset frequencies most sensitive for the detection of glucose. Sampling a small
portion of the offset frequencies instead of the whole Z-spectrum allows more time
to repeat acquisitions in order to gain CNR.
For a hypothetical glucoCEST experiment in which glucose concentration in tis-
sues increases by 10 mMolar, it was estimated that around 30 CEST repetitions
would be needed in order to detect glucoCEST signal with 95% CI in a clinical set-
ting. These figures were estimated assuming a variability (as the standard deviation)
in the CEST measurements to be twice the expected GCE signal. These values were
justified based on 1) the mean GCE obtained from phantoms at different glucose
concentrations and 2) the variability of the signal measured in healthy volunteers.
A set of the phantom data used for these estimations can be seen in figure 2.5.2
(Chapter 2). These experiments showed an average of 3% GCE for 10 mmolar
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glucose increase. Additionally, the standard deviation from the mean CEST signal
between scans of the same volunteer was measured to be 3.1% between 2 and 3 ppm,
the most sensitive range for glucose detection at 3T.
Figure 7.1.1.: Reproducibility of the MTR asymmetry in the neck of a
healthy volunteer scanned every 15 minutes. Mean and STD of the CEST
profile over the selected voxel show signal variability (STD) contained
below twice the expected GCE signal in the range between 2 and 3 ppm.
As in fMRI, the low CNR in the glucoCEST data can be dealt by averaging mul-
tiple acquisitions. Using this approach an example of a optimised glucoCEST pro-
tocol is presented in figure 7.1.2.
The CEST block represents CEST measurements at 2.25, 2.5 and 2.75 ppm off-
sets, which provide maximum MTR asymmetry based on phantom data and simu-
lations at 3T. Saturation power should be set at ∼ 2.6𝜇𝑇 for the duration of around
one second, to provide optimum contrast from glucose (see section 3.15). Frequent
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Figure 7.1.2.: Diagram of the suggested fast acquisition protocol for glu-
coCEST experiments. Three pairs of offset frequencies (positive and neg-
ative) are sampled centred around 2.6 ppm to allow for B0 corrections.
Reference and B0 field maps are also acquired regularly to control for
potential field drifts.
B0 maps are also advisable in order to correct for potential field drifts during the
glucoCEST experiment.
This protocol has been successfully tested in a Philips Achieva 3T clinical scanner.
The time required for the acquisition of a CEST block is less that 2 minutes, which
provides effectively 15 glucoCEST acquisitions in 10 minutes, including the B0
field maps.
Protocols similar to the one presented offer an acceptable scan time for a the clin-
ical translation of glucoCEST. Currently an ongoing study at University College
London Hospital (UCLH) aims to scan 80 cancer patients (20 HN squamous cell
carcinoma, 20 Hodgkin’s Lymphoma, 20 Glioma low grade and 20 Glioma high
grade) with glucoCEST during a continuous IV infusion of glucose.
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7.2. 2DG CEST in epilepsy
Epilepsy is the most common serious chronic neurological condition with a preva-
lence of about 1%. About 30% of all people with epilepsy are inadequately treated
by medication; for these people, surgical resection is the best hope of controlling
their seizures, but this necessitates the precise localisation of seizure onset. Cur-
rently the only practical functional imaging technique available for localisation of
seizure onset uses ictal Single Photon Emission Computed Tomography (SPECT)
and this has several shortcomings that significantly restrict its use, including a low
success rate (±60%), short half-life of the tracer and limited availability. A more
readily available method to identify seizure onset zones would therefore be ex-
tremely valuable.
The challenge for such an application is to find a tracer that can be injected at the
time of a seizure on the ward, and imaged later while reporting on the ictal brain
metabolism. As glucose is rapidly used by the brain, glucoCEST signal is likely to
quickly fade away, therefore limiting its efficacy for this application. However, al-
ternative molecules such as 2-Deoxy-D-Glucose (2DG)1 or 3-Oxy-Methyl-Glucose
(3OMG) have been shown to stay within the cells for an extended period of time,2
and could therefore be used as tracers for ictal imaging.
While 2DG has been tried as an adjunct therapy in cancer, some concerns about
its safety within the context of epilepsy have arisen, due to its potential cardiac side
effects. Alternative, 3OMG is considered to be less toxic than 2DG as it does not
serve as a substrate for hexokinase and is therefore entirely excreted by the kidneys.2
Furthermore, 2DG (and likely 3OMG) possesses potent anticonvulsant effects3
that will help localising the seizure onset zone by accumulating within the high
metabolic area, and thereby depriving the cells of the energy needed for seizure
propagation.
Therefore the aim of this work is to investigate whether such molecules can be
used as alternative epileptic tracers withMRI and assess the possibility of eventually
replacing ictal SPECT in patients with epilepsy. As such we plan to test both 2DG
and 3OMG in rat models of epilepsy, to establish detection thresholds, as well as the
potential antiepileptic effects.
This project will go forward from October 2015 onwards thanks to the grand
awarder by UCL as part of the Confidence in Concept Scheme.
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Figure 7.3.1.: MTR of pre- and post- 2DG injection of a rat undergoing
epileptic seizure. Difference images (right) showing a generalised 2DG
signal decrease, except for a local increase in the deep grey matter, com-
patible with increased metabolic activity of the epileptogenic focus.
7.3. Preliminary data
Wehave successfully applied our glucoCEST protocol on rats during epileptic seizures
and preliminary data demonstrated the possibility to detect a glucoCEST signal from
2DG in the expected epileptogenic foci in n=2 animals.
The results showMTR asymmetry in the 2DG-CEST experiment to decrease sig-
nificantly (p<0.05) in the cortical and hippocampal regions. However a significant
signal increase (p<0.05) was observed in the deep grey matter region.
Figure 7.3.2.: Structural image and p-value maps from t-tests (single
tailed) comparing pre and post images (n=5). The first p-value map shows
the pixels with significantly reduced CEST asymmetry.The second p-value
map shows the pixels with significantly increased CEST asymmetry.
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7.3.1. Methods:
Epileptic seizures were induced by a single dose of kainic acid IP in two rats.
The epilepsy rat model chosen for this project, has been established by Professor
Walker’s team from the UCL Institute of Neurology which provides a well charac-
terised pattern of epileptic seizure allowing reproducible experiments.
Acquisition of CEST baselines started one hour after an IP injection of Kainic
acid (10 mg/Kg) to maximize chances of seizure. After 5 CEST baselines 2DG
was injected IP (1g/Kg). During the following hour, 6 post-2DG CEST scans were
acquired.
Anaesthesia protocol: Induction with Isoflurane (3%). Once the animals were
sedated, injection of a bolus of Medetomidine (0.1 mg/Kg) followed by continuous
infusion (0.25 mg/Kg/h). Isoflurane was kept at 0.5% during the experiment.
MRI protocol: High resolution structural image (Fast Spin Echo with 100𝜇m in
plane resolution and 0.5mm slice thickness) was acquired before the CESTmeasure-
ments. CEST images were obtained using the fast gradient echo (Turbo-FLASH)
pulse sequence described in Appendix B (400𝜇m in plane resolution with a 2 mm
slice thickness) with 57 offsets from -4.5 to 4.5 ppm and 2.5 𝜇T. Integration of the
MTR asymmetry was performed in [0.5-1.2] ppm range.
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Figure 7.3.3.: Average 2DG GCE over time. 2DG bolus injected at
time=0 minutes. Mean values were calculated for the pixels with signif-
icant CEST change (p<0.05). Decreased CGE in blue (cortical area in
this case). Increased GCE in red (in the thalamus)
214
7.4. BicarboCEST
7.4. BicarboCEST
Due to upregulated glycolysis, tumours have an acidic extracellular pH (pHe).4 It
has been reported that the acidic extracellular environment promotes invasion and
enhances metastasis, which ultimately offers cancer cells a selective survival advan-
tage.5 Administration of sodium bicarbonate has been shown to increase the pHe of
cancerous (but not in healthy) tissue, leading to reduction of metastasis and tumour
invasion.6 Because of the strong pH dependence of chemical exchange rates, acute
variations in tissue pH due to bicarbonate administrations may be detected in vivo
using CEST MRI.
Under these premises, a small preliminary study was done aimed to explore the
use of bicarbonate as bio-marker of tumour progression using CEST.
7.4.1. Methods
Human GBM cells (3x106) were inoculated intracranially in immune suppressed
(NON-SKID) mice (n=12). One cohort received cells from the solid phenotype
U87 tumour, a second cohort cells from diffuse human GBM and the last cohort
was used as control. Mice were anaesthetized with 1.3% isoflurane and cannulated
via the intra-peritoneal route for administration of bicarbonate while in the MRI
scanner.
Anatomical scans were acquired with high resolution Turbo Spin Echo (TSE) se-
quence (TR= 3s, TE= 20ms, ETL= 6, FOV= 20x20mm2, slice thickness= 0.5mm,
matrix size= 256x256). Three baseline CEST scans were taken prior to the adminis-
tration of 0.3ml of 8.4% bicarbonate solution. CEST scans were acquired one hour
post-bicarbonate infusion. At the severe stage of cancer, animals were culled and
brains were fixed for histological analysis.
The CEST signal enhancement due to bicarbonate was calculated as the change
in MTR asymmetry pre- and post- bicarbonate administration, integrated between
0.5 and 4 ppm. CEST data were acquired using a fast Gradient Echo readout (TR=
2.73ms, TE= 1.52ms, flip angle= 20°, FOV= 20x20mm2, slice thickness= 1.5mm,
matrix size= 64x64) with a saturation train prior the readout of 80 Gaussian pulses at
1.3µT (pulse length= 50ms, flip= 540°, 91% duty cycle). Saturation was applied at
59 equally spaced frequency offsets ranging from -4.5 to 4.5 ppm, giving a temporal
resolution of 5 minutes per Z-spectrum block.
According to the spread of tumours, micewere classified in advanced or early stage
groups. Mice with visible lesions in the T2w-SE image (>10% of the brain volume)
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were considered in advance stage, whereas mice with no appreciable tumour in early
stage.
7.4.2. Preliminary results
Figure 7.4.1.: Coronal brain sections showing T2 weighted SE images
in 1st column and their corresponding overlaid bicarboCEST images in
2nd column. Human specific immunestaining (vimentin) of each tumour
(350x magnification) is shown in 3rd column. The colour code in the bi-
carboCEST images represent ±3% (red positive, blue negative) of theMTR
asymmetry.
Following bicarbonate administration, glioma-bearing mice display a significant
increase (p<0.05) of the overall bicarboCEST signal across the brain. In contrast,
control animals show a flat response to the bicarbonate. See figures 7.4.1 and 7.4.2.
In the solid phenotype group, an elevated bicarboCEST signal is observed outside
areas of consolidated glioma, and lower signal in the core of the tumour. This pat-
tern is less clear in the diffuse tumour phenotype group.
An explanation for this behaviour could rely on themorphology of both cancer types.
Dense nuclear regions in the core of solid tumours are less perfused, hence less af-
fected by bicarbonate. Diffuse cancers with sparse nuclei allow a more homoge-
neous perfusion. See 3rd column in figure 7.4.1 for a comparison of tumour cell
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density.
Figure 7.4.2.: Mean bicarboCEST signal in the brain (measured as the
average of all voxels) per animal. Cancer stage groups are separated in
columns and tumour type groups in rows. Controls shown in green.
At the early stage of cancer, while solid tumours still display no significant signal,
diffuse gliomas already show increased bicarboCEST levels compared to controls
(see figure 7.4.2). At this stage lesions are not appreciable in T2w SE images.
7.4.3. Discussion and conclusion
A proof of concept for a new application of CESTMRI is proposed for early assess-
ment of tumour progression by means of bicarbonate administration. Although very
preliminary, the results of the study show encouraging distinction between different
tumour types and controls.
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Signal in the tumour area appears to be reduced at late stage (similar to what was
observed with glucoCEST). Admittedly the trends reported in both glucoCEST and
bicarboCEST studies are suspiciously alike.
The fact that in areas of well developed tumour the CEST signal from both methods
is hypo-intense, might be a consequence of poor blood perfusion in the region, re-
sulting in a lack of sugar increase or pH change. However, the hyper-intense signal
around the tumour-core observed in both techniques is more difficult to interpret. A
possible physiological response that would explain these results would be an acute
intracellular acidification as a consequence of the bicarbonate administration. In
fact numerous studies have reported this effect, producing a ∼ 0.2 units of intracel-
lular pH reduction.7,8,9 In this situation the fast exchanging amines would produce
higher CEST signal favoured by the reduced pH environment. On the other hand,
signal from amide protons would not experience a significant change provided that
the initial pH was already basic (assumption based on the relationships for amide
and amine groups described in section 1.4.5 of Chapter 1).
In this context, bicarbonate and glucose have concomitant effects andwould likely
produce an enhancement of the CEST contrast when used in combination.
Nonetheless, a more thorough study is required to validate this hypothesis and as-
sess the significance of bicarboCEST signal. A collaboration with Prof. Brandner’s
group from UCL Institute of Neurology, is already established to take this study
further and explore the feasibility of bicarboCEST as an early biomarker of diffused
glioma.
Aim to explore the use of natural pH buffers such as bicarbonate as bio-marker
of tumour progression using CEST.
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8. Summary and final remarks
Within this thesis the foundations of glucoCEST technique have been studied through
mathematical models, phantom work and in vivo experiments. A summary of the
work presented is outlined below.
The multi-pool Bloch-McConnell model presented in Chapter 3 has been funda-
mental for the understanding of the CEST mechanism and the interaction between
variables that ultimately govern the image contrast. This model, both in its steady
state and dynamic formulations (included in Appendices E and F), help predict the
expected outcomes of experiments and serve as powerful tools for the optimisation
of the parameters involved in a CEST pulse sequence. Predictions from this model,
supported by experimental data, have been used to challenge long established and
important concepts such as the required amount of power for optimum glucoCEST
results.
The CEST contrast observed in sugars formed along the glycolytic pathway, set
the basis for the possibility of intracellular measurements of glucoCEST signal. The
results from the phantom study presented in Chapter 4 revealed positive CEST signal
in all four molecules studied; particularly intense in the G6P, which is present only
inside the cell. Provided that intracellular sugar concentrations are sufficiently ele-
vated in tumours (as has been shown in several documented studies), these findings
strongly support the feasibility of exploring cancer metabolism with glucoCEST
MRI. The study of the expected glucoCEST signal with a System Dynamics model
in Chapter 5 also supports the idea that intracellular signal detection is a likely pos-
sibility, despite the extremely fast glycolysis inside the cell.
Results of the animal study in Chapter 6 revealed the complexity in the behaviour
of the glucoCEST signal. GlucoCEST produces a hypo-intense signal in well devel-
oped tumours compared to the surrounding tissues. Moreover, glucoCEST appears
to highlight the cancer-affected areas before the appearance of significant changes
in the tissue structure, which suggests the possibility of glucoCEST being particu-
larly sensitive to early phases of cancer. However, the significance of these results
is unclear due to the difficulty in the interpretation of the data, the low n numbers
and reduced SNR in these experiments. Further studies with rigorous validation of
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in vivo measurements are needed, in which glucoCEST can be compared to data
from established imaging modalities like 18F-FDG PET.
Clinical translation of CEST will require a big coordinated effort to standardise
imaging protocols and measurements before the technique can become a valuable
contrast mechanism. With the CEST field rapidly evolving, the future will see new
applications and refinements in the data quality. Together with the advancement to-
wards higher field strength MRI systems and fast acquisition protocols, glucoCEST
and other CESTmodalities could become a complementary addition to imaging pro-
tocols for the characterisation of cancer and assessment to treatment response in
hospitals across the world.
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A. Essential equations in NMR
Equation of motion
The equation of motion that governs the evolution of the magnetisation vector inside
a magnetic field is:
𝑑M(𝑡)
𝑑𝑡 = 𝛾M(𝑡)×B(𝑡) (A.0.1)
Where 𝛾 is the gyromagnetic ratio of the nuclear spin,M(𝑡) is the magnetisation
vector and B(𝑡) is the magnetic field.
This equation, which can be taken as a fundamental rule, is at the heart of the the
rotation and precession in MRI. Acknowledging that only the perpendicular com-
ponent ofM(𝑡) will be affected by B(𝑡), the precession frequency ofM(𝑡), Larmor
frequency, can be expressed as ￿0 = 𝛾B0 where B0 represents the static magnetic
field.
A useful mathematical device to understand the evolution of the magnetisation
vectorM(𝑡), is the use of a rotating frame of reference. The equation of motions
in a frame of references rotating around the laboratory frame can be written as:
(𝑑M𝑑𝑡 )𝑅𝑜𝑡
= (𝑑M𝑑𝑡 )𝐿𝑎𝑏
+￿′×M (A.0.2)
(𝑑M𝑑𝑡 )𝑅𝑜𝑡
= 𝛾M×B +￿′×M = 𝛾M×(B− ￿
′
𝛾 ) (A.0.3)
where ￿′ represents the angular frequency vector of the rotating frame with re-
spect to the laboratory frame.
In the laboratory frame, spins precess at the Larmor frequency, however from
the point of view of a frame rotating at the Larmor frequency parallel to the static
magnetic field, ￿′=￿0, the spins will appear stationary:
(𝑑M𝑑𝑡 )𝑅𝑜𝑡
= 𝛾M×(￿0𝛾 −
￿′
𝛾 ) = 0 (A.0.4)
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Figure A.0.1.: 90º RF pulse seen from different reference frames.
a) laboratory frame. b) frame rotating at Larmor frequency.
The concept of the rotating frame makes it easier to visualize and understand the
dynamics of the magnetisation vector. Figure A.0.1 shows an example of a radio-
frequency (RF) pulse applied perpendicular to the magnetisation vector M, from
both the laboratory and rotating frames. While in the laboratory frame the vectorM
precesses around the 𝑧 axis until it aligns with the 𝑦 axis, the same event from the
rotating frame is described as a single rotation along the 𝑥′ axis.
Relaxation
The recovery of themagnetisation vectorM(𝑡) towards its thermal equilibrium value
is called relaxation. This process is mediated by two different physical phenomena,
spin-lattice and spin-spin interactions.
The longitudinal (or spin-lattice) relaxation, associated with the T1 characteristic
time, derives from the redistribution of the spin states in order to reach the thermal
equilibrium. As a consequence, the z component of the nuclear spin magnetisation,
Mz, evolves towards the thermal equilibrium value, 𝑀0. This relationship can be
expressed as:
𝑀𝑧(𝑡) =𝑀0−[𝑀0−𝑀𝑧(0)]𝑒−𝑡/𝑇1 (A.0.5)
The transverse (or spin-spin) relaxation corresponds to the loss of coherence of the
transverse magnetisation𝑀⟂, perpendicular to the static magnetic field 𝐵0. T2 is
the decay constant for the spin-spin relaxation process. From an initial state𝑀⟂(0)
at time zero, the transverse magnetisation decays as follows:
𝑀⟂(𝑡) =𝑀⟂(0)𝑒−𝑡/𝑇2 (A.0.6)
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Bloch equations
The combination of the two relaxation processes with the equation of motion results
in what is called the Bloch equations:
𝑑M(𝑡)
𝑑𝑡 = 𝛾M(𝑡)×B(𝑡)−
M∥−M0
𝑇1
−M⟂𝑇2
(A.0.7)
whereM∥ andM⟂are respectively the parallel and perpendicular projections of the
magnetisation vectorM along the static magnetic field B0.
Choosing the static magnetic field to be along the z axis and breaking down the
vectorial identity into its Cartesian components yields to:
𝑑𝑀𝑥(𝑡)
𝑑𝑡 = 𝛾 [𝑀𝑥(𝑡)𝐵𝑧(𝑡)−𝑀𝑧(𝑡)𝐵𝑦(𝑡)]−
𝑀𝑥(𝑡)
𝑇2
𝑑𝑀𝑦(𝑡)
𝑑𝑡 = 𝛾 [𝑀𝑧(𝑡)𝐵𝑥(𝑡)−𝑀𝑥(𝑡)𝐵𝑧(𝑡)]−
𝑀𝑦(𝑡)
𝑇2
(A.0.8)
𝑑𝑀𝑧(𝑡)
𝑑𝑡 = 𝛾 [𝑀𝑥(𝑡)𝐵𝑦(𝑡)−𝑀𝑦(𝑡)𝐵𝑥(𝑡)]−
𝑀𝑧(𝑡)−𝑀0
𝑇1
Given an isolated set of spins in a magnetic fieldM(𝑡), the behaviour of the mag-
netisation vectorM(𝑡) is fully described by the Bloch equations.
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B. Pulse sequences and
relaxometry analysis
B.1. T1 map sequence
Quantification of the longitudinal relaxation time T1 was performed using a modi-
fied Inversion Recovery Gradient Echo sequence. A global adiabatic inversion pulse
was applied on resonance with water followed by an inversion time TI and a GE
readout with echo time set at the minimum possible value (TE= 1.09ms). Phase
encoding lines were acquired from low to high frequency (inverse centric k-space
sampling), providing fast images but heavily weighted on the centre of k-space. TE
was set to 1.09ms (minimum possible) and 𝑇𝑅𝑅𝑂 (which refers to TR between
readouts) to 2.03ms. Each acquisition was followed by a 20 seconds delay and
spoiler gradients (duration = 1.3s and amplitude = 2G/cm) to obtain full signal re-
covery before the next inversion pulse. The sequence was repeated 20 times with
different TI values, exponentially spaced from 70ms to 20s. Figure B.1.1 shows the
diagram of the pulse sequence.
B.2. T2 map sequence
Quantification of the transverse relaxation time T2 was done using a Carr Purcell
Meiboom Gill (CPMG) sequence. It consisted of a 90 degree excitation pulse in the
x axis (sinc shaped and 1ms long) followed by 40 refocusing pulses in the y axis
(flip angle 180°, sinc shaped and 1ms long).
B.3. CEST sequence
The CEST sequence consisted of two parts, pre-saturation at a frequency offset (fsat)
followed by turbo-flash GE readout (same as for T1 maps). Saturation was achieved
with a train of 80 Gaussian shaped pulses, each at 50ms duration and with an inter-
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Figure B.1.1.: Illustration of the T1 map sequence. RF pulses are shown
in green, slice select and frequency encoding gradients in black and phase
encoding gradients in blue. The orange brackets indicate the array of
18 TI values.𝐺𝑆𝑆, 𝐺𝑃𝐸, 𝐺𝑅𝑂 correspond to the slice selection, phase
encoding and readout gradients respectively. TI represents to the wait time
between the application of the inversion recovery and the readout pulses
Figure B.2.1.: Illustration of the CPMG sequence used for the quantifi-
cation of T2 maps. The RF pulses are shown in green, the gradients in
black and the phase encode table in blue. Orange colour represents the
array of echo times (NE=40), where each echo corresponds to a differ-
ent T2 weighted image. Slice refocusing crushers were applied for 2ms at
amplitude 10G/cm.
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pulse delay of 1ms. The flip angle of the saturation pulses (∝B1 power) was adjusted
to obtain CEST profiles at different saturation power.
Figure B.3.1.: Illustration of the CEST sequence used. All RF pulses
are displayed in green. Slice select and frequency encoding gradients in
black and phase encoding gradients in dark blue. The light blue bracket
indicates the number of saturation pulses applied (NP). The saturation
RF pulse prior to the excitation pulse is applied with no inter-pulse delay
(total number of saturation pulses 80). 𝐹𝐴𝑠𝑎𝑡 indicates the flip angle
of each saturation pulse. 𝑇𝑅𝑅𝑂 refers to the readout time alone, while
𝑇𝑅𝑡𝑜𝑡𝑎𝑙 to the total aquisition time between frequency offsets in the Z-
spectrum. The loop corresponding to the Z-offset frequncies (NF) is dis-
played in orange
B.4. Relaxometry
Quantification of T1 values was done assuming a mono-exponential longitudinal
relaxation to fit the data to equation B.4.1:
𝑀𝑧(𝑇 𝐼) =𝑀𝑒𝑞.|1−2𝑒−𝑇𝐼/𝑇1| (B.4.1)
where𝑀𝑒𝑞 is the signal at full recovery, T1 the longitudinal relaxation time and TI
the inversion time.
Quantification of T2 values was done assuming a mono-exponential traverse re-
laxation and fitting the data to equation B.4.2:
𝑀𝑧(𝑇𝐸) =𝑀0.𝑒−𝑇𝐸/𝑇2 (B.4.2)
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where𝑀0 is the constant representing the intensity at zero echo time, T2 the traverse
relaxation time and TE the echo time. In order to avoid errors from inhomogeneous
RF pulses, only the even echoes were used in the fitting.
All the data analysis was done in a pixel by pixel basis using in-house made Mat-
lab codes.
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C. CEST in amino acids
As mentioned in section 5.6, 13C NMR spectroscopy of SW1222 and LS174T tu-
mours revealed that glucose is transformed into lactate and a number of different
amino acids, as part of the metabolic activity of these cancer cells. Amino acids
contain -NH and -OH groups that are susceptible to be detected by CEST and hence
may contribute to the measured glucoCEST signal. In order to investigate this, a
new experiment was carried out in which a set of phantoms with molecules found
in the tumours were scanned to evaluated their CEST response.
Amino acids phantom study:
Method Phantoms with solutions (1% PBS) of the following substances were
prepared: lactate, glutamate, glutamine, taurine and alanine, which accounted for
the most abundant amino acids found in 13C NMR.1 The samples were arranged in
10 and 50 mMolar concentrations and scanned with two different RF powers, 1𝜇𝑇
and 2𝜇𝑇 . Temperature was set to 37°C and pH calibrated at 7.4. The pulse sequence
and scan parameter used were the same as in the previous study.
Figure C.0.1.: Exchangeable sites in amino acids
Results In contrast to the broad glucose peak observed at 1 ppm, results from the
amino acids showed distinct CEST peaks centred around 2.9 ppm. The reason for
the different resonant frequencies is attributable to the type of exchangeable site in-
volved, -NH in the case of amino acids while -OH in glucose. It is worth noting that
contained within the structure of these amino acids, there are also hydroxyl groups
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which do not display any CEST peak. The extreme mobility of small molecules
confers a very fast exchange rate, which becomes too fast for sites like the hydroxyl
groups that resonate close to water, at around 1 ppm. Hence, the signal derives es-
sentially from -NH groups with a minor contributions from -OH, as can be seen in
lactate, which contains no -NH sites.
Figure C.0.2.: CEST effect from amino acids
Z- and MTRasym spectra from glucose, lactate, glutamine, glutamate, ala-
nine and taurine. While lactate shows negligible signal, amino acids show
distinct CEST peaks centred at around 2.9 ppm.
In in vivo experiments, CEST peaks appear much less defined than in vitro, which
is why it is customary to calculate an overall CEST signal over a range of frequen-
cies. The average CEST signal (integrated between 0 and 4 ppm) from glutamine,
glutamate, taurine and alanine was 77% of that found in glucose. On the other hand,
lactate showed a smaller CEST effect, accounting for 10% of the signal from glu-
cose. These ratios get even more stretched when the MTRasym is integrated from
0.75 to 4 ppm (as done for our initial study1), leading to ratios of 83% for the amino
acids and a negligible 4% in the case of lactate.
Under the assumption that increased glucose uptake in tumours would also bring
an up-regulation of amino acid production, the results suggest that glucoCEST signal
could be consequence of an increase in both glucose and amino acids concentration.
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D. Endogenous CEST in
xenograft glioblastoma
models
As seen in Chapter 1, endogenous APT contrast has been shown to be a useful tech-
nique for the investigation of cancer, as it can inform on various important aspects
of tumour physiology such as pH or protein concentration levels and it has been pro-
posed as a powerful method to differentiate necrosis and recursive tumour tissue.
While the main focus of this work was the study of the glucoCEST method, the
data acquired for the study presented in Chapter 6 is also useful to explore the native
CEST contrast in glioblastomas. A brief summary of the findings in the endogenous
CEST profile of these tumours is accounted in this appendix. As part of the same
study, the methodology and animal models used are the same as the ones described
in Chapter 6. In this section, APT-CEST is compared to relaxation times T1 and T2
over the progression of different glioblastoma models inoculated in mice.
T1 and T2 maps show a clear increase in the tumour affected areas both in solid
and diffused phenotype cell-lines. Figures D.0.1 and D.0.2 show increased values
for the core of the tumour followed by elevation in the proliferating region at a later
stage. The regions labelled as no tumour (not affected by inspection of T2wSE),
do not show any significant increase in the relaxation times; only at the late state
of the diffused cases. APT on the other hand, displays a distinct pattern with an
initial increase of the mean MTR asymmetry followed by a sudden decrease at cer-
tain a phase in the development of the cancer. The abrupt change the APT response
manifests at different times in individual cell-lines, as it would be expected from
different growth rates. It is worth noting that when the APT signal starts chang-
ing the contrast between core, proliferation and non tumour regions increases too.
Remarkably regions with no apparent tumour display a fast signal decrease, which
could be associated to either a reduction of the endogenous amide concentration or
to an increase in the aliphatic NOEs. These phenomena might be linked to changes
in protein concentrations or pH as the result of cancer. What is more relevant of
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Figure D.0.1.: Evolution of the T1 relaxation time for different glioblas-
toma models. Colour-bars represent the median T1 value in the specific
ROIs. Horizontal axis represents weeks after inoculation of cancer cells.
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Figure D.0.2.: Evolution of the T2 relaxation time for different glioblas-
toma models. Colour-bars represent the median T2 value in the specific
ROIs. Horizontal axis represents weeks after inoculation of cancer cells.
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Figure D.0.3.: Evolution of the APT (MTR asymmetry at 3.5 ppm) signal
different glioblastoma models.
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this behaviour is that it occurs before changes in the T1 or T2 maps are apparent.
Inspection of pH in these tissues could shed more light and clarify this hypothesis.
As a last remark, is also interesting to point out that APT appears to distinguish the
effects the injury caused by the intracraneal injection better than T1 or T2 maps (see
the first week 2 after inoculations).
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E. 9-Pool exchange model based
on Bloch-McConnell
equations. Time dependent
simulation.
E.1. Definition of the model
frame
%% 9 Pool Bloch−McConell Model
function dM=Cool9Pool_Model(t,M,RFppm)
global glucoseMolarity num_gauss interpuseDelay duration B0 FlipA gamma ppm ppmb ppmc ppmd ppme ppmf ppmg
ppmh ppmi M0a M0b M0c M0d M0e M0f M0g M0h M0i T2a T1a T2b T1b T2c T1c T2d T1d T2e T1e T2f T1f T2g T1g
T2h T1h T2i T1i kb kc kd ke kf kg kh ki B1eq
format long
dM=zeros(25,1);
%% Constants
w0=gamma*B0;
D=w0*10^−6/(2*pi)*RFppm;
dc=w0*10^−6/(2*pi)*ppmc;
dd=w0*10^−6/(2*pi)*ppmd;
de=w0*10^−6/(2*pi)*ppme;
df=w0*10^−6/(2*pi)*ppmf;
dg=w0*10^−6/(2*pi)*ppmg;
dh=w0*10^−6/(2*pi)*ppmh;
di=w0*10^−6/(2*pi)*ppmi;
db=w0*10^−6/(2*pi)*ppmb;
t0=0;
tmax=(t0+duration/2);
s=duration/5.86;
% figure,plot(tt,Agilent_gaussian,tt,exp(−((tt−tmax)/s).^2/2),'r')
% timeperstep=duration/shape_points;
% nstepstoadd=round(interpuseDelay/timeperstep);
% gaussianBlock=cat(1,Agilent_gaussian,zeros(nstepstoadd,1));
% gaussTrain=repmat(gaussianBlock,[20,1]);
% trainLenght=num_gauss*(duration+interpuseDelay);
% time=linspace(0,trainLenght,numel(gaussTrain));
% figure,plot(time,gaussTrain)
% FA = gamma * Amp*s*sqrt(2*pi)
FA=FlipA*pi/180;%[rad]
Amp=FA/(s*sqrt(2*pi)*gamma);
% yy=0; %for the begining of the loop
% for n=1:num_gauss
% yy=yy+exp(−((tt−(tmax+(n−1)*(duration+interpuseDelay)))/s).^2/2);
% end
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% GaussTrain=Amp*yy;
% figure,plot(tt,GaussTrain)
yy=0; %for the begining of the loop
for n=1:num_gauss
yy=yy+exp(−((t−(tmax+(n−1)*(duration+interpuseDelay)))/s).^2/2);
end
B1=Amp*yy;
%% Overwrte Pulses and use constant equivalent B1
B1=B1eq;
%% %%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
% %Square pulse a
% ti=0.3;
% tf=5;
% Ba=0;
% if (ti <= t) && (tf > t)
% Ba=B1;
% end
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%% %%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
% %Square pulse b
% delay=0.00372;
% ti2=tf+delay;
% tf2=0.55+delay;
% Bb=0;
% if (ti2 <= t) && (tf2 > t)
% Bb=0*1*B1;
% end
% % %%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
% B1=Ba+Bb;
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%Pulse Sequence
% mtcrusher=3*10^−3; %time duration at the end of sat pulse train.
% Bef_Read=0.008; %time delay before the readout pulse.
% Aft_Read=4.5*10^−3; %time delay after the readout pulse.
%
% %%% Saturation pulses train
% SatFlip=7000; %in degree.
% SatPulse=50*10^−3; %time duration of the sat pulse.
% SatDelay=4*10^−6; %time duration between sat pulses.
%
% SatFlipRad=SatFlip*pi/180;
% %B1c_Sat=SatFlipRad/(gamma*(SatPulse+SatDelay)); i thinks its worng
% sigmaSat=SatPulse/7;
% A_Sat=SatFlipRad/(sqrt(2*pi)*gamma*sigmaSat);
%
% b0=4*10^−6;
% t0=3.5*sigmaSat;
% b=0;
% B1=0; %just to start with
%
% for p=1:10
% spike=A_Sat*(exp(−(t−t0−b−Aft_Read).^2/(2*sigmaSat^2)));
% b=b+b0+SatPulse+SatDelay;
% B1=B1+spike;
% end
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
% % Readout pulse
% ReadFlip=90; %in degree too.
% ReadPulse=20*10^−3; %time duration of the readout pulse.
% Bef_Read=12*10^−6;
% mtcrusher=12*10^−6;
% sigmaRead=ReadPulse/7;
% ReadFlipRad=ReadFlip*pi/180;
% %B1c_Read=ReadFlipRad/(gamma*(ReadPulse)); % [T] For 20 degrees, 2ms pulse
% A_Read=ReadFlipRad/(sqrt(2*pi)*gamma*sigmaRead);
% Readout=A_Read*(exp(−(t−(mtcrusher+Bef_Read+ReadPulse/2)−b).^2/(2*sigmaRead^2)));
Readout=0;
B1=B1+Readout;
% B1=10^−6
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
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%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%B1=0 %% To apply no pulses at all &&&
% TR=b0+p*(SatPulse*SatDelay)+mtcrusher+Bef_Read+Aft_Read+ReadPulse;
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%Triangular pulse
% tia=0.0;
% tfb=0.05;
% tfa=(tfb−tia)/2;
% tib=tfa;
% B1=0;
% if (tia <= t) && (tfa >= t)
% B1=200*5*20*0.1175*10^−6*t;
% end
% if (tib < t) && (tfb > t)
% B1=200*5*20*0.1175*10^−6*(2*tfa−t);
% end
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
w1=gamma*B1;
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
% if (w1==0)
% D=0;
% dc=0;
% end
if t> num_gauss*(duration+interpuseDelay) %%sets the offset of the readout pulse to the water freq
D=0;
end
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%% Superlorentzian function
q=10000;
% p=1000;
o = linspace(0, pi/2, q);
%D=1000*logspace(log10(0.01),log10(213),p);
%o_m=repmat(o',1,p);
%D_m=repmat(D,q,1);
value=sin(o).*(2/pi).^0.5*T2b./abs(3*cos(o).^2−1).*exp(−2*((D−db).*T2b./(abs(3*cos(o).^2−1))).^2); % −dcb
added to shift the mt pool
da=pi/(2*(q−1)).*value;
Amt=sum(da); %superlorentzian function for every D
Rrfb=Amt*w1^2*pi; %Rrfb(1,p)=1*Amt*w1^2; not sure if we have to multiply by w1^2
%% EQUATIONS
dM(1) =(−1/T2a−kc*M0c−kd*M0d−ke*M0e−kf*M0f−kg*M0g−kh*M0h−ki*M0i)*M(1) +(−2*pi*D)*M(2)+ M0a*(kc*M(4)+kd*M(7)+ke
*M(10)+kf*M(13)+kg*M(16)+kh*M(19)+ki*M(22));
dM(2)=2*pi*D*M(1)+(−1/T2a−kc*M0c−kd*M0d−ke*M0e−kf*M0f−kg*M0g−kh*M0h−ki*M0i)*M(2) −w1*M(3)+M0a*(M(5)*kc+M(8)*kd
+M(11)*ke+M(14)*kf+M(17)*kg+M(20)*kh+M(23)*ki);
dM(3)=w1*M(2)+(−1/T1a−kc*M0c−kd*M0d−ke*M0e−kf*M0f−kg*M0g−kh*M0h−ki*M0i)*M(3)+ M0a*(M(6)*kc+M(9)*kd+M(12)*ke+M
(15)*kf+M(18)*kg+M(21)*kh+M(24)*ki) +M0a/T1a;
dM(4)=kc*M0c*M(1)+(−1/T2c−kc*M0a)*M(4)−2*pi*(D−dc)*M(5);
dM(5)=kc*M0c*M(2)+2*pi*(D−dc)*M(4)+(−1/T2c−kc*M0a)*M(5)−w1*M(6);
dM(6)=kc*M0c*M(3)+w1*M(5)+(−1/T1c−kc*M0a)*M(6)+M0c/T1c;
dM(7)=kd*M0d*M(1)+(−1/T2d−kd*M0a)*M(7)−2*pi*(D−dd)*M(8);
dM(8)=kd*M0d*M(2)+2*pi*(D−dd)*M(7)+(−1/T2d−kd*M0a)*M(8)−w1*M(9);
dM(9)=kd*M0d*M(3)+w1*M(8)+(−1/T1d−kd*M0a)*M(9)+M0d/T1d;
dM(10)=ke*M0e*M(1)+(−1/T2e−ke*M0a)*M(10)−2*pi*(D−de)*M(11);
dM(11)=ke*M0e*M(2)+2*pi*(D−de)*M(10)+(−1/T2e−ke*M0a)*M(11)−w1*M(12);
dM(12)=ke*M0e*M(3)+w1*M(11)+(−1/T1e−ke*M0a)*M(12)+M0e/T1e;
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dM(13)=kf*M0f*M(1)+(−1/T2f−kf*M0a)*M(13)−2*pi*(D−df)*M(14);
dM(14)=kf*M0f*M(2)+2*pi*(D−df)*M(13)+(−1/T2f−kf*M0a)*M(14)−w1*M(15);
dM(15)=kf*M0f*M(3)+w1*M(14)+(−1/T1f−kf*M0a)*M(15)+M0f/T1f;
dM(16)=kg*M0g*M(1)+(−1/T2g−kg*M0a)*M(16)−2*pi*(D−dg)*M(17);
dM(17)=kg*M0g*M(2)+2*pi*(D−dg)*M(16)+(−1/T2g−kg*M0a)*M(17)−w1*M(18);
dM(18)=kg*M0g*M(3)+w1*M(17)+(−1/T1g−kg*M0a)*M(18)+M0g/T1g;
dM(19)=kh*M0h*M(1)+(−1/T2h−kh*M0a)*M(19)−2*pi*(D−dh)*M(20);
dM(20)=kh*M0h*M(2)+2*pi*(D−dh)*M(19)+(−1/T2h−kh*M0a)*M(20)−w1*M(21);
dM(21)=kh*M0h*M(3)+w1*M(20)+(−1/T1h−kh*M0a)*M(21)+M0h/T1h;
dM(22)=ki*M0i*M(1)+(−1/T2i−ki*M0a)*M(22)−2*pi*(D−di)*M(23);
dM(23)=ki*M0i*M(2)+2*pi*(D−di)*M(22)+(−1/T2i−ki*M0a)*M(23)−w1*M(24);
dM(24)=ki*M0i*M(3)+w1*M(23)+(−1/T1i−ki*M0a)*M(24)+M0i/T1i;
dM(25)=kb*M0b*M(3)+(−Rrfb*M0b−1/T1b−kb*M0a)*M(25)+M0b/T1b;
E.2. Execution of the model
frame
%% Executes 9 Pool Bloch−McConnell Model
clear all
format long
tic
global glucoseMolarity num_gauss interpuseDelay duration B0 FlipA gamma ppm ppmb ppmc ppmd ppme ppmf ppmg
ppmh ppmi M0a M0b M0c M0d M0e M0f M0g M0h M0i T2a T1a T2b T1b T2c T1c T2d T1d T2e T1e T2f T1f T2g T1g
T2h T1h T2i T1ikb kc kd ke kf kg kh ki B1eq
gamma=42.576*10^6*2*pi; %[ s−1 T−1]
B0=9.384;
FlipA=540;%1666%1200%793;%793;
num_gauss=118;
interpuseDelay=1*10^−3; % [in s].........
duration=50*10^−3;%.1*10^−3;
ppm=0*1.2; %Rf pulse off resonance frequency from water pool
%% B1eq calculation
nsigma=5.84; %number of sigmas the pulse shape uses. Calculated from shape lib.
% gamma=267.513*10^6; %Gyromagnetic ratio (/s/T)
% FA=input('What is the saturation flip angle (per Gaussian) [degrees]? ');
FA=FlipA*pi/180; %to radians
Duration=duration
IntDelay=interpuseDelay
sigma=duration/nsigma;
intePercentage=erf(nsigma/sqrt(2));
B1eq=sqrt(FA^2*sqrt(pi)/(2*pi*sigma*gamma^2*(Duration+IntDelay)*intePercentage))
%% Ofset frequency of each pool
ppmc=1.1; %CEST pool off resonance frequency from water pool
ppmd=2;
ppme=2.9;
ppmf=2.1;
ppmg=3.5;
ppmh=−2;
ppmi=−3.15;
ppmb=0;
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%% Initial Pool Concentrations
% 10%glucose=10g/100ml=555mMolar of glucose in h2o
glucoseMolarity=125;%[mMolar]
M0a=1;
M0c=1*glucoseMolarity/(1000*55*1); %Glucose pools
M0d=1*glucoseMolarity/(1000*55*1); %Glucose pools
M0e=1*glucoseMolarity/(1000*55*1); %Glucose pools
M0f=0.003272;%1/611;%AMINE
M0g=0.001472;%1/786;%AMIDE
M0h=0/100;
M0i=M0a/31;%NOE
M0b=M0a/11;%MT %i had it 75
%% exchange rates
pH=7.6;
% AminesEx=10.^(pH−5.2);
AminesEx=10.^(pH−4.5); %At 2ppm
% AmidesEx=5.57*10.^(pH−7.2);
AmidesEx=5.57*10.^(pH−6.4); % At 3.5 ppm
incrfac=0.0025*10.^(pH−4.3)+0.5; %At 2ppm
kc=700*incrfac;
kd=2500*incrfac;
ke=1700*incrfac;
kf=AminesEx;
kg=AmidesEx;
kh=10;
ki=5;%NOE
kb=50;%MT
%% Relaxation times
% T2a=0.04; T1a=1.85;
T2a=0.06; T1a=2.5; %% in tumour
T2c=0.006; T1c=1.2;
T2d=0.017; T1d=1.2;
T2e=0.017; T1e=1.2;
T2c=0.1; T1c=1.2;
T2d=0.1; T1d=1.2;
T2e=0.07; T1e=1.2;
T2f=0.0006; T1f=1.1;%Amines
T2g=0.0018; T1g=1.1;%Amides
T2h=0.005; T1h=1;
T2i=0.00042; T1i=1;%NOE
T2b=0.00001; T1b=1;%MT
if B0==3
T2a=0.069; T1a=1.085;
T2c=0.006*1.4; T1c=0.9;
T2d=0.017*1.4; T1d=0.9;
T2e=0.017*1.4; T1e=0.9;
T2f=0.0010*1.4; T1f=0.8;%Amines
T2g=0.0015*1.4; T1g=0.8;%Amides
T2h=0.005*1.4; T1h=0.8;
T2i=0.00042*1.4; T1i=0.8;%NOE
T2b=0.00001*1.4; T1b=0.8;%MT
end
tspan = linspace(0,6,6001);
% M=zeros(64*5000,9);
% T=zeros(64*5000,1);
M0=[0,0,M0a,0,0,M0c,0,0,M0d,0,0,M0e,0,0,M0f,0,0,M0g,0,0,M0h,0,0,M0i,M0b];
ppmrange=4
offsetpoints=51;%77
% options=odeset('MaxStep',0.0001);
t=zeros(numel(tspan),offsetpoints);
M=zeros(numel(tspan),numel(M0),offsetpoints);
RFppm_array=−ppmrange+(1:offsetpoints−1)*2*ppmrange/(offsetpoints−1); %Rf frequency from water pool
for ii=1:offsetpoints;%81;
% RFppm_array(ii)=−ppmrange+(ii−1)*2*ppmrange/(offsetpoints−1); %Rf frequency from water pool
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RFppm=RFppm_array(ii);
% [t, M] = ode45(@Cool9Pool_Model, tspan, M0,options);
% [t, M] = ode15s(@Cool9Pool_Model, tspan, M0);
%[t, M ] = ode45(@Cool9Pool_Model, tspan, M0);
[t(:,ii), M(:,:,ii) ] = ode45(@(t,M) Cool9Pool_Model_28Aug2015(t,M,RFppm), tspan, M0);
ii
end
All_M=M;
t=t(:,1);
offset=1:offsetpoints;
% ppm=−ppmrange+(offset−1)*2*ppmrange/(offsetpoints−1); %Rf frequency from water pool
dirname='C:\Users\ftorrealda\Dropbox\PhD\'
% filename=(['cool9pool_results_incrfactX2_3T_WM', sprintf('%.2g%',10^6*B1eq),'uT_', sprintf('%.0f%',
glucoseMolarity), 'Mmglucose']);
filename='DinamicModelResults_2'
fullname=([dirname,filename])
save(fullname,'All_M','t','RFppm_array');
toc
%% Plots
figure,plot(t,squeeze(All_M{offset}(:,3))),title('Mz of Water')
transverseM=squeeze(sqrt(All_M{offset}(:,1).^2+All_M{offset}(:,2).^2));
figure,plot(t,−squeeze(All_M{offset}(:,1))),
hold on, plot(t,−squeeze(All_M{offset}(:,2)),'g')
hold on, plot(t,transverseM,'k')
title('Mx of Water in blue, My in green, total transverse in black')
t2fit=0
if t2fit==1
%% FIT
%% Fit: 'Observed T2 fit'.
[xData, yData] = prepareCurveData( t, transverseM );
% Set up fittype and options.
ft = fittype( 'exp1' );
ex = excludedata( xData, yData, 'box', [0.001 5 0 1] );
opts = fitoptions( 'Method', 'NonlinearLeastSquares' );
opts.Display = 'Off';
opts.StartPoint = [1.00019005897766 −1.75734781332529];
opts.Exclude = ex;
% Fit model to data.
[fitresult, gof] = fit( xData, yData, ft, opts );
% Plot fit with data.
figure( 'Name', 'Observed T2 fit' );
h = plot( fitresult, xData, yData, ex );
legend( h, 'Transverse M vs. time', 'Excluded points', 'Fitted T2 curve', 'Location', 'NorthEast' );
% Label axes
xlabel( 'Time' );
ylabel( 'Transverse M' );
grid on
hold on
%% ENDOF FIT
end %end of t2fit
clear Mzall Mza
TE=0.002 % TE (in seconds)
for ii=1:offsetpoints
Mzall(ii,:)=(All_M{ii}(:,3)*exp(−TE./T2a)+All_M{ii}(:,6)*exp(−TE./T2c)+All_M{ii}(:,9)*exp(−TE./T2d) + All_M{ii
}(:,12)*exp(−TE./T2e)+All_M{ii}(:,3)*exp(−TE./T2f) + All_M{ii}(:,15)*exp(−TE./T2g) + All_M{ii}(:,18)*exp
(−TE./T2h)+All_M{ii}(:,21)*exp(−TE./T2i) + All_M{ii}(:,24)*exp(−TE./T2b) + All_M{ii}(:,25)*exp(−TE./T2a))
./(M0a +M0b+ M0c+ M0d+ M0e+ M0f+ M0g+ M0h+ M0i);
Mza(ii,:)=All_M{ii}(:,3);
end
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
normRange=[4 4.5];
normR= [round(normRange(1)*(offsetpoints/2/ppmrange)+offsetpoints/2) : round(normRange(2)*(offsetpoints/2/
ppmrange)+offsetpoints/2)];
normRi= [offsetpoints−round(normRange(2)*(offsetpoints/2/ppmrange)+offsetpoints/2) : offsetpoints−round(
normRange(1)*(offsetpoints/2/ppmrange)+offsetpoints/2)];
norm=(mean(Mzall(normR,:))+mean(Mzall(normRi,:)))/2;
Mzall_norm=Mzall./repmat(norm,[offsetpoints,1]);
% ZAsym=flip(ZSpectra(1:round(np/2),:),1)−ZSpectra(round(np/2):np,:);
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%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
ppms=linspace(−ppmrange,ppmrange,offsetpoints);
ppms_half=linspace(0,ppmrange,round(offsetpoints/2));
Asym=flip(Mzall_norm(1:round(offsetpoints/2),:),1)−Mzall_norm(round(offsetpoints/2):end,:);
figure,plot(ppms_half,Asym(:,1:1000:end))
A725=Asym;
diff=(A7220−A725);
figure,plot(ppms_half,100*diff(:,300:300:end))
[X,Y]=meshgrid(ppms_half(1:round(offsetpoints/2)),squeeze(tspan(1,1:200:end)));
figure,surfc(X,Y,100*Asym(:,1:200:end)')
figure,surfc(X,Y,100*(A7220(:,1:200:end)'−A725(:,1:200:end)'))
% figure,surfc(X,Y,100*A6820(:,1:102:end)')
% figure,surfc(X,Y,100*A685(:,1:102:end)')
% [X,Y]=meshgrid(ppms,squeeze(tspan(1,1:102:end)));
% figure,surfc(X,Y,Mzall_norm(:,1:102:end)')
% zlim([−15 20])
% xlim([0 startppm])
% hold on
% ss=surf(X,Y,100*Asym(:,1:102:end)')
ss=findobj(gca,'Type','surface')
ss.FaceColor = 'interp'
% ss.FaceAlpha = 0.4
ss.LineWidth = 0.1
ss.LineStyle = '−'
ss.EdgeColor = [0.1 0.1 0.1]%'interp'%[0.2 0.2 0.2]%'none'
hh=gca;
hh.Projection='perspective'
title([{'%MTR_{asym} in time'},{'[glc]=5 mMolar'}])
title('Time evolution of GCE ')
title({'GCE \Delta[glc] = 15 mMolar'})
xlabel('\Delta\omega (ppm)')
ylabel('Time (s)')
zlabel('% MTR_{asymmetry}')
% zlabel([{'\Delta %MTR_{asymmetry}'},{'(\Delta[glc] = 15 mMolar)'}])
set(gca,'FontSize',13);%,'fontWeight','bold')
set(findall(gcf,'type','text'),'FontSize',14,'FontName','Georgia')
% hh.XColor='full'
% set(gca)
% shading interp
%%
figure
[~,h] = contourf(X,Y,100*diff(:,1:200:end)'); %# get handle to contourgroup object
% [~,h] = contourf(X,Y,100*Asym(:,1:200:end)'); %# get handle to contourgroup object
% [~,h] = contourf(X,Y,100*A7220(:,1:200:end)'); %# get handle to contourgroup object
%# change the ZData property of the inner patches
hh = get(h,'Children'); %# get handles to patch objects
% set(hh, {'ZData'}, cellfun(@(X) −10*ones(size(X)), get(hh,{'XData'}), 'UniformOutput',false))
h.ShowText = 'off';
h.LevelStep = 0.0333;
h.LineWidth = 0.1
xlabel('\Delta\omega (ppm)')
ylabel('Time (s)')
zlabel('% MTR_{asymmetry}')
% zlim([−10 5])
% xlim([0 ppmrange])
title('%MTR_{asym} in time 20')
set(gca,'FontSize',15);%,'fontWeight','bold')
% set(findall(gcf,'type','text'),'FontSize',27)
set(findall(gcf,'type','text'),'FontSize',15,'FontName','Georgia')
%%
figure,
for read=1:nreads
readtime=tspan(1)+read/nreads*timespan; %time at which you want to inspect the magnetizatio
h=plot(ppms,squeeze(Mzall(:,read)),ppms_half,10*Asym(:,read));
axis([−ppmrange ppmrange −1 2])
text(.1,.5,['\fontsize{16} \color[rgb]{0 .5 .5}Saturation lenght ', sprintf('%.1f%', readtime)])
F(read)=getframe;
end
%% DISPLAY ANIMATION
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figure
axis([−6 6 0 1])
movie(F,1)
%% SHOW MTRasym in time
figure
plot (t,M(:,3)/1,'b')%,T,M(:,9)/(0.0054),'m')%,T,M(:,2))
% plot (t,m(:,3)/1,'r',t,m(:,9)/(0.0054),'b')
title('5 sat pulses/readout')
xlabel('t [s]')
ylabel('Mz/M0 water')
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F. Steady-State 8-Pool
Bloch-McConnell model
frame
%% Bloch−McConnell Equations. STEADY STATE solution of an 8 Pool Model
clear all
format long
tic
inWaterGlucoseSolution=0
inwhitematter=0 %Otherwise values for white matter are taken.
ingreymatter=0
intumour=1
interaction_CD=0; %to add a connection between pools C and D
%% Constants
gamma=42.576*10^6*2*pi; %[Radians s−1 T−1]
B0= 9.384; %T
w0=gamma*B0;
np=301;%77;%;1001;
One_ppm=w0/2/pi*10^−6;
maxmynumMT=2%4; % MT array
maxmynumNOE=2%; % NOE array
maxmynumAmine=2%; % Amines array
maxmynumAmide=2%; % Amides array
maxmynumpH=4; % pH array
maxmynumT1=2; % T1a array
maxmynumT2=2; % T2a array
maxmynumB1=10; % B1 array
maxmynumG=3;% Glucose concentration array
superMM=zeros(22,np,maxmynumG,maxmynumB1,maxmynumT2,maxmynumT1,maxmynumpH,maxmynumAmide,maxmynumAmine,
maxmynumNOE,maxmynumMT);
for mynumMT=2:maxmynumMT
mynumMT
for mynumNOE=2:maxmynumNOE
mynumNOE
for mynumAmine=2:maxmynumAmine
for mynumAmide=2:maxmynumAmide
for mynumpH=4:maxmynumpH
for mynumT1=2:maxmynumT1
for mynumT2=2:maxmynumT2
for mynumB1=1:maxmynumB1
for mynumG=1:maxmynumG
% B1equivalent for Agilent Gaussian
nsigma=5.84; %number of sigmas the pulse shape uses. Calculated from shape lib.
FAarray=[540,793,1100,1605,2000,3000,4500,6000,9000,12000];
FAarray=[360,540,793,1100,1605,2000,3000,4500,6000,9000];
FA=FAarray(mynumB1);
FA=FA*pi/180; %to radians
% Duration=input('What is duration of the pulse [ms]? ');
Duration=50;
Duration=Duration/1000; %to secs
% IntDelay=input('Do you have an interpulse delay? How many milli seconds? ');
IntDelay=1;
IntDelay=IntDelay/1000; %to secs
sigma=Duration/nsigma;
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intePercentage=erf(nsigma/sqrt(2));
B1eq=sqrt(FA^2*sqrt(pi)/(2*pi*sigma*gamma^2*(Duration+IntDelay)*intePercentage));
B1=B1eq;
% B1eqA=10^−6*[1 2 5 9 15];
% B1=B1eqA(mynumB1);
B1array(mynumB1)=B1;
% B1=((mynumB1−1)*1+0.5)*10^−6
%%
w1=gamma*B1;% %w1 goes in rad/s whereas delta ,ppmc and exRates in Hz in the equations delta is
multiplied by 2pi
%% Pool parameters
%% Relative concentration
M0a=1; %water
proteinConc=90*1;%in mMolar
glucoseMolarity=5+120*(mynumG−1);%in mMolar
glucoseMol_array(mynumG)=glucoseMolarity;
%pool sizes
M0b=1*M0a/11; %MT pool
M0b=M0b/2*mynumMT;
if inwhitematter==1
M0b=0.14*M0a; %White Matter MT pool
elseif ingreymatter==1
M0b=0.06*M0a; %Grey MatterMT pool
% M0b=0.14*M0a; %Grey MatterMT pool
end
M0c=2*proteinConc/(1000*55); %Amine
M0c=M0c/2*mynumAmine;
M0d=0.90*proteinConc/(1000*55);%Amide
M0d=M0d/2*mynumAmide;
M0f=1*M0a/31; % NOE
M0f=M0f/2*mynumNOE;
% % % % % % M0e=3*glucoseMolarity/(1000*55)/2; %%Glucose pools
% % % % % % M0g=1*glucoseMolarity/(1000*55)/2; %
% % % % % % M0h=0.2*glucoseMolarity/(1000*55)/2; %
M0e=1*glucoseMolarity/(1000*55)/1; %%Glucose pools
M0g=1*glucoseMolarity/(1000*55)/1; %
M0h=1*glucoseMolarity/(1000*55)/1; %
M0e_array(mynumG)=M0e;
M0g_array(mynumG)=M0g;
M0h_array(mynumG)=M0h;
%% pH
pH=6.5+0.25*(mynumpH−1);
% pH=6.6+(mynumpH−1)*(0.2)
pH=7.6
pHarray(mynumpH)=pH;
% pHRange(mynumpH,:)=char(['pH ',sprintf( '%.1f%',pH)]);
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%% Relaxation Times of each spin species
% T1s
T1a=1.65+0.2*(mynumT1−1);
T1b=1;%for MT
T1c=1.1;
T1d=1.1;
T1f=1; %for fat or NOE
T1e=1.2; %glucose1
T1g=1.2;%glucose2
T1h=1.2;%glucose3
% T2a=3.2*exp(−M0b*140);%T2a=0.04;
T2a=0.02+0.02*(mynumT2−1);
T2b=0.00001;%for MT*1.8
T2c=0.0006;
T2d=0.0018;
T2f=0.00042;% NOE
T2e=0.1;
T2g=0.1;%
T2h=0.07;%
if intumour==1
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T1a=2.5;
T2a=60*10^−3;
end
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%% AT 3T Relaxation Times
if B0==3
% T1s
B0factorT1=0.81;
T1a=T1a*B0factorT1;%
T1b=T1b*B0factorT1;%for MT
T1c=T1c*B0factorT1;
T1d=T1d*B0factorT1;
T1f=T1f*B0factorT1; %for fat or NOE
T1e=T1e*B0factorT1;
T1g=T1g*B0factorT1;
T1h=T1h*B0factorT1;
if inwhitematter==1
T1a=1.084;
elseif ingreymatter==1
T1a=1.820;
elseif intumour==1
T1a=2.5;
end
% T2s
B0factorT2=1.9;
T2a=T2a*B0factorT2;
T2b=T2b*B0factorT2;%for MT*1.8
T2c=T2c*B0factorT2;
T2d=T2d*B0factorT2;
T2f=T2f*B0factorT2;% NOE
T2e=T2e*B0factorT2;
T2g=T2g*B0factorT2;%
T2h=T2h*B0factorT2;%
if inwhitematter==1
T2a=69*10^−3;
elseif ingreymatter==1
T2a=99*10^−3;
elseif intumour==1
T2a=140*10^−3;
end
end
%%%%%%%%%%%%%%%%%%%%%
T2array(mynumT2)=T2a;
T1array(mynumT1)=T1a;
%% Resonant frequencies from water
ppmb=0*−3.5;
ppmc=+2.1; %AMINE
ppmd=3.5; % AMIDE
ppmf=−3.15;%−3.2; NOE
ppme=1.1;
ppmg=2;
ppmh=2.9;
%% Tranfer rates
% K0=0;Ka=25;Kb=1.2*10^10;pKw=14; % values that allow lower exchange rates for acidic environments
% K0=1000;Ka=25;Kb=0.7*10^10;pKw=14; % values that match Chan, van Zijl MRM2012
% KexG=K0+Ka*10.^(−pH)+Kb*10.^(pH−pKw);
% Rb=50; %fot MT
% Rc=KexG*0.55; %s^(−1)
% Rd=KexG*0.75;
%from pH mapping based on the ratiometric amide and amine relationship from
%endogenous CEST Kim Desmond1, Greg Stanisz 1,2
% pH=[6.4 6.7 7 7.3]
AminesEx=10.^(pH−5.2);
AminesEx=0.5*10.^(pH−4.5); %At 2ppm
AminesEx=10.^(pH−4.5); %At 2ppm FROM THE COOL9POOL model
AmidesEx=5.57*10.^(pH−7.2);
AmidesEx=5.57*10.^(pH−6.4); % At 3.5 ppm
Rc=1*AminesEx;
Rd=1*AmidesEx;
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Rf=5; %for fat or NOE
Rb=50; %MT
% incrfac=2;
incrfac=0.0025*10.^(pH−4.3)+0.5; %At 2ppm
% Re=935*incrfac;
% Rg=1700*incrfac;
% Rh=1250*incrfac;
%
Re=700*incrfac;%700
Rg=2500*incrfac; %4000
Rh=1700*incrfac; %1700
%Pool sizes taking the saturation efficency into account.
PUT_SAT_EFFIENCIENCY=0;
if PUT_SAT_EFFIENCIENCY==1
% alphab=w1^2/(w1^2+Rb^2);
alphac=w1^2/(w1^2+Rc^2);
alphad=w1^2/(w1^2+Rd^2);
alphae=w1^2/(w1^2+Re^2);
alphaf=w1^2/(w1^2+Rf^2);
alphag=w1^2/(w1^2+Rg^2);
alphah=w1^2/(w1^2+Rh^2);
%%New Saturation efficiecy to account for relaxation in XY plane
% alphab=w1^2/(w1^2+Rb^2*T2b);%%%%%%%%%%%%%%%%%%%%%%%% You might want to use the previous one
alphac=w1^2/(w1^2+Rc^2*T2c);%%%%%%%%%%%%%%%%%%%%%%%% You might want to use the previous one
alphad=w1^2/(w1^2+Rd^2*T2d);%%%%%%%%%%%%%%%%%%%%%%%% You might want to use the previous one
alphae=w1^2/(w1^2+Re^2*T2e);%%%%%%%%%%%%%%%%%%%%%%%% You might want to use the previous one
alphaf=w1^2/(w1^2+Rf^2*T2f);%%%%%%%%%%%%%%%%%%%%%%%% You might want to use the previous one
alphag=w1^2/(w1^2+Rg^2*T2g);%%%%%%%%%%%%%%%%%%%%%%%% You might want to use the previous one
alphah=w1^2/(w1^2+Rh^2*T2h);%%%%%%%%%%%%%%%%%%%%%%%% You might want to use the previous one
%%Endof New Saturation efficiecy to account for relaxation in XY plane
% M0b=M0b*alphab;
M0c=M0c*alphac;
M0d=M0d*alphad;
M0e=M0e*alphae;
M0f=M0f*alphaf;
M0g=M0g*alphag;
M0h=M0h*alphah;
end
% Rcd=abs(AmidesEx−AminesEx)./(AmidesEx+AminesEx)/4/(1−abs(1−M0d/M0c));
% Rinteract=20*M0a./(M0d+M0c).*Rcd;
Rinteract=5000 ;%pH independent. For NH2 to NH exchange rate [H+] not important inside the protein structure
. can it be??
%% %%%%%%%%%%%%%%%%%%%%%%%%%%%
%% IF PHANTOM
if inWaterGlucoseSolution==1 && B0>9 && B0<10
ppme=1.2;
ppmg=2.1;
ppmh=2.88;
M0b=0;
M0c=0;
M0d=0;
M0f=0;
T1a=5;
T2a=0.08;
T1e=1.2;
T1g=1.2;
T1h=1.2;
T2e=0.1;
T2g=0.1;%
T2h=0.1;%
factor=1
Re=700*factor;%700
Rg=2500*factor; %4000
Rh=1700*factor; %1700
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end
%%
dcb=w0*10^−6/(2*pi)*ppmb;
dcc=w0*10^−6/(2*pi)*ppmc;
dcd=w0*10^−6/(2*pi)*ppmd;
dce=w0*10^−6/(2*pi)*ppme;
dcf=w0*10^−6/(2*pi)*ppmf;
dcg=w0*10^−6/(2*pi)*ppmg;
dch=w0*10^−6/(2*pi)*ppmh;
%for the cone picture
% wrf=w0*(1+ppm*10^−6);
% B0eff=(w0−wrf)/gamma; %in Z direction
%Beff=[B1,0,B0eff];
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
MM=zeros(22,np);
Rrfb=zeros(1,np);
D=zeros(1,np);
ppm=zeros(1,np);
maxoffsetppm=6;
ppms=linspace(−maxoffsetppm,maxoffsetppm,np);
% ppms=logspace(0,5,np);
for p=1:np
% ppm=2*maxoffsetppm/(np−1)*(p−1)−maxoffsetppm;
ppm=ppms(p);
D=w0*10^−6/(2*pi)*ppm;
% ppm(p)=ppm;
%% Superlorentzian function
q=10000;
o = linspace(0, pi/2, q);
% value=sin(o).*(2/pi).^0.5*T2b./abs(3*cos(o).^2−1).*exp(−2*(2*pi*(D−dcb).*T2b./(abs(3*cos(o).^2−1))).^2); % −
dcb added to shift the mt pool
value=sin(o).*(2/pi).^0.5*T2b./abs(3*cos(o).^2−1).*exp(−2*((D−dcb).*T2b./(abs(3*cos(o).^2−1))).^2); % −dcb
added to shift the mt pool
da=pi/(2*(q−1)).*value;
Amt=sum(da); %superlorentzian function for every D
Rrfb=Amt*w1^2*pi; %Rrfb(1,p)=1*Amt*w1^2; not sure if we have to multiply by w1^2
Rrfb_all(p)=Rrfb;
%% 8 pool system
%% Tranfer rates
Rbp=Rb;%Rb; %fot MT
Rcp=Rc;%s^(−1)
Rdp=Rd;
Rep=Re;
Rfp=Rf;
Rgp=Rg;
Rhp=Rh;
dm1=[(−1/T2a−Rc*M0c−Rd*M0d−Re*M0e−Rf*M0f−Rg*M0g−Rh*M0h),−2*pi*D,0,0,Rc*M0a,0,0,Rd*M0a,0,0,Re*M0a,0,0,Rf*M0a
,0,0,Rg*M0a,0,0,Rh*M0a,0,0];
dm2=[2*pi*D,(−1/T2a−Rc*M0c−Rd*M0d−Re*M0e−Rf*M0f−Rg*M0g−Rh*M0h),−w1,0,0,Rc*M0a,0,0,Rd*M0a,0,0,Re*M0a,0,0,Rf*M0a
,0,0,Rg*M0a,0,0,Rh*M0a,0];
dm3=[0,w1,(−1/T1a−Rbp*M0b−Rcp*M0c−Rdp*M0d−Rep*M0e−Rf*M0f−Rg*M0g−Rh*M0h),Rbp*M0a,0,0,Rcp*M0a,0,0,Rdp*M0a,0,0,
Rep*M0a,0,0,Rfp*M0a,0,0,Rgp*M0a,0,0,Rhp*M0a];
dm6=[0,0,Rbp*M0b,(−1/T1b−Rrfb*M0b−Rbp*M0a),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0];
if interaction_CD==1 % Interaction between Pool C and Pool D
dm7=[Rc*M0c,0,0,0,(−1/T2c−Rc*M0a−Rinteract*M0d),−2*pi*(D−dcc),0,Rinteract*M0c,0,0,0,0,0,0,0,0,0,0,0,0,0,0];
dm8=[0,Rc*M0c,0,0,2*pi*(D−dcc),(−1/T2c−Rc*M0a−Rinteract*M0d),−w1,0,Rinteract*M0c,0,0,0,0,0,0,0,0,0,0,0,0,0];
dm9=[0,0,Rcp*M0c,0,0,w1,(−1/T1c−Rcp*M0a−Rinteract*M0d),0,0,Rinteract*M0c,0,0,0,0,0,0,0,0,0,0,0,0];
dm10=[Rd*M0d,0,0,0,Rinteract*M0d,0,0,(−1/T2d−Rd*M0a−Rinteract*M0c),−2*pi*(D−dcd),0,0,0,0,0,0,0,0,0,0,0,0,0];
dm11=[0,Rd*M0d,0,0,0,Rinteract*M0d,0,2*pi*(D−dcd),(−1/T2d−Rd*M0a−Rinteract*M0c),−w1,0,0,0,0,0,0,0,0,0,0,0,0];
dm12=[0,0,Rdp*M0d,0,0,0,Rinteract*M0d,0,w1,(−1/T1d−Rdp*M0a−Rinteract*M0c),0,0,0,0,0,0,0,0,0,0,0,0];
else
dm7=[Rc*M0c,0,0,0,(−1/T2c−Rc*M0a),−2*pi*(D−dcc),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0];
dm8=[0,Rc*M0c,0,0,2*pi*(D−dcc),(−1/T2c−Rc*M0a),−w1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0];
dm9=[0,0,Rcp*M0c,0,0,w1,(−1/T1c−Rcp*M0a),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0];
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dm10=[Rd*M0d,0,0,0,0,0,0,(−1/T2d−Rd*M0a),−2*pi*(D−dcd),0,0,0,0,0,0,0,0,0,0,0,0,0];
dm11=[0,Rd*M0d,0,0,0,0,0,2*pi*(D−dcd),(−1/T2d−Rd*M0a),−w1,0,0,0,0,0,0,0,0,0,0,0,0];
dm12=[0,0,Rdp*M0d,0,0,0,0,0,w1,(−1/T1d−Rdp*M0a),0,0,0,0,0,0,0,0,0,0,0,0];
end
% ENDOF Interaction between Pool C and Pool D
dm13=[Re*M0e,0,0,0,0,0,0,0,0,0,(−1/T2e−Re*M0a),−2*pi*(D−dce),0,0,0,0,0,0,0,0,0,0];
dm14=[0,Re*M0e,0,0,0,0,0,0,0,0,2*pi*(D−dce),(−1/T2e−Re*M0a),−w1,0,0,0,0,0,0,0,0,0];
dm15=[0,0,Rep*M0e,0,0,0,0,0,0,0,0,w1,(−1/T1e−Rep*M0a),0,0,0,0,0,0,0,0,0];
dm16=[Rf*M0f,0,0,0,0,0,0,0,0,0,0,0,0,(−1/T2f−Rf*M0a),−2*pi*(D−dcf),0,0,0,0,0,0,0];
dm17=[0,Rf*M0f,0,0,0,0,0,0,0,0,0,0,0,2*pi*(D−dcf),(−1/T2f−Rf*M0a),−w1,0,0,0,0,0,0];
dm18=[0,0,Rfp*M0f,0,0,0,0,0,0,0,0,0,0,0,w1,(−1/T1f−Rfp*M0a),0,0,0,0,0,0];
dm19=[Rg*M0g,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,(−1/T2g−Rg*M0a),−2*pi*(D−dcg),0,0,0,0];
dm20=[0,Rg*M0g,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2*pi*(D−dcg),(−1/T2g−Rg*M0a),−w1,0,0,0];
dm21=[0,0,Rgp*M0g,0,0,0,0,0,0,0,0,0,0,0,0,0,0,w1,(−1/T1g−Rgp*M0a),0,0,0];
dm22=[Rh*M0h,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,(−1/T2h−Rh*M0a),−2*pi*(D−dch),0];
dm23=[0,Rh*M0h,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2*pi*(D−dch),(−1/T2h−Rh*M0a),−w1];
dm24=[0,0,Rhp*M0h,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,w1,(−1/T1h−Rhp*M0a)];
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%% Put into a matrix
A=[dm1;dm2;dm3;dm6;dm7;dm8;dm9;dm10;dm11;dm12;dm13;dm14;dm15;dm16;dm17;dm18;dm19;dm20;dm21;dm22;dm23;dm24];
B=[0;0;M0a/T1a;M0b/T1b;0;0;M0c/T1c;0;0;M0d/T1d;0;0;M0e/T1e;0;0;M0f/T1f;0;0;M0g/T1g;0;0;M0h/T1h];
M=A\(−B); %look "matrix division"
MM(:,p)=M;
end
superMM(:,:,mynumG,mynumB1,mynumT2,mynumT1,mynumpH,mynumAmide,mynumAmine,mynumNOE,mynumMT)=MM;
end
end
end
end
end
end
end
end
end
%% Signal attenuation with T2
T2=[T2a,T2b,T2c,T2d,T2e,T2f,T2g,T2h];
% AllMz=cat(3,squeeze(superMM(3,:,:,1,1)),squeeze(superMM(4,:,:,1,1)),squeeze(superMM(7,:,:,1,1)),squeeze(
superMM(10,:,:,1,1)),squeeze(superMM(13,:,:,1,1)),squeeze(superMM(16,:,:,1,1)),squeeze(superMM
(19,:,:,1,1)));
clear AllMz
AllMz=cat(ndims(superMM),squeeze(superMM(3,:,:,:,:,:,:,:,:,:,:,:,:,:)),squeeze(superMM
(4,:,:,:,:,:,:,:,:,:,:,:,:,:)),squeeze(superMM(7,:,:,:,:,:,:,:,:,:,:,:,:,:)),squeeze(superMM
(10,:,:,:,:,:,:,:,:,:,:,:,:,:)),squeeze(superMM(13,:,:,:,:,:,:,:,:,:,:,:,:,:)),squeeze(superMM
(16,:,:,:,:,:,:,:,:,:,:,:,:,:)),squeeze(superMM(19,:,:,:,:,:,:,:,:,:,:,:,:,:)),squeeze(superMM
(22,:,:,:,:,:,:,:,:,:,:,:,:,:)));
TE=0.002;
if B0==3
TE=0.007;
end
T2DECAY=exp(−TE./T2)';
tosize=size(AllMz);
tosize=tosize(1:end−1);
T2DECAY=repmat(T2DECAY,[1 tosize]);
T2DECAY = shiftdim(T2DECAY,1);
T2DECAY=reshape(T2DECAY,size(AllMz));
M0=[M0a,M0b,M0c,M0d,M0e,M0f,M0g,M0h];
M0_mat=repmat(M0', [1,3]);
M0_mat(5,:)=M0e_array; M0_mat(7,:)=M0g_array; M0_mat(8,:)=M0h_array;
M0_mat = sum(M0_mat,1);
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thesize=size(AllMz);
Norm_M0 = repmat(M0_mat', [1, thesize(1),thesize(3:end−1)]);
Norm_M0=permute(Norm_M0, [2,1,3,4,5,6,7,8,9,10,11,12]);
ZSpectraR_pure=nansum(AllMz.*T2DECAY,ndims(superMM));%./Norm_M0;
ZSpectraR_pure=reshape(ZSpectraR_pure,[thesize(1:end−1)]);
% clear AllMz T2DECAY Norm_M0 superMM Norm_M0
% ZSpectraR=sum(AllMz,3)/sum(M0);
% ZSpectraR=squeeze(superMM(3,:,:,1,1));
%% ADD NOISE
rawNoiseAmp=0.00/100*mean(M0_mat); %Amplidtude of the raw noise
rawNoise=rawNoiseAmp*randn(size(ZSpectraR_pure));%typically in our scans 300/12000
phyN=zeros(1,np);
phyamp=0*1/100*mean(M0_mat); %Amplidtude of the physiological noise
phyfrequency=70/100;
rnN=rand(size(ZSpectraR_pure));
rnN(rnN>phyfrequency)=0;
phyNoise=phyamp*rnN.*(randn(size(ZSpectraR_pure))−1);
ZSpectraR=abs(rawNoise+ZSpectraR_pure.*(1+phyNoise));
clear phyNoise phyN rnN rawNoise T2DECAY
%% NORMALISE
NormalisedAtM0=1
if NormalisedAtM0==1%dont change this
Size_1freq=size(ZSpectraR);
Size_1freq=[1,Size_1freq(2:end)];
norm=mean(M0_mat)*ones(Size_1freq);
ZSpectra=ZSpectraR./repmat(norm,[np,1]);
else
normRange=[4.3 4.5];
normRange=[2 3];
normR=[round(normRange(1)*(np/2/maxoffsetppm)+np/2):round(normRange(2)*(np/2/maxoffsetppm)+np/2)];
% normRi=[np−round(normRange(2)*(np/2/maxoffsetppm)+np/2):np−round(normRange(1)*(np/2/maxoffsetppm)+np/2)
];
norm=(mean(ZSpectraR_pure(normR,:,:,:,:,:,:,:,:,:,:)));%+mean(ZSpectraR_pure(normRi,:,:,:,:,:,:,:,:,:,:)))
/2;
ZSpectra=ZSpectraR./repmat(norm,[np,1]);
end
%% Select what power, pH... to plot
whatpower = 6; whatpH = 4;
whatT2 = 2; whatT1 = 2;
whatAmide = 2; whatAmine = 2;
whatNOE = 2; whatMT = 2;
ZSpectra_plot=ZSpectra(:,:,whatpower,whatT2,whatT1,whatpH,whatAmide,whatAmine,whatNOE,whatMT);
ZAsym=flip(ZSpectra_plot(1:round(np/2),:,:,:,:,:,:,:,:,:,:),1)−ZSpectra_plot(round(np/2):np
,:,:,:,:,:,:,:,:,:,:);
% sprintf('%.1f%',B1eq*10^6)
figure
subplot(3,1,1),titl=[{'Glucose increase \it{in vivo} \rm\bfconditions'},{['B1=',sprintf('%.1f%',B1array(
whatpower)*10^6),'\muT']}];
title(titl), hold on
plot(ppms,squeeze(ZSpectra_plot),'LineWidth',1),legend('5 mM','15 mM','25 mM','Location','southwest'),legend('
boxoff')
ylabel('Z−Spectra')
set(gca, 'xdir','reverse')
% axis([−1.5 4 0.6 1.01])
xlim([−1.5 4])
subplot(3,1,2)
plot(ppms(round(np/2):end),100*squeeze(ZAsym),'LineWidth',1),hold on,
ylabel('%MTR_A_s_y_m')
set(gca, 'xdir','reverse')
axis([0 4 −8 5])
legend('5 mM','15 mM','25 mM','Location','northwest'),legend('boxoff')
subplot(3,1,3)
plot(ppms(round(np/2):end),100*(ZAsym(:,3)−ZAsym(:,1)),'g'),hold on,
plot(ppms(round(np/2):end),100*(ZAsym(:,2)−ZAsym(:,1)),'Color',[0.1,0.4,0.6],'LineWidth',1)
set(gca, 'xdir','reverse')
axis([0 4 0 7])
hold on,
ylabel([{'%MTR_A_s_y_m'},{'difference'}])
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xlabel('Frequency (ppm)')
legend('\Delta [glc] 20 mM','\Delta [glc] 10 mM','Location','northwest'),legend('boxon')
set(gca, 'LooseInset', get(gca,'TightInset'))
legend('boxoff')
set(gca,'FontSize',13);%,'fontWeight','bold')
% set(findall(gcf,'type','text'),'FontSize',27)
set(findall(gcf,'type','text'),'FontSize',15,'FontName','Georgia')
figurename=(['C:\Users\ftorrealda\Dropbox\1_FiguresPhD\simulations\','NOISYglucosechange_',sprintf('%.2g%'
,10^6*B1array(whatpower)),'uT']);
figurename = strrep(figurename, '.', '');
% saveas(gcf,figurename,'fig')
% saveas(gcf,figurename,'png')
% close
%%%%%%
%% MTRex
plotMTRex=0;
if plotMTRex==1
MTrex=−1./flip(ZSpectra_plot(1:round(np/2),:,:,:,:),1)+1./ZSpectra_plot(round(np/2):np,:,:,:,:);
% sprintf('%.1f%',B1eq*10^6)
figure
subplot(3,1,1),titl=[{'Glucose increase \it{in vivo} \rm\bfconditions'},{['B1=',sprintf('%.1f%',B1array(
whatpower)*10^6),'\muT']}];
title(titl), hold on
plot(ppms,squeeze(ZSpectra_plot),'LineWidth',1),legend('5 mM','15 mM','25 mM','Location','southwest'),legend('
boxoff')
ylabel('Z−Spectra')
set(gca, 'xdir','reverse')
% axis([−1.5 4 0.6 1.01])
xlim([−1.5 4]);
subplot(3,1,2)
plot(ppms(round(np/2):end),100*squeeze(MTrex),'LineWidth',1),hold on,
ylabel('%MT_{Rex}')
set(gca, 'xdir','reverse')
axis([0 4 −8 5])
legend('5 mM','15 mM','25 mM','Location','northwest'),legend('boxoff')
subplot(3,1,3)
plot(ppms(round(np/2):end),100*(MTrex(:,3)−MTrex(:,1)),'g'),hold on,
plot(ppms(round(np/2):end),100*(MTrex(:,2)−MTrex(:,1)),'Color',[0.1,0.4,0.6],'LineWidth',1)
set(gca, 'xdir','reverse')
axis([0 4 0 7])
hold on,
ylabel([{'%MT_{Rex}'},{'difference'}])
xlabel('Frequency (ppm)')
legend('\Delta [glc] 20 mM','\Delta [glc] 10 mM','Location','northwest'),legend('boxon')
set(gca, 'LooseInset', get(gca,'TightInset'))
legend('boxoff')
set(gca,'FontSize',13);%,'fontWeight','bold')
% set(findall(gcf,'type','text'),'FontSize',27)
set(findall(gcf,'type','text'),'FontSize',15,'FontName','Georgia')
figurename=(['C:\Users\ftorrealda\Dropbox\1_FiguresPhD\simulations\','MTRex_NOISYglucosechange_',sprintf('%.2g
%',10^6*B1array(whatpower)),'uT']);
figurename = strrep(figurename, '.', '');
% saveas(gcf,figurename,'fig')
% saveas(gcf,figurename,'png')
% close
end
%% BiggerErroratHighPower
runErroratHighPower=1;
if runErroratHighPower==1
NumRepetitions=5 % Calculates the standard error based on how many cest measurements you have.
Nleves=[1 1/2.5 1/10 1/100];
% Nleves=[0.1 0.5 2.5 10];
figure
mycolor={'−r','−y','−g','−b','k'}
clear actualNoiseamp
for ii=1:4
ZSpectra_pure_n=ZSpectraR_pure./repmat(norm,[np,1]);
% ZSpectra_pure_n=−1./ZSpectra_pure_n; %To Show MTRex instead of MTRasym (in the GCE vs Power and Noise
graph)
ZS= squeeze(ZSpectra_pure_n(:,2,:,whatT2,whatT1,whatpH,whatAmide,whatAmine,whatNOE,whatMT) − ZSpectra_pure_n
(:,1,:,whatT2,whatT1,whatpH,whatAmide,whatAmine,whatNOE,whatMT));
ZAsym= flip(ZS(1:round(np/2),:,:,:,:),1)−ZS(round(np/2):np,:,:,:,:);
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intRange=[2 3];
intRangeR=[round(intRange(1)*(np/2/maxoffsetppm)+np/2):round(intRange(2)*(np/2/maxoffsetppm)+np/2)];
intRangeRh=[round(intRange(1)*(np/2/maxoffsetppm)+np/2):round(intRange(2)*(np/2/maxoffsetppm)+np/2)] −round(np
/2)+1;
IntMean=mean(ZAsym(intRangeRh,:),1);
actualNoiseamp(ii)=rawNoiseAmp*Nleves(ii);
Err_sigma=(actualNoiseamp(ii)./squeeze(norm(1,1,:,whatT2,whatT1,whatpH,whatAmide,whatAmine,whatNOE,whatMT)));
Err_sigma=sqrt(2)*sqrt(2)*Err_sigma; %sqrt(2)*sqrt(2)* to account for substraction of Left and Right sides +
the same for 2 glucose concentrations
SEM=Err_sigma/sqrt(NumRepetitions*numel(intRangeRh));
SEM_post_processed=Err_sigma/sqrt(9*3*NumRepetitions*numel(intRangeRh));
hold on,shadedErrorBar_new(B1array*10^6,100*IntMean,100*SEM,mycolor{ii})
end
bestPoint=IntMean'./SEM;
bestPoint=0.1*bestPoint/max(bestPoint);
hold on,plot(B1array*10^6,bestPoint,mycolor{5})
ylabel([{'\Delta %MTR_A_s_y_m'},{'from 5 to 15 mM glucose'}])
xlabel('Saturation Power (\muT)')
% legend('\Delta 10 mM','\Delta 20 mM','Location','northwest'),legend('boxoff')
title([{'Sensitivity of GCE vs B1 power \itin vivo\rm\bf conditions'},{['Integration range from ',sprintf('
%.1f%',intRange(1)), ' to ',sprintf('%.1f%',intRange(2)),' ppm']}])
legend(['SNR=',sprintf('%.0f%',1/actualNoiseamp(1))], ['SNR=',sprintf('%.0f%',1/actualNoiseamp(2))] ,['SNR=',
sprintf('%.0f%',1/actualNoiseamp(3))], ['SNR=',sprintf('%.0f%',1/actualNoiseamp(4))] ,['GCE/SE'], '
Location','best','FontName','Georgia')
set(gca,'FontSize',13);%,'fontWeight','bold')
set(findall(gcf,'type','text'),'FontSize',14,'FontName','Georgia')
figurename=(['C:\Users\ftorrealda\Dropbox\1_FiguresPhD\simulations\','GCEvsB1power',sprintf('%.1f%',intRange
(1)), 'to',sprintf('%.1f%',intRange(2))]);
if B0==3
figurename=(['C:\Users\ftorrealda\Dropbox\1_FiguresPhD\simulations\','At3T_GCEvsB1power',sprintf('%.1f%',
intRange(1)), 'to',sprintf('%.1f%',intRange(2))]);
end
figurename = strrep(figurename, '.', '')
axis([10^6*B1array(1),10^6*B1array(end),−0.1,1.6])
set(gca,'TickDir','out','TickLabelInterpreter','latex')
% saveas(gcf,figurename,'fig')
% saveas(gcf,figurename,'png')
end
%% Calculation of best B1 power
ZS_all=squeeze(ZSpectra_pure_n(:,2,:,:,:,:,:,:,:,:)−ZSpectra_pure_n(:,1,:,:,:,:,:,:,:,:));
ZAsym_all=flip(ZS_all(1:round(np/2),:,:,:,:,:,:,:,:),1)−ZS_all(round(np/2):np,:,:,:,:,:,:,:,:);
ppms_h=ppms(round(np/2):end);
actualNoiseamp=rawNoiseAmp;
Err_all=2*(actualNoiseamp./squeeze(norm(1,1,:,:,:,:,:,:,:,:)));
SEM_all=Err_all/sqrt(NumRepetitions);
SEM_mat(1,:,:,:,:,:,:,:,:,:,:,:)=SEM_all;
ZAsym_all1=ZAsym_all./repmat(SEM_mat, size(ZAsym_all,1),1,1,1,1,1,1,1,1,1,1,1);
% % % Plot GCE/SEM vs B1 vs ppm at diferent T2s
% for ii=1:numel(T2array)
% whatT2=ii;
% GCE_SEM=squeeze(ZAsym_all1(:,:,whatT2,whatT1,whatpH,whatAmide,whatAmine,whatNOE,whatMT));
% figure,contourf(B1array*10^6,ppms_h,GCE_SEM)
% ylabel('\Delta\Omega [ppm]'); zlabel('GCE/SEM'); xlabel('B1 [\muT]')
% title(['T2=',sprintf('%.0f%','T2array(whatT2)'), 'ms'])
% % % end
%endof Plot GCE/SEM vs B1 vs ppm
%% Contour Plots
do_contour=0
if do_contour==1
[~,best_B1]=max(ZAsym_all1,[],2);
best_B1=squeeze(best_B1);
best_B1array=B1array(best_B1);
ppm_t2_b1=best_B1array(:,:,whatT1,whatpH,whatAmide,whatAmine,whatNOE,whatMT); %[Freqs and T2s,:,:,:]
figure,contour(T2array*10^3 ,ppms_h,ppm_t2_b1*10^6,'levellist',B1array(1:2:end)*10^6,'showtext','off'),
colormap('jet')
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ylabel('\Delta\Omega [ppm]'); xlabel('T2 [ms]'); zlabel('B1 [\muT]')
title('Surface of maximal GCE/SEM')
% intRange=[3 3];
intRangeR=[round(intRange(1)*(np/2/maxoffsetppm)+np/2):round(intRange(2)*(np/2/maxoffsetppm)+np/2)];
intRangeRh=[round(intRange(1)*(np/2/maxoffsetppm)+np/2):round(intRange(2)*(np/2/maxoffsetppm)+np/2)] −round(np
/2)+1;
IntMean_all=squeeze(mean(ZAsym_all1(intRangeRh,:,:,:,:,:,:,:,:),1));
% actualNoiseamp=rawNoiseAmp;
% Err_all=2*(actualNoiseamp./squeeze(norm(1,1,:,:,:,:,:,:,:,:)));
% SEM_all=Err_all/sqrt(NumRepetitions*numel(intRangeRh));
% bestPoint=IntMean_all./SEM_all;
% bestPoint=0.1*bestPoint./repmat(max(bestPoint,[],1), maxmynumB1, 1,1,1,1,1,1,1);
% [~, pbp]=max(bestPoint, [], 1);
% pbp=squeeze(pbp);
% BpT2=pbp(:,whatT1,whatpH,whatAmide,whatAmine,whatNOE,whatMT);
% for bb=1:numel(BpT2)
% B1T2(bb)=B1array(BpT2(bb));
% end
% figure, plot(T2array*10^3, B1T2*10^6)
% xlabel('T2 [ms]'); ylabel('B1 [uT]')
%% Calculation of the min CNR for GCE detection
SNRarray=[900,1000,1200,1600,2000,2500,3000,4000,5000];
SNRarray=[70 80 95 120 150 200 250 400 700 1000];
Noisearray=1./SNRarray;
SensMap=zeros(size(ZAsym_all,1),size(ZAsym_all,3));
GCEideal=zeros(size(ZAsym_all,1),size(ZAsym_all,3));
Err_min=zeros(size(ZAsym_all,1),size(ZAsym_all,3));
SensMapA=zeros(size(ZAsym_all,1),size(ZAsym_all,3),numel(SNRarray));
for ii=1:numel(SNRarray)
Noise=Noisearray(ii);
Err_all=2*(Noise./squeeze(norm(1,1,:,:,:,:,:,:,:,:)));
Err_rep=Err_all(:,:,whatT1,whatpH,whatAmide,whatAmine,whatNOE,whatMT);
ZAsym_rep=ZAsym_all(:,:,:,whatT1,whatpH,whatAmide,whatAmine,whatNOE,whatMT);
NumRepetitions=1;
SEM_rep=Err_rep/sqrt(NumRepetitions);
for ippm=1:numel(ppms_h)
for jT2=1:numel(T2array)
[~,B1pos]=find(B1array == ppm_t2_b1(ippm,jT2));
GCEideal(ippm,jT2)=ZAsym_rep(ippm,B1pos,jT2);
Err_min(ippm,jT2)=SEM_rep(B1pos,jT2);
end
end
MinDiff=GCEideal−Err_min;
ppp=MinDiff>0;
% SensMap=SensMap+ppp*SNRarray(ii);
% SensMap(SensMap~=SNRarray(ii))=0;
% SensMapA(:,:,ii)=SensMap;
SensMapA(:,:,ii)=ppp
% figure, surf(T2array*10^3,ppms_h,MinDiff),caxis([−0.00001,0.00001])
end
SensMapS=sum(SensMapA,3);
for ii=1:numel(SNRarray)
SensMapS(SensMapS==ii)=SNRarray(numel(SNRarray)+1−ii);
end
% figure,surf(SensMapS)
figure,contourf(T2array*10^3,ppms_h,SensMapS,'levellist',SNRarray,'showtext','on')
ylabel('\Delta\Omega [ppm]'); xlabel('T2 [ms]'); zlabel('GCE−\sigma')
title('Signal detection threshold (CI=95%) for 10 mMolar glucose increase. SNR ')
end
%% APT peak Calculations
APTpeakCalculations=0;
if APTpeakCalculations==1
measureAtppm=3.5
dd=measureAtppm−ppmS
dfrac=dd/ppmGap
SPoint=round(np*(maxoffsetppm+ppmS)/(2*maxoffsetppm))
258
EPoint=round(np*(maxoffsetppm+ppmE)/(2*maxoffsetppm))
measuredPoint=round(np*(maxoffsetppm+measureAtppm)/(2*maxoffsetppm))
ValueLine=ZSpectra(SPoint,:)+dfrac*(ZSpectra(EPoint,:)−ZSpectra(SPoint,:))
Valuemeasured=ZSpectra(measuredPoint,:)
APTp=ValueLine−Valuemeasured
figure,plot(APTp,pHarray)
end
%% PLOT MTR asym
ZSpectra_plot2=squeeze(ZSpectra(:,:,:,whatT2,whatT1,whatpH,whatAmide,whatAmine,whatNOE,whatMT));
% ZSpectra_pure_n=−1./ZSpectra_pure_n; %To Show MTRex instead of MTRasym (in the GCE vs Power and Noise
graph)
ZAsym=flip(ZSpectra_plot2(1:round(np/2),:,:,:,:,:,:,:,:,:),1)−ZSpectra_plot2(round(np/2):np,:,:,:,:,:,:,:,:,:)
;
Dg1=glucoseMol_array(2)−glucoseMol_array(1);
Dg2=glucoseMol_array(3)−glucoseMol_array(1);
% % figure
% % axis([−1.5 4 0.6 1.01])
% % area(ppms(round(np/2):end),100*squeeze(ZAsym(:,:)),'LineWidth',1),hold on,
% % ylabel('%MTR_A_s_y_m')
% % xlabel('\Delta\omega [ppm]')
% % set(gca, 'xdir','reverse')
% % legendCell = cellstr(num2str(B1array'*10^6, ['B1=%.1f','\mu T']))
% % legend(legendCell)
% % title(['GCE with ',sprintf('%.0f%',Dg1),' mM glucose increase VS Power'])
% % legendCell2=cellstr([legendCell(1);'';'';legendCell(2);'';'';legendCell(3);'';'';legendCell(4);'';'';
legendCell(5);'';'';legendCell(6);'';'';legendCell(7);'';'';legendCell(8);'';'';legendCell(9);'';'';
legendCell(10);'';''])
%%%%%%
colors=jet(maxmynumB1);
figure,hold on,
for ii=1:size(ZSpectra_plot2,3)
plot(ppms,squeeze(ZSpectra_plot2(:,1,ii)),'Color',[colors(ii,:)],'LineWidth',1)
end
for ii=1:size(ZSpectra_plot2,3)
% plot(ppms,squeeze(ZSpectra_plot2(:,2,ii)),'Color',[colors(ii,:)],'LineWidth',2,'',:),
plot(ppms,squeeze(ZSpectra_plot2(:,2,ii)),'Color',[colors(ii,:)],'LineWidth',2,'LineStyle',':'),
%plot(ppms(round(np/2):end),1*squeeze(ZAsym(:,1,ii)),'Color',[colors(ii,:)],'LineWidth',1)
%plot(ppms(round(np/2):end),1*squeeze(ZAsym(:,2,ii)),'Color',[colors(ii,:)],'LineWidth',1)
plot(ppms(round(np/2):end),1*squeeze(ZAsym(:,2,ii,:,:,:,:,:,:,:,:)−ZAsym(:,1,ii,:,:,:,:,:,:,:,:)),'Color',[
colors(ii,:)],'LineWidth',2)
plot(ppms,zeros(size(ppms)),'k', 'LineWidth',0.2,'color',[0.3 0.3 0.3])
end
ylim([−0.1 1.1])
ylabel('Z−Spectra')
set(gca, 'xdir','reverse')
legendCell = cellstr(num2str(B1array'*10^6, ['B1=%.1f','\mu T']))
legend(legendCell)
%%%%%%
figure,hold on
for ii=2:2%1:size(ZSpectra_plot2,3)
plot(ppms,squeeze((ZSpectra_plot2(:,1,ii)+0.07752*0)/(max(ZSpectra_plot2(:,1,ii))+0.07752*0)),'Color',[colors(
ii,:)],'LineWidth',1)
%legend([sprintf('%.0f%',glucoseMol_array(1)),' mM'],[sprintf('%.0f%',glucoseMol_array(2)) ,' mM'],'Location
','southwest'),legend('boxoff')
end
legend(legendCell)
hold on,
for ii=2:2%1:size(ZSpectra_plot2,3)
plot(ppms,squeeze((ZSpectra_plot2(:,2,ii)+0.07752*0)/(max(ZSpectra_plot2(:,1,ii))+0.07752*0)),'Color',[colors(
ii,:)],'LineWidth',1,'LineStyle','−.')
plot(ppms(round(np/2):end),1*squeeze(ZAsym(:,1,ii)),'Color',[colors(ii,:)],'LineWidth',1)
plot(ppms(round(np/2):end),1*squeeze(ZAsym(:,2,ii)),'Color',[colors(ii,:)],'LineWidth',1,'LineStyle','−.')
% plot(ppms(round(np/2):end),1*squeeze(ZAsym(:,2,ii)−ZAsym(:,1,ii)),'Color',[colors(ii,:)],'LineWidth',1)
plot(ppms,zeros(size(ppms)),':')
end
ylabel('MTRasymmetry & Z−Spectra')
xlabel('Saturation Power (\muT)')
set(gca, 'xdir','reverse')
%%%%%%%
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%% plot the asymmetry only
figure,hold on,
for ii=4:4%size(ZSpectra,3)
plot(ppms(round(np/2):end),1*squeeze(ZAsym(:,2,ii)−ZAsym(:,1,ii)),'Color',[colors(ii,:)],'LineWidth',1)
end
ylabel('MTRasymmetry & Z−Spectra')
xlabel('Saturation Power (\muT)')
legend(legendCell)
set(gca, 'xdir','reverse')
figure,hold on
for ii=2:2%1:size(ZSpectra_plot2,3)
plot(ppms,squeeze((ZSpectra_plot2(:,1,ii)+0.07752*0)/(max(ZSpectra_plot2(:,1,ii))+0.07752*0)),'k','LineWidth'
,1.5)
%legend([sprintf('%.0f%',glucoseMol_array(1)),' mM'],[sprintf('%.0f%',glucoseMol_array(2)) ,' mM'],'Location
','southwest'),legend('boxoff')
end
legend(legendCell)
hold on,
for ii=2:2%1:size(ZSpectra_plot2,3)
plot(ppms,squeeze((ZSpectra_plot2(:,2,ii)+0.07752*0)/(max(ZSpectra_plot2(:,1,ii))+0.07752*0)),'k','LineWidth'
,1.5)
plot(ppms(round(np/2):end),1*squeeze(ZAsym(:,1,ii)),'k','LineWidth',1.5)
plot(ppms(round(np/2):end),1*squeeze(ZAsym(:,2,ii)),'k','LineWidth',1.5)
% plot(ppms(round(np/2):end),1*squeeze(ZAsym(:,2,ii)−ZAsym(:,1,ii)),'Color',[colors(ii,:)],'LineWidth',1)
plot(ppms,zeros(size(ppms)),'k', 'LineWidth',0.5)
end
ylabel('MTRasymmetry & Z−Spectra')
xlabel('Saturation Power (\muT)')
ylim([−0.01 1.01])
set(gca, 'xdir','reverse')
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
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G. Compartmental model of
glycolysis and glucose
distribution
G.1. Definition of the model
frame
%% Definition of the glycolysis and glucose distribution model
function [Derivatives_Fluxes]=GlucoseVasculature(t,x,Itype)
global InfusionActivator DesiredBloodConc InfusionControlTime MaximumInfusionFlow InfusionInitialTime
VasculatureRatio_tumour InterstitiumRatio_tumour CellsRatio_tumour VasculatureRatio_normal
InterstitiumRatio_normal CellsRatio_normal pumpStatus PeritonealActivator VascularActivator InjectionDose
InjectionTime
isbraincell=10; % 1 for yes. 100 for no.
aggressiveness=10;%*10 for SW1222, *6 for LS174T
%% Parameters definition
AlostericExponent = 1;
BasalBloodConc = 5.6;
BasalConsumption = 0.1;
EndoAlostericTumor = 1;
EndoAlostericNormal = 1;
EndoGlut1Km = 1;
EndoGlut1KmTumor = EndoGlut1Km;
EndoGlut1NormalVmax = 0.11*isbraincell;
EndoGlut1TumorVmax = EndoGlut1NormalVmax*1;
Glut1Km = 6.9/2;
Glut1NormalVmax = 0.3;
Glut1TumorVmax = Glut1NormalVmax*aggressiveness;%%%
Glut3NormalKm = 0.3;
Glut3TumorKm = Glut3NormalKm;
Glut3NormalVmax = 0.1;
Glut3TumorVmax = Glut3NormalVmax*aggressiveness;%%
NormalHexokinaseAllosExp = 1.5;
NormalKmAldolase = 1;
NormalKmHexokinase = 0.1;
NormalKmPhosphofructokinase = 0.4;
NormalKmPhosphoIsomerase = 0.7;
NormalPhosphokinaseAllosExp = 2;
NormalReversedKmIsomerase = 0.7;
NormalReversedVmaxIsomerase = 4;
NormalVmaxAldolase = 0.7;
NormalVmaxHexokinase = 0.085;
NormalVmaxPhosphofructokinase = 1;
NormalVmaxPhosphoIsomerase = 5;
TumorVmaxHexokinase = NormalVmaxHexokinase*aggressiveness*5; %
TumorHexokinaseAllostExp = NormalHexokinaseAllosExp/2;%%%%%%%
TumorKmAldolase = NormalKmAldolase;
TumorKmHexokinase = NormalKmHexokinase;
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TumorKmPhosphofructokinase = NormalKmPhosphofructokinase;
TumorKmPhosphoIsomerase = NormalKmPhosphoIsomerase;
TumorPhosphokinaseAllostExp = NormalPhosphokinaseAllosExp/2;%%%%%
TumorReversedKmIsomerase = NormalReversedKmIsomerase;
TumorReversedVmaxIsomerase = NormalReversedVmaxIsomerase;
TumorVmaxAldolase = NormalVmaxAldolase*2;%%%%%%%%
TumorVmaxPhosphofructokinase = NormalVmaxPhosphofructokinase*1.25;
TumorVmaxPhosphoIsomerase = NormalVmaxPhosphoIsomerase*1;
NutritionalAdequacy = 1;
VascularDelay = 1;
PeritonealDelay = 35;
% VasculatureRatio = 0.03; % Attention !!!(Make it a global parameter or Modify this parameter also in
IntegrateGlucoseVasculature2)
VasculRecoveryTimeNormal = 1;
VasculRecoveryTimeTumor = 1;
WeightToAstrocytes = 0.5;
WeightToNeurons = 0.5;
%% State variables definition
BloodGlucConc=x(1);
ExtraGlucConcTumor=x(2);
IntraGlucConcTumor=x(3);
Gluc6PhosConcTumor=x(4);
Fruc6PhosConcTumor=x(5);
Fruc16BisConcTumor=x(6);
ExtraGlucConcNormal=x(7);
IntraGlucConcNormal=x(8);
Gluc6PhosConcNormal=x(9);
Fruc6PhosConcNormal=x(10);
Fruc16BisConcNormal=x(11);
Nperitoneal1=x(12);
Nperitoneal2=x(13);
Nperitoneal3=x(14);
Nvascular1=x(15);
VasculatureGlucConcNormal=x(16);
VasculatureGlucConcTumor=x(17);
% Type of injection configurations
InjectionDuration=0.1;
if t<InjectionTime
Injection=0;
elseif t>InjectionTime+InjectionDuration
Injection=0;
else
Injection=InjectionDose/InjectionDuration;
end
Fperitoneal1 = Injection;
Fperitoneal2 = 3 * Nperitoneal1 / PeritonealDelay;
Fperitoneal3 = 3 * Nperitoneal2 / PeritonealDelay;
FperitonealOutput = 3 * Nperitoneal3 / PeritonealDelay;
Fvascular1 = Injection;
FvascularOutput = Nvascular1 / VascularDelay;
% Injections
Intraperitoneal=PeritonealActivator*FperitonealOutput;
Intravascular=VascularActivator*FvascularOutput;
% Infusion configuration
pumpStatus(1)=0;
if t<InfusionInitialTime
IntravascularInfusion=0;
else
%IntravascularInfusion=InfusionActivator*min(MaximumInfusionFlow, max(0,4*(DesiredBloodConc−x(1))/
InfusionControlTime));
if t/2−floor(t/2)<0.1 %% Infusion pump is turned on/off depeding on the Glc level, every 2 minutes
check_pump=(DesiredBloodConc−x(1))>0;
pumpStatus=cat(2,pumpStatus,check_pump);
end
IntravascularInfusion=InfusionActivator*MaximumInfusionFlow*pumpStatus(end);
end
% Insuline control time definition
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if VascularActivator==1
ExpectedInsulinControlTime=50;
else
ExpectedInsulinControlTime=180;
end
%% Equations
AldolCondensationNormal = NormalVmaxAldolase * Fruc16BisConcNormal / ( NormalKmAldolase + Fruc16BisConcNormal
);
AldolCondensationTumor = TumorVmaxAldolase * Fruc16BisConcTumor / ( TumorKmAldolase + Fruc16BisConcTumor );
BasalGlucEntry = NutritionalAdequacy*BasalConsumption;
BloodConcAdjustment=4*(BloodGlucConc−BasalBloodConc)/ExpectedInsulinControlTime+BasalConsumption;
% ExtraGlucNormal = InterstitiumRatio_normal * ExtraGlucConcNormal;
% ExtraGlucTumor = ExtraGlucConcTumor * InterstitiumRatio_tumour;
FrucPhosphorylationNormal = NormalVmaxPhosphofructokinase * Fruc6PhosConcNormal ^ NormalPhosphokinaseAllosExp
/ ( NormalKmPhosphofructokinase ^NormalPhosphokinaseAllosExp + Fruc6PhosConcNormal ^
NormalPhosphokinaseAllosExp);
FrucPhosphorylationTumor = TumorVmaxPhosphofructokinase * Fruc6PhosConcTumor ^ TumorPhosphokinaseAllostExp / (
TumorKmPhosphofructokinase ^ TumorPhosphokinaseAllostExp + Fruc6PhosConcTumor ^
TumorPhosphokinaseAllostExp );
GlucConcIntoBlood = BasalGlucEntry + Intraperitoneal + Intravascular + IntravascularInfusion;
GlucIntoExtraNormal = EndoGlut1NormalVmax * ( VasculatureGlucConcNormal − ExtraGlucConcNormal ) ^
EndoAlostericNormal / ( EndoGlut1Km ^ EndoAlostericNormal + ( VasculatureGlucConcNormal −
ExtraGlucConcNormal )^ EndoAlostericNormal);
GlucIntoExtraTumor = EndoGlut1TumorVmax * ( VasculatureGlucConcTumor − ExtraGlucConcTumor) ^
EndoAlostericTumor / ( EndoGlut1KmTumor ^ EndoAlostericTumor+ ( VasculatureGlucConcTumor −
ExtraGlucConcTumor ) ^ EndoAlostericTumor);
GlucIntoIntraNormal = WeightToAstrocytes * Glut1NormalVmax * ( ExtraGlucConcNormal − IntraGlucConcNormal ) / (
Glut1Km + ( ExtraGlucConcNormal − IntraGlucConcNormal ) ) + WeightToNeurons * Glut3NormalVmax * (
ExtraGlucConcNormal − IntraGlucConcNormal ) / ( Glut3NormalKm + ( ExtraGlucConcNormal −
IntraGlucConcNormal ) );
GlucIntoIntraTumor = WeightToAstrocytes * Glut1TumorVmax * ( ExtraGlucConcTumor − IntraGlucConcTumor ) ^
AlostericExponent / ( Glut1Km ^ AlostericExponent + ( ExtraGlucConcTumor − IntraGlucConcTumor ) ^
AlostericExponent ) + WeightToNeurons * Glut3TumorVmax * ( ExtraGlucConcTumor − IntraGlucConcTumor ) / (
Glut3TumorKm + ( ExtraGlucConcTumor − IntraGlucConcTumor ) );
% GlucInNormalVascul = VasculatureRatio_normal*VasculatureGlucConcNormal;
% GlucInTumorVascul = VasculatureRatio_tumour*VasculatureGlucConcTumor;
GlucIsomerizationNormal = NormalVmaxPhosphoIsomerase * Gluc6PhosConcNormal / ( NormalKmPhosphoIsomerase +
Gluc6PhosConcNormal );
GlucIsomerizationTumor = TumorVmaxPhosphoIsomerase * Gluc6PhosConcTumor / ( TumorKmPhosphoIsomerase +
Gluc6PhosConcTumor );
GlucToNormalMetabolism = NormalVmaxHexokinase * IntraGlucConcNormal ^ NormalHexokinaseAllosExp / (
NormalKmHexokinase ^ NormalHexokinaseAllosExp + NormalVmaxHexokinase ^ NormalHexokinaseAllosExp );
GlucToTumorMetabolism = TumorVmaxHexokinase * IntraGlucConcTumor ^ TumorHexokinaseAllostExp / (
TumorKmHexokinase ^ TumorHexokinaseAllostExp + IntraGlucConcTumor ^ TumorHexokinaseAllostExp );
%IntraTotalNormal = CellsRatio_normal * ( IntraGlucConcNormal + Gluc6PhosConcNormal + Fruc6PhosConcNormal +
Fruc16BisConcNormal );
% IntraTotalTumor = CellsRatio_tumour * ( IntraGlucConcTumor + Gluc6PhosConcTumor + Fruc6PhosConcTumor +
Fruc16BisConcTumor );
RevIsomerizationNormal = NormalReversedVmaxIsomerase * Fruc6PhosConcNormal / ( NormalReversedKmIsomerase +
Fruc6PhosConcNormal );
RevIsomerizationTumor = TumorReversedVmaxIsomerase * Fruc6PhosConcTumor / ( TumorReversedKmIsomerase +
Fruc6PhosConcTumor );
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% TotalGlucInNormal = ExtraGlucNormal+GlucInNormalVascul+IntraTotalNormal;
% TotalGlucInTumor = ExtraGlucTumor+GlucInTumorVascul+IntraTotalTumor;
VasculConcRecoveryNormal=(BloodGlucConc−VasculatureGlucConcNormal)/VasculRecoveryTimeNormal;
VasculConcRecoveryTumor=(BloodGlucConc−VasculatureGlucConcTumor)/VasculRecoveryTimeTumor;
%% Derivatives definition
Derivatives_Fluxes=[GlucConcIntoBlood − BloodConcAdjustment % BloodGlucConc
Derivative
GlucIntoExtraTumor − GlucIntoIntraTumor % ExtraGlucConcTumor
Derivative
GlucIntoIntraTumor − GlucToTumorMetabolism % IntraGlucConcTumor
Derivative
GlucToTumorMetabolism + RevIsomerizationTumor − GlucIsomerizationTumor % Gluc6PhosConcTumor
Derivative
GlucIsomerizationTumor − FrucPhosphorylationTumor − RevIsomerizationTumor % Fruc6PhosConcTumor
Derivative
FrucPhosphorylationTumor − AldolCondensationTumor % Fruc16BisConcTumor
Derivative
GlucIntoExtraNormal − GlucIntoIntraNormal % ExtraGlucConcNormal
Derivative
GlucIntoIntraNormal − GlucToNormalMetabolism % IntraGlucConcNormal
Derivative
GlucToNormalMetabolism + RevIsomerizationNormal − GlucIsomerizationNormal % Gluc6PhosConcNormal
Derivative
GlucIsomerizationNormal − FrucPhosphorylationNormal − RevIsomerizationNormal % Fruc6PhosConcNormal
Derivative
FrucPhosphorylationNormal − AldolCondensationNormal % Fruc16BisConcNormal
Derivative
Fperitoneal1 − Fperitoneal2 % Nperitoneal1
Derivative
Fperitoneal2 − Fperitoneal3 % Nperitoneal2
Derivative
Fperitoneal3 − FperitonealOutput % Nperitoneal3
Derivative
Fvascular1 − FvascularOutput % Nvascular1
Derivative
VasculConcRecoveryNormal − GlucIntoExtraNormal %
VasculatureGlucConcNormal Derivative
VasculConcRecoveryTumor − GlucIntoExtraTumor %
VasculatureGlucConcTumor Derivative
AldolCondensationNormal
AldolCondensationTumor];
%% Fluxes
%Fluxes=[AldolCondensationNormal,AldolCondensationTumor];
G.2. Execution of the model
frame
%% Integration of the glycolysis and glucose distribution model
global InfusionActivator DesiredBloodConc InfusionControlTime MaximumInfusionFlow InfusionInitialTime
VasculatureRatio_tumour InterstitiumRatio_tumour CellsRatio_tumour VasculatureRatio_normal
InterstitiumRatio_normal CellsRatio_normal PeritonealActivator VascularActivator InjectionDose
InjectionTime
%% Time span of the simulation
timespan=[−300,150];
TimeSpan = linspace(timespan(1),timespan(2),(timespan(2)−timespan(1))*60);
%% Initial values of the state variables
BloodGlucConcIni=5.61
ExtraGlucConcTumorIni=5.5043
IntraGlucConcTumorIni=0.02
Gluc6PhosConcTumorIni=0.05
Fruc6PhosConcTumorIni=0.05
Fruc16BisConcTumorIni=0.05
ExtraGlucConcNormalIni=1.7
264
G.2. Execution of the model
IntraGlucConcNormalIni=0.0501
Gluc6PhosConcNormalIni=0.0219
Fruc6PhosConcNormalIni=0.05
Fruc16BisConcNormalIni=0.04
Nperitoneal1Ini=0
Nperitoneal2Ini=0
Nperitoneal3Ini=0
Nvascular1Ini=0
VasculatureGlucConcNormalIni=5.6
VasculatureGlucConcTumorIni=5.5
fluxNomalIni=0.3
fluxTumorIni=3
Initials=[BloodGlucConcIni, ExtraGlucConcTumorIni, IntraGlucConcTumorIni, Gluc6PhosConcTumorIni,
Fruc6PhosConcTumorIni, Fruc16BisConcTumorIni, ExtraGlucConcNormalIni, IntraGlucConcNormalIni,
Gluc6PhosConcNormalIni, Fruc6PhosConcNormalIni, Fruc16BisConcNormalIni, Nperitoneal1Ini, Nperitoneal2Ini,
Nperitoneal3Ini, Nvascular1Ini, VasculatureGlucConcNormalIni, VasculatureGlucConcTumorIni, fluxNomalIni,
fluxTumorIni];
%% volume ratios
GBM=[3,15,82]/100;
SW122=[19,11,70]/100;
LS174T=[12,5,85]/100;
VasculatureRatio_tumour = SW122(1);
InterstitiumRatio_tumour = SW122(2);
CellsRatio_tumour = SW122(3);
VasculatureRatio_normal = 0.04;
InterstitiumRatio_normal = 0.15;
CellsRatio_normal = 0.81;
%% Infusion parameters
InfusionActivator=0;
MaximumInfusionFlow=1.2;
DesiredBloodConc=20;
InfusionControlTime=10;
InfusionInitialTime=0;
%% Boulus injection
PeritonealActivator=1;
VascularActivator=0;
InjectionDose=20;
InjectionTime=−0;
%% Maximum time step
Options=[odeset('InitialStep',0.001)];
%% Runge−Kutta Integrator
[t,x]=ode23(@GlucoseVasculature4b,TimeSpan,Initials,Options);%GlucoseVasculature4
%% Susceptible variables for plotting
BloodGlucConc=x(:,1);
ExtraGlucConcTumor=x(:,2);
IntraGlucConcTumor=x(:,3);
Gluc6PhosConcTumor=x(:,4);
Fruc6PhosConcTumor=x(:,5);
Fruc16BisConcTumor=x(:,6);
ExtraGlucConcNormal=x(:,7);
IntraGlucConcNormal=x(:,8);
Gluc6PhosConcNormal=x(:,9);
Fruc6PhosConcNormal=x(:,10);
Fruc16BisConcNormal=x(:,11);
VasculatureGlucConcNormal=x(:,16);
VasculatureGlucConcTumor=x(:,17);
FluxNormal=x(:,18);
FluxTumor=x(:,19);
IntraTotalNormal = CellsRatio_normal * ( IntraGlucConcNormal + Gluc6PhosConcNormal + Fruc6PhosConcNormal/2 +
Fruc16BisConcNormal/2 );
IntraTotalTumor = CellsRatio_tumour * ( IntraGlucConcTumor + Gluc6PhosConcTumor + Fruc6PhosConcTumor/2 +
Fruc16BisConcTumor/2 );
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IntravascularInfusion=InfusionActivator*min(MaximumInfusionFlow, max(0,4*(DesiredBloodConc−BloodGlucConc)/
InfusionControlTime));
ExtraGlucNormal = InterstitiumRatio_normal * ExtraGlucConcNormal;
ExtraGlucTumor = InterstitiumRatio_tumour * ExtraGlucConcTumor;
GlucInNormalVascul = VasculatureRatio_normal*VasculatureGlucConcNormal;
GlucInTumorVascul = VasculatureRatio_tumour*VasculatureGlucConcTumor;
TotalGlucInNormal = ExtraGlucNormal+GlucInNormalVascul+IntraTotalNormal;
TotalGlucInTumor = ExtraGlucTumor+GlucInTumorVascul+IntraTotalTumor;
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%% PLOTS
xmax=120;
ymax=2.7;
pp=1;%multiplicative factor just to scale the figures
% Tumour Concetrations and Signal contribution
figure(1)
close
figure(1),
annotation('textbox', [0.0032309057637272 0.476697659563142 0.0850159404888416 0.0798969072164947], 'String','
Tumour tissue', 'LineStyle','none','Interpreter','latex' 'FontSize',18, 'FitBoxToText','off');
subplot(1,3,1)
plot(t,VasculatureGlucConcTumor)
hold on, plot(t,pp*GlucInTumorVascul,'−−','LineWidth',2, 'Color',[0.635294 0.07843 0.18431])
title('Vascular compartment')
xlabel('Minutes')
ylabel({['Tumour vasculature [glc] (mMolar)'],['and its CEST signal (dashed red)']})
grid
ylim([0 ymax])
xlim([−5 xmax])
legend({'[Glc]','$ \sum{[Glc]*V_{frcV}}$'},'Interpreter','latex');
subplot(1,3,2)
plot(t,ExtraGlucConcTumor)
hold on, plot(t,pp*ExtraGlucTumor,'−−','LineWidth',2,'Color',[0.0784 0.168622 0.5490197])
title('Interstitial compartment')
xlabel('Minutes')
ylabel({['Tumour interstitial [glc] (mMolar)'],['and its CEST signal (dashed blue)']})
grid
ylim([0 ymax])
xlim([−5 xmax])
legend({'[Glc]','$ \sum{[Glc]*V_{frcI}}$'},'Interpreter','latex');
subplot(1,3,3)
plot(t,IntraGlucConcTumor,t,Gluc6PhosConcTumor,t,Fruc6PhosConcTumor,t,Fruc16BisConcTumor)
hold on, plot(t,pp*IntraTotalTumor,'−−','Color',[0 0.498 0],'LineWidth',2)
title('IntraCellular compartment');
xlabel('Minutes')
ylabel({['Tumour intracellular [sugar] (mMolar)'],['and their CEST signal (dashed green)']})
grid
ylim([0 ymax])
xlim([−5 xmax])
legend1 = legend({'[Glc]','[G6P]','[F6P]','[F16biP]','$ \sum{[sugar]*V_{frcC}}$'},'Interpreter','latex');
set(legend1, 'Position',[0.858951707891635 0.522491349480969 0.065959952885748 0.193771626297578]);
%% Normal tissue Concetrations and Signal contribution
figure(2),
close
figure(2)
annotation('textbox', [0.0032309057637272 0.476697659563142 0.0850159404888416 0.0798969072164947], 'String','
Normal tissue', 'LineStyle','none', 'Interpreter','latex', 'FontSize',18, 'FitBoxToText','off');
subplot(1,3,1)
plot(t,VasculatureGlucConcNormal)
hold on,plot(t,pp*GlucInNormalVascul,'−−','LineWidth',2, 'Color',[0.635294 0.07843 0.18431])
title('Vascular compartment')
xlabel('Minutes')
ylabel({['Normal vasculature [glc] (mMolar)'],['and its CEST signal (dashed red)']})
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grid
ylim([0 ymax])
xlim([−5 xmax])
legend_v = legend({'[Glc]','$ \sum{[Glc]*V_{frcV}}$'},'Interpreter','latex');
subplot(1,3,2)
plot(t,ExtraGlucConcNormal)
hold on,plot(t,pp*ExtraGlucNormal,'−−','LineWidth',2,'Color',[0.0784 0.168622 0.5490197])
title('Interstitial compartment')
xlabel('Minutes')
ylabel({['Normal interstitial [glc] (mMolar)'],['and its CEST signal (dashed blue)']})
grid
ylim([0 ymax])
xlim([−5 xmax])
legend_e = legend({'[Glc]','$ \sum{[Glc]*V_{frcI}}$'},'Interpreter','latex');
subplot(1,3,3)
plot(t,IntraGlucConcNormal,t,Gluc6PhosConcNormal,t,Fruc6PhosConcNormal,t,Fruc16BisConcNormal)
hold on,plot(t,pp*IntraTotalNormal,'−−','Color',[0 0.498 0],'LineWidth',2)
title('IntraCellular compartment');
xlabel('Minutes')
ylabel({['Normal intracellular [sugar] (mMolar)'],['and their CEST signal (dashed green)']})
grid
ylim([0 ymax])
xlim([−5 xmax])
legend1 = legend({'[Glc]','[G6P]','[F6P]','[F16biP]','$ \sum{[sugar]*V_{frcC}}$'},'Interpreter','latex');
%% GCE definitions
baseline=−timespan(1)*60−10;
TumourSignal=TotalGlucInTumor−TotalGlucInTumor(baseline);
NormalSignal=TotalGlucInNormal−TotalGlucInNormal(baseline);
%% Total Signal in tumour and normal tissue
GCE_mMolar_ratio=0.2;
figure(3)
plot(t,GCE_mMolar_ratio*TumourSignal,':','Color',[0.85 0.32 0.098],'Linewidth',2)
hold on, plot(t,GCE_mMolar_ratio*NormalSignal,':','Color',[0 0.447 0.741],'Linewidth',2)
xlabel('Minutes')
ylabel('%GCE signal from Tumour and Normal voxels')
grid
title({'glucoCEST signal (%GCE) in tumour and normal tissue','(all compartments included)'})
%legend2 = legend('Tumour','Normal tissue');
%set(legend2,'Position',[0.758951707891635 0.522491349480969 0.055959952885748 0.193771626297578],'FontSize
',18,'Interpreter','latex');
ylim([−0.2*GCE_mMolar_ratio 4*GCE_mMolar_ratio])
xlim([−5 xmax])
%% Blood glucose level
figure(4)
plot(t,BloodGlucConc,'r')%,t,TumourSignal*8,'.r',t,NormalSignal*8,'.c')
xlabel('Minutes')
ylabel('Blood glucose level [mMolar]')
grid
title({'Blood glucose level'})
%% Glycolytic fluxes
FluxN=(FluxNormal(2:end)−FluxNormal(1:end−1))/(t(2)−t(1));
FluxT=(FluxTumor(2:end)−FluxTumor(1:end−1))/(t(2)−t(1));
t1=t(2:end);
%%%%%%%%
figure(5)
subplot(1,2,1)
plotrange=(baseline−120):length(FluxN);
plot(t1(plotrange),FluxT(plotrange),'LineWidth',2, 'Color',[0.851 0.3250 0.098]);
hold on,plot(t1(plotrange),FluxN(plotrange),'LineWidth',2, 'Color',[0 0.447 0.741]);
xlim([−2,140])
ylim([−0.0 1.0])
xlabel('Minutes')
ylabel('Glycolytic flux & \Deltaflux [mMolar/min]')
grid
title({'Glycolytic flux'})
legend2 = legend('Tumour','Normal');
set(legend2,
'FontSize',14,'Interpreter','latex');
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subplot(1,2,2)
plot(t1(plotrange),FluxN(plotrange)−FluxN(baseline),'−−','LineWidth',2,'Color',[0 0.447 0.741]);
hold on, plot(t1(plotrange),FluxT(plotrange)−FluxT(baseline),'−−','LineWidth',2,'Color',[0.851 0.3250 0.098]);
xlim([−2,140])
xlabel('Minutes')
title('\Deltaflux after administration of glucose')
grid
%% Contribution of each compartmet to the GCE signal
sss=1;
total_GCE_tumour=0+GlucInTumorVascul−sss*GlucInTumorVascul(baseline)+ExtraGlucTumor−sss*ExtraGlucTumor(
baseline)+IntraTotalTumor−sss*IntraTotalTumor(baseline);
vascular_GCE_tumour=100*(GlucInTumorVascul−GlucInTumorVascul(baseline))./total_GCE_tumour;
extra_GCE_tumour=100*(ExtraGlucTumor−ExtraGlucTumor(baseline))./total_GCE_tumour;
intra_GCE_tumour=100*(IntraTotalTumor−IntraTotalTumor(baseline))./total_GCE_tumour;
total_GCE_normal=0+GlucInNormalVascul−sss*GlucInNormalVascul(baseline)+ExtraGlucNormal−sss*ExtraGlucNormal(
baseline)+IntraTotalNormal−sss*IntraTotalNormal(baseline);
vascular_GCE_normal=100*(GlucInNormalVascul−GlucInNormalVascul(baseline))./total_GCE_normal;
extra_GCE_normal=100*(ExtraGlucNormal−ExtraGlucNormal(baseline))./total_GCE_normal;
intra_GCE_normal=100*(IntraTotalNormal−IntraTotalNormal(baseline))./total_GCE_normal;
%% in tumour
figure(6)
subplot(1,2,2)
% plot(t,vascular_GCE_tumour,t,extra_GCE_tumour,t,intra_GCE_tumour)
plot(t,TumourSignal./max(TumourSignal).*vascular_GCE_tumour,'.',t,TumourSignal./max(TumourSignal).*
extra_GCE_tumour,'.',t,TumourSignal./max(TumourSignal).*intra_GCE_tumour,'g.')%,
axis([−5 120 −0.1 101])
xlabel('Minutes')
% ylabel({'Relative GCE signal', '(normalised to the maximum GCE) [%]'})
grid
title({'in TUMOUR tissue'})
%% in normal
subplot(1,2,1)
% plot(t,vascular_GCE_normal,'−−',t,extra_GCE_normal,'−−',t,intra_GCE_normal,'−−')
plot(t,NormalSignal./max(NormalSignal).*vascular_GCE_normal,'.',t,NormalSignal./max(NormalSignal).*
extra_GCE_normal,'.',t,NormalSignal./max(NormalSignal).*intra_GCE_normal,'g.')
axis([−5 120 −0.1 101])
xlabel('Minutes')
ylabel({'Relative GCE signal [%]', '(normalised to the maximum GCE)'})
grid
title({'in NORMAL tissue'})
legend1 = legend('Vascular','Interstitial','Intracellular');
set(legend1, 'Position',[0.346 0.4413399891284 0.188 0.130], 'Interpreter','latex','FontSize',14,'EdgeColor'
,[0.93 0.93 0.933]);
annotation(figure(6),'textbox',[0.217 0.596 0.545 0.068],'String',{['Contribution of each comparment to the
glucoCEST signal'];['$V_{frcV}=0.2,V_{frcI}=0.2,V_{frcC}=0.6$',' and IP bolus protocol)']},'LineStyle'
,'none','Interpreter','latex','FontSize',18,'FontName','Helvetica','FitBoxToText','off');
%% Total CEST splited in compartment Contribution
vascular_GCE_tum=(GlucInTumorVascul−GlucInTumorVascul(baseline))*GCE_mMolar_ratio;
extra_GCE_tum=(ExtraGlucTumor−ExtraGlucTumor(baseline))*GCE_mMolar_ratio;
intra_GCE_tum=(IntraTotalTumor−IntraTotalTumor(baseline))*GCE_mMolar_ratio;
vascular_GCE_nor=(GlucInNormalVascul−GlucInNormalVascul(baseline))*GCE_mMolar_ratio;
extra_GCE_nor=(ExtraGlucNormal−ExtraGlucNormal(baseline))*GCE_mMolar_ratio;
intra_GCE_nor=(IntraTotalNormal−IntraTotalNormal(baseline))*GCE_mMolar_ratio;
figure,
subplot(1,2,1),hold on,
area(t,intra_GCE_nor+extra_GCE_nor+vascular_GCE_nor,'facecolor',[0 0.6 0],'edgecolor','none')
area(t,extra_GCE_nor+vascular_GCE_nor,'facecolor',[0.09 0.3 0.7],'edgecolor','none')
area(t,vascular_GCE_nor,'facecolor',[0.7 0.0 0.1],'edgecolor','none')
axis([−5 120 −0.0 0.9])
xlabel('Minutes')
ylabel({'\%GCE signal'},'fontsize',16,'interpreter','latex')
title({'\bf{Healthy tissue}';['$V_{frcV}=$',sprintf('%.2g%',VasculatureRatio_normal),'$, V_{frcI}=$',sprintf('
%.2g%',InterstitiumRatio_normal),'$, V_{frcC}=$',sprintf('%.2g%',CellsRatio_normal)]},'FontWeight','bold'
,'FontSize',14,'Interpreter','latex');
grid
subplot(1,2,2),hold on,
area(t,intra_GCE_tum+extra_GCE_tum+vascular_GCE_tum,'facecolor',[0 0.6 0],'edgecolor','none')
area(t,extra_GCE_tum+vascular_GCE_tum,'facecolor',[0.09 0.3 0.7],'edgecolor','none')
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area(t,vascular_GCE_tum,'facecolor',[0.7 0.0 0.1],'edgecolor','none')
axis([−5 120 −0.0 0.9])
xlabel('Minutes')
% ylabel({'Relative GCE signal', '(normalised to the maximum GCE) [%]'})
% title({['\bf{Tumour tissue}'];['$V_{frcV}=%',0.2,V_{frcI}=$',sprintf('%.2g%',InterstitiumRatio_normal),'$V_{
frcC}=0.6$']},title({'\bf{Tumour tissue}';['$V_{frcV}=$',sprintf('%.2g%',VasculatureRatio_tumour),'$, V_{
frcI}=$',sprintf('%.2g%',InterstitiumRatio_tumour),'$, V_{frcC}=$',sprintf('%.2g%',CellsRatio_tumour)]},'
FontWeight','bold','FontSize',14,'Interpreter','latex');
legend({'Intracelullar','Interstitial','Vascular'},'interpreter','latex','edgecolor','none','fontsize',12)
grid
% %% Plot inplane contrast (tumour−normal)
% TminusN=(intra_GCE_tum+extra_GCE_tum+vascular_GCE_tum)−(intra_GCE_nor+extra_GCE_nor+vascular_GCE_nor);
% TplusN=(intra_GCE_tum+extra_GCE_tum+vascular_GCE_tum)+(intra_GCE_nor+extra_GCE_nor+vascular_GCE_nor);
% figure,
% hold on,
% area(t,TminusN,'facecolor',[0.3 0.7 0.7],'edgecolor','none')
% axis([−0 120 −0.05 0.4])
% xlabel('Minutes')
% ylabel({'$\% \Delta GCE $'},'fontsize',16,'interpreter','latex')
% % title({'Contrast resolution= $\frac{GCE_{Tumor}−GCE_{Healthy}}{GCE_{Tumor}+GCE_{Healthy}}$'}
% title({'Contrast resolution. [$\Delta(GCE_{Tumor}−GCE_{Healthy})$]'},'FontWeight','bold','FontSize',14,'
Interpreter','latex');
% grid
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